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This work addresses two understudied elements of inflammation and malignancy—
namely, (1) neurolymphatic remodeling during transitions in microenvironmental inflammatory 
status and (2) the systemic paraneoplastic inflammatory syndrome cancer-associated cachexia 
in the context of pancreatic adenocarcinoma (PDAC).  Lymphatic vessels undergo dramatic 
phenotypic changes in initial inflammation, wound recovery, and recurrent inflammation.  We 
identified complementary novel neuroremodeling behaviors under these conditions and 
hypothesized that both nerve and lymphatic remodeling were directed by a tissue remodeling 
factor with overlapping functions.   We found that nerve growth factor (NGF) influenced not 
only nerves but also lymphatics.  NGF stimulated lymphangiogenesis, inhibited lymphatic vessel 
regression during wound recovery, and increased nociception.  NGF induced VEGF-C protein 
expression, and ablation of VEGFR-2/3 signaling abrogated NGF-mediated lymphangiogenesis, 
supporting a hierarchical model of NGF-VEGF signaling with NGF functioning upstream of the 
VEGF family.  We next studied neurolymphatic remodeling in the context of malignancy using a 
novel murine live imaging platform.  Lyve1CreERT2tdT mice inducibly express tdTomato 
fluorescent protein in Lyve-1+ cells.  We implanted fluorescently-labeled tumor cells into cornea 
and pinna and identified tumor-specific neurolymphatic architecture signatures that are distinct 
from those associated with nonmalignant inflammation, including disorganized hypersprouting 
nascent lymphatic vessels and a shift in nerve morphology to a phenotype previously associated 
only with wound recovery.  We also found that manipulating the timing of establishment of 
 
 
inflammation affected tumor cell persistence in tissue.  In the final portion of this work, we 
studied cancer-associated inflammation in a broader context—i.e. the paraneoplastic syndrome 
cancer-associated cachexia.  We sought to address discrepancies in the literature regarding 
cachexia gene expression with a unique set of PDAC skeletal muscle samples harvested at rapid 
autopsy and stratified based on severity of cachexia.  We found differential expression of a 
number of candidate targets in PDAC samples compared to cancer-free controls including FAP-α, 
CAMKIIβ, FBXO32, TIE-1, and TRIM63 and challenged some previous findings.  In summary, we 
defined a novel role for NGF signaling in lymphatics, identified microenvironment-specific 
neurolymphatic architecture signatures, and highlighted the complexity of cancer-associated 
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Pancreatic Ductal Adenocarcinoma 
Statistics and Progression 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth-leading cause of cancer-related 
death in both men and women in the United States (Siegel et al., 2016).  Worldwide, PDAC 
results in over 330,000 deaths annually (Torre et al., 2015).  Unlike the stable or decreasing 
trends of incidence and death rate achieved for other cancers in recent decades, the incidence 
of PDAC continues to rise (Siegel et al., 2016).  These sobering statistics underscore the critical 
need for basic research examining the biology of this disease to drive development of new and 
effective therapies.  PDAC progresses through several histologically-defined classifications of 
pre-malignant lesions, known as pancreatic intraepithelial neoplasias (PanINs), before 
manifesting as infiltrating adenocarcinoma and metastasizing to distant sites.  PanINs do not 
show invasion into lymphatic or blood vessels or nerves (Maitra et al., 2005), but mice bearing 
these lesions had increased levels of neurotrophic factors, sensory innervation, and pain 
(Stopczynski et al., 2014).  Progression through each PanIN stage has been linked to acquisition 
of a specific mutation or set of mutations with HER2/NEU and KRAS associated with PanIN-1A 
and -1B, P16/CDKN2A associated with PanIN-1B and -2, and TP53, SMAD4/DPC4, and BRCA2 
associated with PanIN-3 lesions (Hruban and Adsay, 2009; Wilentz et al., 2000).  The presence of 
an inflammatory pancreatic microenvironment, such as that characteristic of pancreatitis, can 
exacerbate K-Ras oncogene-induced development of PanIN lesions and progression to PDAC by 
facilitating escape from senescence (Guerra et al., 2011) or through pancreatitis-mediated 
acinar to ductal cell metaplasia (Guerra et al., 2007).  Despite our knowledge of this progression 
from normal parenchyma to aggressive malignancy, early detection of these histologic and 
genetic deviations in patients remains challenging.  Most PDAC cases are diagnosed when the 
primary pancreas tumor has already metastasized to regional and distant locations (Siegel et al., 
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2015).  Five-year survival decreases dramatically as stage at diagnosis increases, with PDAC 
localized to the pancreas at diagnosis yielding a modest five-year survival rate of 27% compared 
to just 11% on presentation with regional metastases and a devastating 2% when distant 
metastases are present at diagnosis (Siegel et al., 2016).  The presence of metastasis eliminates 
the only therapeutic strategy with proven curative potential—surgery—and leaves patients with 
debilitating rounds of chemotherapy and radiation as their only recourse to extend life a few 
precious months. 
This work focuses on two microenvironment-responsive tissue networks important in 
cancer progression and metastasis:  lymphatic vessels and nerves.  Both of these systems are 
intimately associated with the pancreas and their functions are markedly altered in both 
inflammation and malignancy—although much remains poorly understood in these regards.  In 
the following sections, we will outline normal lymphatic and nerve biology generally and as it 
relates to the pancreas, explore inflammation-mediated changes on these networks, and 
summarize what is known about their respective roles in the pancreatic tumor 
microenvironment with special emphasis on clinical diagnostic/prognostic metrics, imaging 
techniques, and therapies.  We will also introduce the systemic paraneoplastic inflammatory 
syndrome cancer-associated cachexia in the context of pancreatic ductal adenocarcinoma. 
The Lymphatic System:  Normal Biology and Importance in PDAC 
 
The lymphatic vasculature offers the most direct route from the primary tumor to the 
frequently-invaded draining lymph nodes during PDAC progression.  Cancer metastasis into and 
through the lymphatic vasculature and lymph nodes occurs frequently in PDAC patients 
(DiMagno et al., 1999; Hezel et al., 2006; Katz et al., 2008) and is strongly correlated with poor 
prognosis (Benassai et al., 1999; Delcore et al., 1996; Kedra et al., 2001; Robinson et al., 2012).  
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The lymphatic system is responsible for maintenance of tissue fluid homeostasis, absorption of 
dietary fat, and leukocyte and antigen transport from tissues to lymph nodes for the initiation of 
immune responses (Maby-El Hajjami and Petrova, 2008; Stacker et al., 2014; Tammela and 
Alitalo, 2010).  Originating in nearly all vascularized tissues, blind-ended lymphatic capillaries, or 
initial lymphatics, are specialized for the uptake of interstitial fluids, macromolecules, and 
leukocytes.  They are composed of a single layer of endothelial cells with discontinuous 
intercellular junctions and lack a basement membrane (Baluk et al., 2007; Pflicke and Sixt, 2009).  
The endothelial membrane of the initial lymphatics is attached to the extracellular matrix (ECM) 
via anchoring filaments, which facilitate the opening of the lymphatic lumen during increased 
interstitial fluid pressure (Gerli et al., 2000; Solito et al., 1997).  Upon entry into the lymphatic 
capillaries, lymph and its macromolecular and cellular contents are transported to larger pre-
collecting lymphatic vessels and then to collecting vessels, composed of not just the endothelial 
layer but also smooth muscles to facilitate flow and bi-leaflet valves to prevent backflow 
(Bazigou et al., 2014; Leak and Burke, 1966; von der Weid and Zawieja, 2004).  The afferent 
collecting lymphatics enter the lymph nodes where the lymph is filtered, and upon exiting the 
lymph nodes through the efferent collecting vessels, lymph passes through the major trunks of 
the lymphatic system, the thoracic duct and the right lymphatic trunk, and is then returned to 
the circulatory system (Alitalo and Detmar, 2012; Tammela and Alitalo, 2010). 
The network of lymphatic vasculature and lymph nodes responsible for draining the 
pancreas is quite complex.  In the normal pancreas, lymphatic vessels are typically located near 
blood vessels and are often found in the interlobular spaces of the pancreas (O'Morchoe, 1997).  
Classification of pancreatic nodes has not been uniformly standardized, although pancreatic 
lymph nodes are generally divided into regions based upon their location around the pancreas 
and the areas of drainage of the pancreas:  head/neck, body/tail, left side, or right side 
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(reviewed in (Cesmebasi et al., 2015; Isaji et al., 2004)).  Studies correlating primary tumor 
location and lymph node involvement following resection have helped to identify the regional 
patterns and probabilities of lymph node metastasis, but more analysis is needed for consistent 
accurate prediction of lymph node involvement (Fujita et al., 2010; Kanda et al., 2011; 
Nagakawa et al., 1994; Sun et al., 2010).  
Although clinicians and researchers understand the importance of lymphatic invasion 
and lymph node involvement for pancreatic cancer patient prognosis and therapy selection, the 
biological processes that govern lymphatic invasion and metastasis remain understudied.  For 
example, there is currently disagreement within the field as to whether lymphatic vessel 
expansion at the primary tumor site and draining lymph node is necessary for lymph node 
metastasis.  Also, it has not been conclusively determined whether metastasis to the lymph 
nodes is a sequential step in distant organ spread or a final destination for tumor cells to 
promote immunosuppression.  The potential role of lymphatics supporting immune suppression 
has led to questions of how normal and tumor-associated lymphatic endothelia may contribute 
to immune modulation within the tumor microenvironment and invaded lymph nodes either 
through trafficking functions or direct interactions with immune cells.  These and many more 
questions have yet to be fully explained: how does the lymphatic endothelium regulate the 
entry of tumor cells into vessels; how do tumor cells evade immune cell recognition within 
lymphatic vessels and lymph nodes; what are the therapeutic implications of targeting 




Signaling and Regulation 
While clearly akin to angiogenesis in many regards, progress to define the process of 
lymphangiogenesis has revealed distinct molecular mechanisms that direct its inception, 
regulation, and roles in inflammatory disease and malignancy.  Like angiogenesis, new lymphatic 
vessel growth can be directed by many growth factors and regulated by intra- and extracellular 
signaling mechanisms.  Primary growth factors associated with lymphangiogenesis include 
vascular endothelial growth factor-A (VEGF-A), -C, and -D signaling via vascular endothelial 
growth factor receptor-2 (VEGFR-2) and -3 and neuropilin-2 (NRP-2) (Achen et al., 1998; 
Bjorndahl et al., 2005b; Favier et al., 2006; Joukov et al., 1996; Oh et al., 1997a; Veikkola et al., 
2001), and angiopoietin-1 (ANG-1) and -2 signaling through receptor TIE-2 (tyrosine kinase with 
immunoglobulin-like and EGF-like domains 2) (Morisada et al., 2005; Yan et al., 2012).  Recent 
evidence shows that in addition to the VEGFs and angiopoietins, several other chemical 
messengers are also capable of directly or indirectly inducing lymphangiogenesis in vitro and/or 
in vivo in experimental model systems.  Such mediators include growth factors fibroblast growth 
factor-2 (FGF-2) (Kubo et al., 2002), platelet-derived growth factor-BB (PDGF-BB) (Cao et al., 
2004a; Miyazaki et al., 2014), nerve growth factor (NGF) (Fink et al., 2014) (discussed in Chapter 
I), insulin-like growth factor-1 (IGF-1) and -2 (Bjorndahl et al., 2005a), and hepatocyte growth 
factor (HGF) (Cao et al., 2006); inflammatory cytokines interleukin-1β (IL-1β) (Peppicelli et al., 
2014; Ristimaki et al., 1998) and tumor necrosis factor-α (TNF-α) (Du et al., 2014; Peppicelli et 
al., 2014; Ristimaki et al., 1998); and other non-traditional signaling molecules lipid sphingosine-
1-phosphate (Huang et al., 2013), cyclooxygenase 2 (COX2), and surface protein EP3/4 (Hosono 
et al., 2011).  A role for integrins in lymphangiogenesis has been revealed with evidence of 
binding of VEGF-A, -C, and -D to lymphatic endothelial-specific integrin-α9β1 (Oommen et al., 
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2011; Vlahakis et al., 2005).  While each of these factors does induce new lymphatic vessel 
growth, not all lymphangiogenesis is created equal; a study of corneal lymphangiogenesis in 
response to VEGF-A, VEGF-C, or FGF-2-loaded micropellets revealed differences in both 
structure and function of lymphatic vessels and the proportion of blood to lymphatic vessels 
induced by these growth factors (Cao et al., 2004b).  In the case of indirect stimulation of 
lymphangiogenesis, paracrine signals such as IL-1β (Peppicelli et al., 2014; Ristimaki et al., 1998) 
and TNF-α (Du et al., 2014; Peppicelli et al., 2014; Ristimaki et al., 1998) can drive increased 
expression of the VEGFs, most notably VEGF-C.  This likely occurs through activation of the 
nuclear factor kappa B (NFκB) promoter to induce VEGF-C expression (Du et al., 2014).  Other 
indirect inducers of lymphangiogenesis include COX2 and EP3/4, which may increase expression 
of VEGF-C and -D to modulate cell growth during inflammation (Hosono et al., 2011), and NGF, 
which increased expression of VEGF-C, but not VEGF-A, in a mouse corneal model of 
lymphangiogenesis (Fink et al., 2014).  Some studies have attributed the secondary production 
of VEGFs, specifically VEGF-C, to an infiltrating macrophage population during periods of 
inflammation and malignancy (Cursiefen et al., 2004; Huang et al., 2013; Murakami et al., 2008; 
Peppicelli et al., 2014).  Huang, et al., have also identified B cells and dendritic cells (DCs) as 
candidate immune cell populations that may secrete VEGF-A, -C, and -D to influence lymphatic 
vessel organization and growth (Huang et al., 2013).  B cells have also been shown to modulate 
lymphangiogenesis within lymph nodes in the context of tissue inflammation following 
experimental immunization (Angeli et al., 2006).  In addition to their role in secretion of 
lymphangiogenic growth factors, Hall, et al., have shown that tissue macrophages may directly 
contribute to new lymphatic vessel growth by transdifferentiation into a lymphatic endothelial 
progenitor-like phenotype and incorporation into growing vessels (Hall et al., 2012).  The roles 
8 
 
of tumor-associated macrophages (TAMs) in lymphangiogenesis in the tumor microenvironment 
are discussed in more detail below. 
Lymphangiogenesis is further controlled by regulation of growth factor and cytokine 
receptors on the lymphatic endothelial surface.  Gene expression of VEGFR-1, -2, and -3 and 
NRP-1, and -2 is regulated by transcription factors GATA-binding protein 2 (GATA2) and LIM 
domain only 2 (LMO2) to influence both angiogenesis and lymphangiogenesis (Coma et al., 
2013).  Another transcription factor, COUP transcription factor 2 (COUP-TFII), increases 
expression of Nrp-2 to augment VEGF-C signaling (Lin et al., 2010).  VEGFR-2 and -3 signaling is 
further modulated by bone marrow kinase in X chromosome (BMX) following its upregulation 
upon VEGF-A stimulation of lymphatic endothelial cells (LECs) (Jones et al., 2010).  H-, N-, and K-
Ras can also regulate VEGFR-3 signaling by inducing the up- or downregulation of that receptor 
(Ichise et al., 2010).  Another mechanism of VEGFR-3 pathway signaling regulation in LECs is the 
IL-1β-dependent induction of microRNA-1236 (Jones et al., 2012) and the molecular scaffolding 
protein apoptosis signal-regulating kinase interacting protein-1 (AIP-1) (Zhou et al., 2014). The 
SLIT2-ROBO4 (Slit homolog 2-Roundabout homolog 4) signaling axis has been shown to regulate 
surrogate lymphangiogenesis behaviors in lung LECs in culture by modulating VEGF-C/VEGFR-3 
pathway signaling (Yu et al., 2014).  NFκB pathway signaling has been shown to further 
modulate inflammatory lymphangiogenesis by upregulating prospero-related homeobox-1 
(Prox-1) and VEGFR-3 in a mouse model of peritonitis (Huang et al., 2013). 
Tumor-Associated Lymphangiogenesis 
The discussion above has primarily focused on the regulation of inflammatory 
lymphangiogenesis typical of an injury or infection.  A related, but in many ways physiologically 
distinct process, is that of tumor-associated lymphangiogenesis (TALA).  Factors elaborated by 
9 
 
tumor cells and other supporting cell types of the tumor microenvironment, such as cancer-
associated fibroblasts (CAFs), TAMs, and DCs, interact with cognate receptors on the lymphatic 
endothelium both locally and in lymph nodes to influence lymphangiogenesis, lymph node 
metastasis, and tumor progression.  Studies of human pancreatic cancer tissues have identified 
a role for TALA in lymph node metastasis and patient outcomes.  Kurahara, et al., found that 
high lymphatic vessel density (LVD) in PDAC head tumors predicted increased lymph node 
metastasis and decreased survival; they also showed increased LVD within metastatic lymph 
nodes (Kurahara et al., 2010).  Wang, et al., found that increased peritumoral LVD in human 
pancreatic carcinoma tissues correlated with unfavorable tumor differentiation status, increased 
lymphatic vessel invasion (LVI), and more lymph node metastasis, while this was not the case for 
intratumoral LVD (Wang et al., 2012).  These data highlight the importance of peripancreatic 
lymphatics in the progression and metastasis of pancreatic cancer and their potential utility as 
both a predictor of patient outcomes and a possible therapeutic target.  
As in inflammatory lymphangiogenesis, the VEGF-C/D signaling pathways appear to play 
an important role in TALA, although the exact mechanisms of their activity remain somewhat 
less clear.  Kurahara, et al., found increased VEGF-C and -D expression in patient PDAC tumor 
margins compared to the tumor interior and reported that high VEGF-C and -D expression in 
tumor margins correlated with increased LVI (VEGF-C) and lymph node metastasis (VEGF-C/D) 
and decreased five-year survival; expression levels of these proteins did not correlate with 
either hematogenous invasion or distant metastasis (Kurahara et al., 2004).  A similar study of 
patient samples also showed increased VEGF-C and -D immunostaining at PDAC tumor margins 
that correlated with increased LVD, lymphatic and blood vessel invasion, lymph node 
metastasis, and overall survival (Zhang et al., 2007).  Von Marschall, et al., corroborated these 
findings with their evidence of increased VEGF-D and VEGFR-3 expression in human PDAC tissue 
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and of increased LVI, presence of intra- and peritumoral lymphatics, and lymph node metastasis 
(Von Marschall et al., 2005).  Deletion of VEGF-D in mice resulted in impaired peritumoral 
lymphangiogenesis and decreased lymph node metastasis while having no effect on lymphatic 
development or inflammatory lymphangiogenesis suggesting a tumor microenvironment-
specific role for VEGF-D signaling (Koch et al., 2009).  In a Rip1Tag2 model of pancreatic β-cell 
carcinogenesis, Kopfstein, et al., showed that VEGF-D expression in these tumors induced 
peritumoral lymphangiogenesis and lymph node and lung metastases (Kopfstein et al., 2007); a 
very similar study examining the role of VEGF-C in this context found increased 
lymphangiogenesis and lymph node metastasis but not distant metastases (Mandriota et al., 
2001).  In an orthotopic PDAC model, treatment with anti-VEGF-C short hairpin  RNA decreased 
tumoral LVD and inhibited tumor growth (Shi et al., 2013).  A role for microRNAs may also exist 
in the regulation of pancreatic TALA.  Keklikoglou, et al., recently described a mechanism of 
regulation of VEGF-C production in PDAC cells by miR-206.  They showed that, in addition to 
regulating KRAS and annexin-A2 gene expression, restoration of miR-206 expression blocked 
tumor-associated angiogenesis and lymphangiogenesis, and its overexpression in pancreatic 
cancer cell lines disrupted the cell cycle restricting proliferation, impaired migration and 
invasion in vitro, and delayed tumor xenograft growth in vivo (Keklikoglou et al., 2014).  While 
the role of hypoxia in lymphangiogenesis remains unclear, hypoxia-inducible factor 1 alpha (HIF-
1α) expression has been shown to correlate with VEGF-C expression in PDAC of the pancreatic 
head and may be responsible for increased lymphangiogenesis and lymph node (LN) metastasis 
(Tao et al., 2006).  Contrary to these studies, Sipos, et al., examined the expression levels of 
lymphangiogenic factors, LVD, and effects on lymph node metastasis in human PDAC and 
orthotopic PDAC mouse models and found that VEGF-C and -D were not overexpressed in tumor 
tissues and that LVD within tumors was decreased while peritumoral LVD was increased.  They 
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found no correlation between LVD or expression of VEGF-C or -D and rate of lymph node 
metastasis or patient outcomes and concluded that PDAC metastasis is independent of 
lymphangiogenesis (Sipos et al., 2005).   
In vitro experiments have examined the effects of tumor-secreted VEGF-C on LEC 
surrogate lymphangiogenesis behaviors.  Supernatant from a high VEGF-C-secreting cell line, 
MiaPaCa-2, increased LEC migration, and MiaPaCa-2 co-culture with LECs increased LEC 
tubulogenesis (Ochi et al., 2007).  These effects may be dependent on kangai-1 (KAI-1; CD82) 
regulation as overexpression of that gene in MiaPaCa-2 resulted in decreased VEGF-C secretion, 
lymphangiogenesis, and lymph node metastasis (Liu et al., 2014a).  Re-expression of tumor 
suppressor p16 in a MiaPaCa-2 orthotopic model had no effect on levels of VEGF-C or -D, but 
nevertheless resulted in decreased lymphangiogenesis, LVD, and lymph node metastasis 
suggesting an alternate mechanism of regulation (Schulz et al., 2008). 
Overall, many studies examining the relationships among VEGF-C/D expression and 
lymphatic-related phenotypes have found that high VEGF-C/D levels correlate with increased 
lymphangiogenesis, lymphatic vessel invasion, and lymph node metastasis (or their surrogate in 
vitro counterpart behaviors).  Whether a direct pathway can be drawn from tumor-associated 
lymphangiogenesis, to tumor cell invasion into lymphatic vessels, to tumor cell trafficking to 
lymph nodes, to establishment of lymph node metastases, to tumor cell exit of the lymph node 
by blood or lymphatic vessels and seeding of metastases at distant sites, to direct effects on 
patient outcomes is still unclear.  Some of the studies we have discussed have supported 
portions of this pathway from lymphangiogenesis to distant metastases, but other data suggest 
that disease progression does not necessarily follow this linear sequence—i.e. the concept that 
lymphangiogenesis may not be required for lymphatic vessel invasion due to entry into pre-
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existing lymphatics, or the possibility of trafficking of tumor cells to lymph nodes through blood 
vessels, or the results from Sipos, et al., showing that lymph node metastasis and patient 
prognosis are not linked to VEGF-C/D levels (Sipos et al., 2005).  Also complicating this discussion 
is the fact that tumor cells may themselves respond to VEGF-C/D signals in an autocrine manner 
further influencing their metastatic behaviors.  Additional studies to systematically dissect each 
of the biological components of this proposed metastatic pathway are needed to concretely 
define their connections and contributions to disease progression. 
Traditional neural signaling molecules also act to influence lymphatic vessel biology in 
the tumor microenvironment.  Suppression of neural cell adhesion molecule (NCAM) induced 
VEGF-C and -D expression resulting in increased lymphangiogenesis and lymph node metastasis 
in the Rip1Tag2 mouse model (Crnic et al., 2004), while the presence of NCAM expression in 
pancreatic cancer tissues from patients correlated with better prognosis (Tezel et al., 2001).  In 
another example derived from the Rip1Tag2 model, Slit2 induced Robo1 in LECs to increase 
lymphangiogenesis and lymph node metastasis (Yang et al., 2010).  As previously mentioned, 
signaling of Slit2 through another receptor, Robo4, may also influence lymphangiogenesis 
behaviors such as growth, migration, and tubulogenesis, by modulating VEGF-C/VEGFR-3 
signaling (Yu et al., 2014).  NRP-2, a classical semaphorin receptor and VEGF pathway co-
receptor, has also been shown to be a key regulator of TALA.  It is expressed on intra- and 
peritumoral lymphatic vessels and lymph nodes; blocking its function in vivo decreased TALA, 
impaired tumor-associated lymphatic vessel function, and reduced lymph node and distant 
metastases (Caunt et al., 2008).  These effects may be the result of impaired lymphatic sprouting 
(Xu et al., 2010).  NRP-1 and -2 are also expressed on pancreatic tumor cells themselves (Dallas 
et al., 2008; Fukahi et al., 2004).  In a model of colorectal cancer, TALA was stimulated by 
upregulation of Nrp-2 in LECs, and LVD correlated with the level of Nrp-2 expression; this Nrp-2 
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induction was mediated by integrin-α9β1 signaling in a VEGF-C/VEGFR-3 pathway-independent 
manner (Ou et al., 2015). 
Other signaling pathways have also been implicated in regulation of TALA.  In a mouse 
model of pancreatic β-cell carcinoma, both Ang-1 and -2 induced peritumoral 
lymphangiogenesis, but this new lymphatic vessel growth did not result in increased metastasis 
to either local lymph nodes or distant sites (Fagiani et al., 2011).  Ang-2 expression in orthotopic 
PDAC xenografts resulted in increased LVD and lymphatic metastasis, and high levels of ANG-2 
in patient serum samples correlated with lymph node metastasis and decreased survival.  In 
MiaPaCa-2 cells, ANG-2 altered message levels of cytoskeletal and motility pathway molecules 
as well as decreasing expression of tumor suppressor genes (Schulz et al., 2011).  The 
transforming growth factor-β (TGF-β) pathway may also be involved in TALA as expression of 
endoglin on intra- and peritumoral blood and lymphatic vessels in PDAC correlated with poor 
patient prognosis (Yoshitomi et al., 2008). 
PDAC Invasion of Lymphatic Vessels and Metastasis to Lymph Nodes 
Background 
Lymphatic vessel invasion and subsequent metastasis to the lymph nodes are early and 
significant events frequently observed during pancreatic cancer progression (DiMagno et al., 
1999; Hezel et al., 2006).  Although lymphatic invasion and metastasis to the lymph nodes does 
not directly contribute to PDAC morbidity in patients, these pathologies are important indicators 
of the metastatic potential of this disease.  In the clinical setting, lymph node status is used to 
assess disease progression, to select appropriate therapies, and to predict survival (Kawada and 
Taketo, 2011; Nathanson et al., 2015).  Nearly all studies concur that lymph node status 
correlates with poor prognosis for pancreatic cancer patients (Benassai et al., 1999; Delcore et 
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al., 1996; Liu et al., 2015b; Robinson et al., 2012).  Studies also agree that invasion of lymph 
nodes by PDAC occurs most frequently through the lymphatic vasculature rather than through 
direct/contiguous extension of the primary tumor to the lymph node (Buc et al., 2014; 
Konstantinidis et al., 2010; Pai et al., 2011), although direct extension to lymph nodes through 
nerves is often a feature of perineural invasion.  The prognostic value of mode of lymph node 
invasion is still debated:  some studies report poorer overall survival in patients with lymphatic 
vessel-directed metastasis as compared to direct invasion (Pai et al., 2011), while other reports 
show no survival difference between the two modes of lymph node invasion (Buc et al., 2014; 
Konstantinidis et al., 2010).  Although lymph node invasion by PDAC occurs most frequently 
through the lymphatic vasculature, the LVD at the tumor site has not been conclusively 
correlated with either lymph node metastasis or prognosis due to conflicting study results (Sipos 
et al., 2005; Von Marschall et al., 2005; Wang et al., 2012; Zorgetto et al., 2013).  This is also true 
for studies examining the expression of pro-lymphangiogenic factors such as VEGF-C and -D 
(Schneider et al., 2006; Sipos et al., 2005; Tang et al., 2001) (and in pancreatic endocrine tumors 
(Rubbia-Brandt et al., 2004)).  The lack of standardized protocols for quantifying LVD in patients 
makes comparative analysis among collected data sets difficult.  Some studies enumerate only 
intratumoral lymphatics in whole tumor sections, while others examine tumor margins for 
peritumoral lymphatics, and still others examine the sum of lymphatic vessels in both regions.  
In the continued absence of a standardized method, LVD has limited value as a metric for 
assessing pancreatic cancer progression.  
PDAC tumors are often hypovascular with only sporadic blood and lymphatic vessels 
found among the tumor cells (Feig et al., 2012).  These intratumoral lymphatic vessels are 
typically collapsed and nonfunctional due to direct compression by the tumor cells and the high 
internal pressure of the PDAC tumor microenvironment (Olszewski et al., 2012; Padera et al., 
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2002; Schneider et al., 2006).  However, even in the absence of functioning intratumoral 
lymphatic vessels, tumor cells are still capable of disseminating to lymph nodes, although 
identification of reliable sentinel lymph nodes remains challenging (Kanda et al., 2011).  The 
lymphatic vessels located at the tumor margins are frequently described as enlarged with open 
lumens capable of being filled with tumor cells (Olszewski et al., 2012; Schneider et al., 2006), 
and drainage studies show that these peritumoral lymphatic vessels are, in fact, functional 
(Padera et al., 2002).  Sipos and colleagues demonstrated that even in the absence of elevated 
LVD values and active lymphangiogenesis, PDAC patients still frequently presented with lymph 
node metastases (Sipos et al., 2005).  This suggests that PDAC cells are capable of invading the 
pre-existing lymphatic vasculature, especially enlarged vessels at tumor margins.  
Mechanisms/Players 
Mechanisms regulating lymphatic invasion are not completely understood, but are 
gaining increasing research interest.  Most of our knowledge of vascular invasion has come from 
studies of the blood vasculature that are now being extended to studies of lymphatic vessel 
properties and function.  Initially, invasion of lymphatic vessels by tumor cells was considered to 
be a passive process with increased interstitial fluid pressure driving tumor cells into draining 
lymphatic vessels (Hartveit, 1990).  Although increased interstitial pressure may contribute to 
tumor cell invasion, the concept of lymphatic-mediated tumor metastasis as a process that 
utilizes a “path of least resistance” is greatly oversimplified, and proteomics studies have 
identified distinctions between primary pancreatic tumors and their corresponding lymph node 
lesions (Naidoo et al., 2012).  Comparisons of pancreas tumors with and without lymph node 
metastases revealed differences in protein expression intrinsic to these two pathological tumor 
presentations (Cui et al., 2009).  In an effort to better understand the potential drivers of 
lymphatic metastasis, results of studies of leukocyte intravasation into lymphatic vessels are 
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now being examined for commonalities to tumor cell intravasation.  Three key molecular players 
of invasion have emerged as likely candidates in the regulation of tumor-lymphatic interactions 
and metastasis:  chemokine signaling, paired binding of adhesion protein partners, and 
alterations in lymphatic vessel barrier integrity.  
Chemokines 
Chemokines secreted by lymphatic endothelial cells contribute to inflammation and 
initiation of immune responses in part by regulating the chemotaxis of antigen presenting cells 
to the lymph nodes.  These same molecules are also being studied for similar roles in tumor 
metastasis to lymph nodes.  Two widely researched candidate chemokines are CCL21 
(chemokine (C-C motif) ligand 21) and CXCL12 (chemokine (C-X-C motif) ligand 12) and their 
respective G-protein coupled receptors (GPCRs), CCR7 (chemokine (C-C motif) receptor 7) and 
CXCR4 (chemokine (C-X-C) motif receptor 4). 
During normal immune responses, lymphatic endothelial cells secrete CCL21 to increase 
migration of CCR7+ DCs toward the vessel and then to guide DCs to the lymph nodes (Tal et al., 
2011; Vigl et al., 2011).  Tumor cells, including those of pancreatic cancer, overexpress CCR7 and 
are capable of responding to CCL21 cues to facilitate their dissemination to the lymph nodes 
(Gunther et al., 2005; Hwang et al., 2012; Irino et al., 2014; Muller et al., 2001; Zhao et al., 
2011).  Guo, et al., noted a correlation between CCR7 expression in tumor cells and frequency of 
lymph node metastasis in pancreatic cancer patients (Guo et al., 2013).  Sperveslage, et al., 
confirmed these results and also demonstrated that lymphatic vessels of PDAC patients had 
significantly higher expression of CCL21 compared to lymphatic vessels of the normal pancreas.  
Expression of CCL21 in lymphatic vessels correlated with increased lymphatic invasion and 
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lymph node metastasis in these patients, as did overexpression of CCR7 in pancreatic tumor 
cells in vivo (Sperveslage et al., 2012).  
The expression of CCL21 in lymphatic endothelial cells is regulated by numerous 
inflammatory cytokines including TNF-α and IL-1β and is also influenced by increases in 
transmural flow (Miteva et al., 2010), both of which are often present in tumor 
microenvironments.  In vitro co-culture work has demonstrated that CCR7-expressing tumor 
cells have increased chemotaxis toward CCL21-expressing lymphatic endothelial cells (Emmett 
et al., 2011; Issa et al., 2009; Shields et al., 2007).  This chemotactic axis is used by tumor cells 
specifically for invasion into lymphatic vessels; tumor cell chemoattraction to blood endothelial 
cells does not use this mechanism (Issa et al., 2009; Pang et al., 2015).  Blocking CCR7 or CCL21 
expression and/or function inhibits lymphatic vessel invasion and metastasis to the lymph nodes 
in vitro and in vivo (Shields et al., 2007; Wiley et al., 2001; Yu et al., 2008b).  This chemokine 
signaling axis appears to be regulated by and to work in concert with VEGF-C to synergistically 
promote lymphatic invasion of CCR7+ and VEGFR-3+ tumor cells (Issa et al., 2009).  
Another chemokine axis that influences lymphatic metastasis is that of CXCL12-CXCR4.  
It has been widely documented that CXCR4-expressing tumor cells, including PDAC cells, home 
to organs with high CXCL12 expression, such as the lungs, bone marrow, and lymph nodes 
(Cardones et al., 2003; Cui et al., 2011; Kaifi et al., 2005; Muller et al., 2001).  In PDAC patient 
tissues, high expression of CXCR4 was found in tumors, while lymph nodes expressed high levels 
of CXCL12 (Cui et al., 2011; Wehler et al., 2006).  This expression pattern positively correlated 
with increased LVD values in the pancreas, lymph node metastasis frequency, and poor disease 
prognosis.  Tumor-associated, but not normal uninflamed, LECs secrete ample amounts of 
CXCL12 in the tumor microenvironment and attract CXCR4+ tumor cells to lymphatic vessels and 
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lymph nodes (Hirakawa et al., 2009; Kim et al., 2010b).  Blocking the CXCR4-CXCL12 signaling 
axis has resulted in impaired lymph node metastasis in numerous tumor models (Chu et al., 
2007; Liu et al., 2014b; Uchida et al., 2011).   An in vitro breast cancer model demonstrated that 
CXCL12-treated LECs permitted greater transendothelial migration by breast cancer cells, and 
this permissiveness could be reversed by blocking CXCR4 in the LECs (Yagi et al., 2011).  An in 
vivo model of melanoma demonstrated that stem-like, dual positive CD133+/CXCR4+ tumor cells 
were strongly associated with CXCL12-producing LECs and that these cells were resistant to 
chemotherapy (Kim et al., 2010b).  Combinational treatment with a CXCR4 antagonist relieved 
this resistance and increased the efficacy of chemotherapy thereby reducing tumor growth and 
metastasis.  This study suggested that CXCL12 secretion from lymphatic vessels supported a pro-
metastatic and pro-survival niche for tumor cells.  Further studies are required to elucidate 
whether or not these types of mechanisms are employed in PDAC and/or its tumor 
microenvironment. 
Adhesion Proteins 
Physical interactions between tumor cells and lymphatic endothelial cells may be 
another crucial regulator of tumor cell intravasation.  Adhesion molecules such as E-selectin, 
intercellular adhesion molecule 1 (ICAM-1), and vascular adhesion molecule 1 (VCAM-1) are 
typically used by DCs to gain entry into inflamed lymphatic vessels during migration toward 
lymph nodes (Johnson et al., 2006; Miteva et al., 2010).  Mounting evidence indicates that these 
same leukocyte adhesion molecules may also be important for controlling tumor cell entry into 
lymphatic vessels (Kawai et al., 2008; Viola et al., 2013; Yan et al., 2014).  In a non-inflamed 
state, the lymphatic endothelium does not express or only very weakly expresses these 
adhesion molecules (Johnson et al., 2006; Sawa et al., 2007).  Inflammatory conditions—such as 
those found during infection or tumor development—or a wound healing response quickly 
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increase the expression of these molecules on the lymphatic endothelium (Johnson et al., 2006; 
Miteva et al., 2010).  Increased transmural flow, also characteristic of an inflamed 
microenvironment, upregulates ICAM-1 and E-selectin expression on an in vitro lymphatic 
endothelium resulting in increased DC binding (Miteva et al., 2010).  A recent report shows that 
binding and transendothelial migration of breast cancer cells is also influenced by in vitro fluid 
flow, although the mechanisms governing these behaviors have not been elucidated (Pisano et 
al., 2015).  When placed in co-culture with tumor cells, LECs display marked upregulation of 
adhesion molecules.  Kawai, et al. (2008 and 2009), have demonstrated that invasive breast 
cancer cells, which express the αLβ2 ligand for ICAM-1, are capable of inducing the expression of 
E-selectin and ICAM-1 on lymphatic endothelial cells. They also demonstrated that blocking 
ICAM-1 impaired the ability of these tumor cells to bind to a lymphatic endothelium (Kawai et 
al., 2008; Kawai et al., 2009).  Studies of the ability of adhesion proteins on lymphatic vessels to 
regulate tumor cell entry should be expanded to pancreatic cancer cell lines to determine if 
PDAC tumor cells can use similar mechanisms to bind and gain access to the lymphatic 
vasculature.  
Lymphatic Vessel Barrier Integrity 
The intrinsic cellular and molecular organizational characteristics of lymphatic vessels 
facilitate entry of immune cells and fluids from a collecting tissue bed—properties that may also 
allow these vessels to support tumor cell metastasis.  The initial lymphatic capillaries within 
tissues are composed of only a single layer of endothelial cells with loose junctions between 
neighboring cells (Leak, 1976; Maby-El Hajjami and Petrova, 2008).  Unlike the tightly-formed, 
continuously-arranged  junctions between neighboring endothelial cells of the blood vasculature 
(Dejana et al., 2009), the junctional proteins—vascular endothelial cadherin (VE-cadherin), 
platelet/endothelial cell adhesion molecule-1 (PECAM-1), claudins, occludins, etc.—of initial 
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lymphatic vessels are discontinuously arranged, creating gaps between overlapping lymphatic 
endothelial cells (Baluk et al., 2007).  These discontinuous junctions along with preformed 
openings in the basement membrane (Pflicke and Sixt, 2009) enable uptake of macromolecules, 
fluids, and cells by the initial lymphatic capillaries.  As lymph and cells are transported up the 
lymphatic vasculature to the collecting lymphatic vessels, the discontinuous intercellular 
junctions become more constant and successive to prevent leakage prior to arrival at the lymph 
nodes (Baluk et al., 2007).  
Data suggest that tumor cells are capable of modulating the barrier integrity of the 
lymphatic endothelium to further facilitate lymphatic vessel invasion (Kerjaschki et al., 2011).  
Lipoxygenase secretion by breast cancer cells has been shown to disrupt VE-cadherin junctions 
and induce endothelial cell repulsion, resulting in breaches in the lymphatic endothelium.  
Tumor-secreted VEGF-C also facilitates invasion by creating leaky lymphatic vasculature.  VEGF-C 
induces the internalization of VE-cadherin, which, in turn, promotes tumor cell transendothelial 
migration (He et al., 2005; Tacconi et al., 2015).  In a pancreatic tumor model, inhibiting Ang-2 
signaling with a soluble Tie-2 receptor decreased lymphatic-directed metastasis to the lymph 
nodes (Schulz et al., 2011).  This result may be explained by studies demonstrating that Ang-2 
disrupts the barrier integrity of the lymphatic endothelium and increases lymphatic permeability 
through phosphorylation of VE-cadherin resulting in button-junction formation in the initial 
lymphatic capillaries (Zheng et al., 2014).  
Comparative Tools and Models to Study Lymphatic Biology and Tumor-Lymphatic Interactions 
The discoveries of lymphatic endothelium markers such as lymphatic vessel hyaluronan 
receptor-1 (Lyve-1) (Banerji et al., 1999), Prox-1 (Wigle and Oliver, 1999), VEGFR-3 (Kaipainen et 
al., 1995), and podoplanin (PDPN) (Breiteneder-Geleff et al., 1997; Schacht et al., 2003; 
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Wetterwald et al., 1996) have facilitated the development of new research methodologies and 
models with which to study lymphatic vessel biology under homeostasis and various disease 
pathologies as well as interactions between lymphatic endothelial cells, immune cells, and 
tumor cells in vivo.  The mouse cornea and skin have emerged as two popular mammalian 
platforms for this type of work.  Historically used for studies of angiogenesis, the murine corneal 
model system has proven equally informative for studies of lymphatic biology because of its 
unique characteristics.  The normal healthy cornea harbors a single limbal lymphatic vessel ring 
at its periphery and is otherwise devoid of lymphatic vessels.  Upon insult or injury, 
inflammatory lymphangiogenesis occurs resulting in extension of newly-synthesized lymphatic 
vessels from the limbal arcade toward the site of the stimulus.  Corneal injury can be 
recapitulated experimentally by placement of sutures, mechanical debridement, or chemical 
burn.  A refinement of this inflammatory model enabling more mechanistic dissection of 
lymphatic vessel behavior is the corneal micropocket assay in which a micropellet can be loaded 
with a protein or drug of interest and implanted into the cornea (Cao et al., 2011; Fink et al., 
2014; Kenyon et al., 1996).  Further modifications of traditional acute inflammatory protocols 
can induce wound recovery (Fink et al., 2014; Kelley et al., 2011a) and recurrent inflammation 
(Fink et al., 2014; Kelley et al., 2013a)—two additional distinct physiological microenvironments 
with implications for wound healing, chronic inflammatory disease, and tumor 
microenvironment research.  Anatomical sites commonly used in skin imaging studies include 
murine dorsal surface, foot pad, and pinna.  Unlike the cornea, the skin is vascularized with a 
dense network of lymphatic capillaries under steady state conditions.  This presents an ideal 
system for studies of lymphatic vessel homeostasis and remodeling, local inflammatory 
lymphangiogenesis, and endothelium-immune/tumor interactions.   
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Both cornea and skin have also been employed in real time live-imaging and intravital 
microscopy studies (Kilarski et al., 2013; Li et al., 2012; Pflicke and Sixt, 2009; Steven et al., 
2011).  Early experiments of this type relied on injection and uptake of large fluorescent 
conjugate molecules such as FITC-dextran or explant immunostaining (Reviewed in (Tran Cao et 
al., 2011)) to label vasculature and other tissue antigens, but recently several genetically 
engineered mouse models (Bianchi et al., 2015; Choi et al., 2011; Connor et al., 2016; Hagerling 
et al., 2011; Martinez-Corral et al., 2012; Truman et al., 2012) have enabled more sophisticated 
lymphatic vessel-specific experimental designs.  In these immunocompetent models, fluorescent 
protein expression is driven by lymphatic endothelium-specific promoters such as Prox-1, Lyve-
1, or VEGFR-3 in either a constitutive or inducible manner.  Inducible systems offer the 
advantages of titration and temporal control of fluorescence expression within the lymphatic 
endothelial compartment.  Fluorescently labeled tumor or immune cells may be delivered to 
and tracked along with endogenously fluorescent lymphatic vessels providing insight into 
intravasation/extravasation behavior, cell trafficking and fate, and spread to draining lymph 
nodes.  Translation of these techniques to studies of the pancreatic lymphatic vasculature 
specifically would provide insight into organ-specific lymphatic vessel biology and pancreatic 
tumor microenvironment contributions to lymphatic remodeling and lymphatic-mediated 
metastasis.  We suggest combination of several existing technologies to examine these 
questions.  First, crossing a spontaneous pancreatic ductal adenocarcinoma model containing a 
fluorescent reporter gene, such as the PKCY (Rhim et al., 2012) or KPCT mouse (Stopczynski et 
al., 2014), with one of the available lymphatic-specific reporter mice would facilitate 
visualization of cells of pancreatic origin and lymphatic vessels in two colors.  Implantation of a 
pancreas window (Ritsma et al., 2013) in these animals could enable long term intravital 
microscopy studies of lymphatic vessel biology and tumor metastasis throughout the course of 
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disease progression, from PanIN formation through advanced metastatic disease.  Finally, use of 
the CLARITY technique as previously described for brain (Chung and Deisseroth, 2013; Chung et 
al., 2013a) in concert with multiphoton microscopy and immunofluorescent staining would 
allow deep tissue visualization and reconstruction of full lymphatic vascular networks as well as 
detection of other important microenvironmental structures (such as nerve and blood vascular 
networks) and signaling molecules both peri- and intratumorally.   
Other research and pre-clinical imaging models have further studied lymphatic vessel- 
and lymph node-related pathologies in cancer.  High resolution magenetic resonance imaging 
(MRI) has proven an effective non-invasive strategy for mapping involved mouse lymph nodes in 
pancreatic ductal adenocarcinoma (Zhang et al., 2013).  Multiphoton laser scanning microscopy 
work in a model of melanoma showed that functional lymphatic vessels are not present within 
the tumor proper and that functional peri-tumoral lymphatic vessels are sufficient to mediate 
metastasis (Padera et al., 2002).  Other methods of lymph node and metastasis imaging 
(reviewed in (Tran Cao et al., 2011)) have included injection of dyes or radiotracers such as 
Lymphoseek for lymphoscintigraphy, injection and uptake of cancer-specific radio-labeled 
antibodies and their accumulation in affected lymph nodes, injection of fluorescent antibody 
conjugates against the lymphatic endothelium in combination with fluorescent reporter-
expressing pancreatic cancer cells, and use of combinatorial bioluminescence and fluorescence 
resonance energy transfer (BRET-FRET) nanoparticles for mapping lymphovascular and node 
networks (Xiong et al., 2012).  Fluorescence lifetime imaging microscopy (FLIM)-FRET (Nobis et 
al., 2013), optical coherence tomography (Huang et al., 1991), optical frequency domain imaging 
(Vakoc et al., 2009), photoacoustic tomography (Wang et al., 2003), higher-order harmonics 
generation (Wu et al., 2015), and Raman spectroscopy (Krafft and Popp, 2015) imaging 
technologies offer other options for reconstructive deep tissue imaging and analysis of single 
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cell signaling within an intact tumor microenvironment.  Jeong and Jones, et al., have also 
established a chronic lymph node window to facilitate long-term live imaging microscopy studies 
of lymph node biology, angiogenesis and lymphangiogenesis, and nodal deposition of metastatic 
tumor cells (Jeong et al., 2015).  Application of CRISPR-Cas9 gene editing technology (Cong et al., 
2013) may also prove useful in generating new pre-clinical models suitable for lymphatic vessel 
imaging in disease. 
Clinical Imaging Techniques to Detect Pancreatic Cancer Lymph Node Metastasis 
Despite research advances in comparative lymphatic vessel imaging, clinical imaging of 
pancreatic cancer patient lymphatic networks and lymph node status has remained challenging.  
Several groups have examined the utility of traditional clinical imaging platforms for detection of 
lymph node metastasis with limited success.  Roche, et al., have shown that examination of 
peripancreatic lymph nodes by computed tomography (CT) cannot accurately predict presence 
of metastatic deposits (Roche et al., 2003).  Similarly, Imai, et al., showed that CT, magnetic 
resonance imaging (MRI), and fluorodeoxyglucose-positron emission tomography (FDG-PET) 
were not consistently accurate in predicting pre-operative para-aortic lymph node involvement 
in pancreatic cancer patients (Imai et al., 2010).  Conversely, another group had some success 
using endoscopic ultrasound (EUS) to differentiate benign and cancerous lymph nodes and to 
identify diseased pancreas; this technique has not been fully developed for widespread clinical 
use (Kumon et al., 2010).  Cesmebasi, et al., have recently reviewed other advances in clinical 
imaging techniques including EUS and lymphotropic nanoparticle-enhanced MRI, reporting that 
further refinement of these techniques may make them promising options to identify patterns 
of pancreatic cancer spread (Cesmebasi et al., 2015).  Other groups have focused efforts on 
imaging routes of pancreatic drainage in attempts to identify sentinel lymph nodes for 
pancreatic tumors arising in various locations within the pancreas.  Injection of indocyanine 
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green fluorescent dye into the pancreatic surface during pancreat(ic)oduodenectomy (PD) 
surgery allowed visualization of pancreatic lymphatic vessels intraoperatively and resulted in 
identification of seven routes of lymphatic drainage highlighting the complexity of the 
pancreatic lymphatic vascular network (Hirono et al., 2012).  In a similar study methylene blue 
dye was injected peri- and intratumorally during pancreatic cancer resection, but the authors 
concluded that detection of patterns of pancreatic lymphatic drainage and sentinel lymph node 
identification were not feasible with this protocol (Kocher et al., 2007).  Another group injected 
activated carbon particles or regular insulin colloid at resection and examined their patterns of 
spread to surgically-removed lymph nodes by histology.  They documented uptake in several 
groups of lymph nodes and recommended new radical resection guidelines based on their 
findings (Nagakawa et al., 1994).  Development and testing of additional lymphatic imaging 
technologies and their adaptation to pancreatic adenocarcinoma patients may make pre-
operative identification of lymph node metastases a reality in the future (Karaman and Detmar, 
2014; Nune et al., 2011; Sevick-Muraca et al., 2014). 
Lymphatic Vessel-Nerve Interactions 
Nerves and vasculature directly interact within the pancreatic microenvironment and can be 
influenced by overlapping signaling pathways in development and disease.  Studies have shown 
that lymphatic vessels (Carlson et al., 1995; Mignini et al., 2012) and lymph nodes (Kayahara et 
al., 2007) are innervated, while dorsal root ganglia (DRGs) are known to be vascularized 
(Jimenez-Andrade et al., 2008).  In the context of malignancy, these connections may represent 
an additional route of metastatic dissemination of tumor cells from either network to the other 
(Cheng et al., 2012; Ishikawa et al., 1988; Jimenez-Andrade et al., 2008; Kayahara et al., 2007).  
Tracts of continuous cancer cells with fingers projecting into perineural spaces and lymphatic 
vessels and lymph nodes have also been described (Kayahara et al., 2007; Suzuki et al., 1994).  It 
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is well documented that vasculature and nerves can respond to the same molecular cues—
termed neurovascular guidance molecules—for development and remodeling (Bouvree et al., 
2012a; Caunt et al., 2008; Fink et al., 2014; Xu et al., 2010; Yang et al., 2010; Zhang et al., 2015), 
and many of these molecules, such as NRP-1 and -2, NGF, brain-derived neurotrophic factor 
(BDNF), FGF, IGF-2, netrin-1, semaphorin-3A, ephrin receptor B4, SLIT2, and ROBO1 may be 
differentially expressed or have altered signaling functions in the pancreatic tumor 
microenvironment, implicating them in cancer progression (Dallas et al., 2008; Fukahi et al., 
2004; Gohrig et al., 2014; He et al., 2013a; Li and Zhao, 2013; Li et al., 2014; Mancino et al., 
2011; Muller et al., 2007; Zhu et al., 1999a).  As well, somatic alterations in axon guidance 
pathway genes are observed in a subset of pancreatic cancer genomes (Biankin et al., 2012).  
Remarkably, Chen, et al., showed that in the absence of both perineural and lymphovascular 
invasion, the five-year survival rate for pancreatic adenocarcinoma patients was 71% (Chen et 
al., 2010).  These studies underscore the importance of both lymphatics and nerves in the 
pancreatic tumor microenvironment and highlight the need for further mechanistic work 
interrogating the specific contributions of these tissue networks to disease progression and 
metastasis.  
Pancreas-Associated Peripheral Nervous System:  Normal Biology and Importance in PDAC  
Nerve Microanatomy 
 Peripheral nerves are complex structures.  The outer layer of a nerve is a tough matrix of 
collagen and elastin fibers known as the epineurium.  The epineurium protects and houses 
several fascicles.  Each fascicle is encased by a layer of endothelial cells called the perineurium 
and contains several bundles of nerve fibers, often myelinated, and their supporting glia 
(Schwann cells).  The highly vascularized matrix within the perineurium and surrounding nerve 
fiber bundles is the endoneurium (Bapat et al., 2011a).  Each bundle of nerve fibers contains 
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several axons projecting away from their parent cell body (residing in the brain, spinal cord, 
ganglion, etc.); efferent and afferent fibers and those of different branches of the nervous 
system (parasympathetic, sympathetic, sensory, etc.) may be contained within a single nerve. 
Pancreatic Innervation 
 Nervous tissue surrounding the pancreas can be divided into six distinct regions 
detectable by MRI or CT:  namely, the aortic, hepatic, splenic, and celiac plexuses, the superior 
mesenteric artery plexus, and the pancreatic head plexus (Zuo et al., 2012b).  From this densely 
innervated peripancreatic region, sensory, sympathetic, and parasympathetic nerve fibers 
extend into the pancreas in nerves often closely associated with blood vessels (Bockman, 2007; 
Christians and Evans, 2009; Fernandez-Cruz et al., 1999). The two primary nerve systems 
innervating the pancreas are splanchnic and vagus; splanchnic nerves comprise efferent 
sympathetic fibers and afferent sensory fibers; vagal nerves comprise parasympathetic efferents 
and sensory afferents.  Initial cell bodies of sympathetic neurons forming connections in the 
splanchnic system reside in the thoracic intermediolateral cell columns of the spinal cord; these 
fibers traverse sympathetic ganglia without synapse and eventually end in celiac plexus ganglia; 
postganglionic sympathetic fibers terminate near cells of intrapancreatic blood vessels, exocrine 
cells, or islets (Bockman, 2007).  Neuronal cell bodies of parasympathetic fibers making up the 
vagus nerve reside in the brainstem; unlike their splanchnic counterparts, these do not 
terminate in the celiac plexus, but rather pass through it and terminate in intrapancreatic 
ganglia; postganglionic fibers then extend out to exocrine cells or islets (Bockman, 2007).  The 
main function of pancreatic nerves is to control secretion of exocrine and endocrine products 
including digestive enzymes and hormones.  Direct connections between gut and pancreas, 
termed the entero-pancreatic axis, also contribute to the intricacy of pancreatic innervation and 
modulate pancreatic secretions (Kirchgessner and Gershon, 1990).  Indirect control of islets due 
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to regulation of blood flow by sympathetic innervation of vascular smooth muscle has also been 
described (Rodriguez-Diaz et al., 2011).  While sensory fibers serve primarily as informers of 
pancreatic damage via transmission of pain signals, sensory responses to tastes and smells, as 
well as detection of glucose levels in blood or duodenum, can induce a change in pancreatic 
secretions (Bockman, 2007).  
Perineural Invasion and Neuroremodeling in PDAC 
Background 
Perineural invasion (PNI) causes intense pain, often precludes curative resection, and 
may provide a mechanism of recurrence following otherwise successful surgery.  A feature of 
several types of cancer, this devastating pathology complicates nearly all PDAC cases (Bapat et 
al., 2011b; Fernandez-Cruz et al., 1999; Sergeant et al., 2009) and contributes to decreased 
patient quality-of-life and reduced overall survival.  As described above, the peripancreatic 
region is densely innervated and the pancreas parenchyma houses intrinsic ganglia.  The term 
perineural invasion encompasses several specific nerve-tumor interactions including the 
following:  presence of tumor immediately adjacent to intra- or extrapancreatic nerve, often 
applying pressure; infiltration of tumor cells into the nerve itself (may be into perineurium, 
epineurium, or endoneurium); or engulfment of peripancreatic nerve plexus or intrinsic ganglia 
by tumor-associated stroma (Farrow et al., 2008) or tumor proper.  Nerves may also be 
recruited into the primary tumor as a result of neurotrophic factor release by tumor and stellate 
cells.  Once inside a nerve, a tumor may extend within this space without invasion back out from 
nerve into adjacent tissue (Pour et al., 2003) or intraneural tumor may be linked to extraneural 
tumor at several places along an invaded nerve or continuous with tumor cells in lymphatics 
(Suzuki et al., 1994).  Studies have characterized patterns of perineural spread from PDAC 
tumors arising in different parts of the pancreas.  Pancreatic head tumors have been shown to 
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travel along the posterior hepatic plexus to the celiac plexus and ganglion, while tumors arising 
in the uncinate process may follow the innervation along the inferior pancreatoduodenal artery 
to the superior mesenteric artery (Yi et al., 2003).  Another study classified tumors according to 
their origins in either dorsal or ventral pancreas based on embryologic pancreatic development; 
dorsal PDAC invaded the common hepatic artery plexus and plexus within the hepatoduodenal 
ligament while ventral carcinoma invaded pancreatic head plexus 1 and 2 and superior 
mesenteric artery plexus (Makino et al., 2008).  Evidence suggests that PNI is an early event in 
the progression of PDAC.  PNI was present in two very small PDAC tumors detected incidentally 
at autopsy (Case 1: 4 x 2 mm; Case 2:  two separate lesions 2.6 x 0.7 mm and 1.2 x 0.5 mm) 
(Kimura et al., 1998) and has been found in samples comprising all stages of PDAC. 
Players and Mechanisms 
PDAC cells and nerves are often described in mutually supportive roles, with each cell 
type expressing receptors/ligands and elaborating factors into the microenvironment that 
support the proliferation, survival, and migration of the opposing cell type.  In vitro work has 
demonstrated the reciprocal benefits of nerve and PDAC co-culture.  T3M4 PDAC cells co-
cultured with rat DRGs or neurons of the myenteric plexus (MP) displayed an elongated 
directional morphology targeted toward neurites prior to cell migration (Ceyhan et al., 2008), 
and MiaPaCa2/mouse DRG co-cultures showed larger PDAC colony size, increased neurite 
extension, enhanced proliferation, increased expression of survival genes MALT1 (mucosa-
associated lymphoid tissue lymphoma translocation protein 1) and TRAF (TNF receptor 
associated factor), and decreased apoptosis (Dai et al., 2007).  Similarly, MP and DRG neurons 
displayed increased neural density and hypertrophy when cultured in the presence of PDAC or 
chronic pancreatitis (CP) tissue extracts or PDAC cell line supernatant (Demir et al., 2010).   
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As with lymphatic-tumor interactions, adhesion proteins play a role in PDAC perineural 
invasion.  Moesin and E-cadherin were significantly associated with PNI, and moesin expression 
in tumors also correlated with higher tumor grade, poor survival, and lymphovascular invasion 
(Torer et al., 2007).  L1 cell adhesion molecule (L1-CAM) correlated with PNI, pain, lymph node 
metastasis, and vascular invasion, and was a negative prognostic factor (Ben et al., 2010).  
Schwann cells surround and support nerve fibers and are responsible for their myelination.  
Myelin-associated glycoprotein (MAG) is expressed by Schwann cells and has been shown to 
bind mucin 1 (MUC1), a mucin overexpressed and aberrantly glycosylated in PDAC (Swanson et 
al., 2007).  Interestingly, the role of NCAM in PNI in PDAC and other cancers is less clear, with 
conflicting reports of its expression and correlation with nerve invasion (Fukuda et al., 2008; 
Kameda et al., 1999; Li et al., 2003; Solares et al., 2009).  CD74 (HLA class II histocompatibility 
antigen gamma chain) has also been identified as a possible contributor to PNI as it is 
overexpressed in PDAC with PNI and in PDAC cell lines with a high propensity for PNI (Koide et 
al., 2006). 
Several studies have demonstrated the importance of the chemokine (C-X3-C motif) 
receptor 1 (CX3CR1) and its sole ligand CX3CL1 (fractalkine) in PDAC PNI.  CX3CR1 is present at 
high levels in PDAC cell lines and patient samples, and its expression is associated with intra- and 
extrapancreatic nerve invasion and tumor recurrence (Marchesi et al., 2008; Marchesi et al., 
2010).  CX3CL1 is present in neural tissue both as a membrane-bound ligand and in a secreted 
form; the secreted protein stimulated PDAC chemotaxis in vitro and PDAC-nerve interactions 
were mediated by the membrane-bound ligand binding its receptor (Marchesi et al., 2008).  
CX3CR1 is important for transendothelial migration of tumor cells (Marchesi et al., 2010) and 
DCs, and CX3CL1 is upregulated and secreted from lymphatics in inflammation, mediating DC 
transendothelial migration (Johnson and Jackson, 2013).  CX3CL1/R1 are also overexpressed in 
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chronic pancreatitis, with highest expression in patients reporting severe pain; this signaling axis 
directs infiltration of inflammatory immune cells into the pancreas parenchyma and 
intrapancreatic nerves and activates supporting glia, implicating it in neuropathic pain (Ceyhan 
et al., 2009c). 
Neurotrophic factors NGF and GDNF (glial cell-derived neurotrophic factor) have well-
documented roles in promoting PDAC PNI and associated pain.  NGF and its primary receptor 
TrkA (NTRK1; neurotrophic tyrosine kinase receptor type 1) are overexpressed in PDAC cells and 
are also present in pancreatic nerves.  Significant differences in expression levels of these 
proteins were not detected among grades or stages of PDAC, but high NGF and TrkA were 
correlated with increased PNI and pain (Zhu et al., 1999b).  NGF, GDNF family member artemin, 
and growth-associated protein 43 (GAP-43) expression levels were increased in PDAC and 
adjacent normal pancreas and associated with neural hypertrophy and density (Ceyhan et al., 
2010). GAP-43 expression has also been linked to increased neural density and hypertrophy in 
CP as well as pain (Ceyhan et al., 2009a).  Gene expression of the primary artemin receptor, 
GFRα3, also correlated with neural hypertrophy (Ceyhan et al., 2010); this study demonstrated a 
field effect in which NGF and artemin induced neural aberrations in areas of the pancreas 
without direct invasion of nerves by tumor.  In addition to its expression in primary tumor, 
artemin has been shown to be overexpressed in metastases, nerves, and blood vessels and to 
promote PDAC invasion along with GFRα3/RET (Proto-oncogene tyrosine protein kinase 
receptor Ret) (Ceyhan et al., 2006).  (GDNF family ligands bind GFRα family receptors; receptor-
ligand complexes bind RET receptor tyrosine kinases to initiate downstream signal transduction 
(Airaksinen et al., 1999)).  GDNF is also overexpressed in PDAC specimens and associated with 
intrapancreatic PNI and pain, while expression of RET has been shown to predict differentiation 
status, post-resection survival, and LVI (Zeng et al., 2008).  In a study interrogating paracrine 
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regulation of PNI by peripheral nerves, GDNF, RET, and GFRα1 were overexpressed in PDAC with 
PNI; GDNF mediated longitudinal PDAC cell migration along nerve in vitro;  PDAC cells 
demonstrated decreased nerve invasion to nerves derived from GDNF+/- mice; and RET inhibition 
with tyrosine kinase inhibitor pyrazolopyrimidine-1 blocked PNI in vivo (Gil et al., 2010).   
Other factors implicated in PDAC PNI include the receptor ligand pair epidermal growth 
factor receptor (EGFR)-TNFα (Bockman et al., 1994), aberrant expression of microtubule-
associated protein MAPRE2 in PDAC and its upregulation in PNI (Abiatari et al., 2009b), and 
upregulation of kinesin family member 14 (KIF14) and rho-GDP dissociation inhibitor beta 
(ARHGDIβ) (Abiatari et al., 2009a). 
Pain 
PDAC patients often suffer from severe pain.  Pancreatic pain is thought to arise from 
two distinct processes—nociception and neuropathy—and may present as visceral pain or 
referred somatic pain.  Sensory nerves transmit nociceptive signals upon activation by noxious 
stimuli within the microenvironment; tissue destruction, inflammatory factors elaborated from 
infiltrating immune cells, and molecules secreted from tumor cells can contribute to stimulation 
of nociception.  Neuropathic pain is caused by damage to nerves themselves; desmoplastic 
stroma associated with PDAC is characterized by increased internal pressure that may damage 
nerves, as can direct invasion of nerves by tumor cells.  Changes in the complement of nerve 
fibers present in nerves supplying the pancreas due to malignancy or inflammation may 
exacerbate pancreatic pain.  One study showed that the number of sympathetic and cholinergic 
nerve fibers in pancreatic nerves, as measured by tyrosine hydroxylase and choline 
acetyltransferase staining, was lower in PDAC and CP, and this change was associated with 
increased patient pain; the authors suggested that a reciprocal increase in sensory nerve fibers 
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may coincide with depletion of sympathetic and cholinergic fibers, thus increasing nociceptive 
capacity (Ceyhan et al., 2009b).  In addition to these intrinsic alterations in nerve fiber bundle 
composition, nerves in PDAC are often present at greater densities within the tissue and display 
hypertrophy, as described above.  Other inflammatory diseases, such as inflammatory bowel 
disease (IBD) are characterized by neuropathic changes such as hypertrophy, hyperplasia, and 
axonal damage (Geboes and Collins, 1998), but these patients do not report the same caliber of 
pain as that experienced by PDAC patients, suggesting that neuroremodeling alone cannot 
explain the pathogenesis of PDAC-associated pain. 
Treatment of PDAC pain has proven challenging.  The location of the celiac plexus as a 
central hub within the pathway of pancreatic innervation has made it a target of pain relief 
techniques.  Celiac plexus blockade (injection of alcohol to destroy nerve tissue) has had limited 
clinical success, likely due to referral of pain to other areas and involvement of nerves synapsing 
in other ganglia.  Opioid pain relievers may offer some palliation, but patients often develop 
tolerance to these medications and become dependent upon ever-increasing doses of 
analgesics, which in turn carry their own sets of undesirable side effects (Inturrisi, 2003). 
PNI and Clinical Outcomes 
As with lymphatics, nerve-specific metrics can be used to predict outcomes in PDAC 
patients.  A retrospective study of 153 resected PDAC patients found an inverse correlation 
between incidence of intrapancreatic PNI and disease-free survival (DFS); tumor stage did not 
predict presence of PNI (Shimada et al., 2011a).  A prospective phase II clinical trial of 110 
resected PDAC patients who received preoperative gemcitabine-based chemoradiation therapy 
identified PNI as the sole predictor of abdominal cavity recurrence, and positive lymph node 
status was the only predictor of distant recurrence; PNI and lymph node involvement were both 
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associated with decreased DFS (Takahashi et al., 2012).  A study of 51 PDAC tumor samples 
found that NGF expression was positively associated with presence and degree (between 
epineurium and endoneurium vs. within endoneurium) of PNI, LN metastasis, and positive 
resection margins; degree of nerve infiltration was also identified as a negative prognostic factor 
and correlated with TrkA expression (Ma et al., 2008).  Finally, a 500+ case study of pancreatic 
nerve alterations and pain found that only PDAC and CP displayed increased nerve density and 
hypertrophy among other pancreatic disease states including serous/mucinous cystadenomas, 
invasive/noninvasive intraductal papillary mucinous neoplasias, benign/malignant 
neuroendocrine tumors, ampullary cancer, and normal pancreas; this study also identified pain 
as a negative prognostic factor in PDAC (Ceyhan et al., 2009a).  MRI and CT imaging have been 
used clinically to detect invaded extrapancreatic neural plexus in patients (Zuo et al., 2012a). 
Perineural invasion has been implicated in local and distant recurrence after resection 
(Fernandez-Cruz et al., 1999; Kayahara et al., 1993; Masui et al., 2013; Shimada et al., 2011b).  
Micrometastatic deposits within nerves may foil an otherwise clean resection, and tumor cells 
may find sanctuary from chemotherapeutic agents in the relatively protected environment of a 
nerve.  In an effort to decrease these effects, it has been suggested that extrapancreatic nerve 
tissue be removed as part of radical pancreatic resection procedures (Fernandez-Cruz et al., 
1999; Kayahara et al., 1991; Kayahara et al., 1993; Masui et al., 2013; Meriggi et al., 2007; Samra 
et al., 2008) 
Other Players in PDAC Microenvironment 
The PDAC microenvironment is arguably one of the most complex of any tumor 
microenvironment, replete with CAFs, immunosuppressive leukocytes, tumor-associated 
blood/lymphatic endothelial networks, nerves, and a considerably dense ECM compartment.  
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Each of these components facilitates PDAC progression and dissemination and has the capacity 
to influence the normal lymphatic vasculature within the pancreas.   
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Figure 1. Pancreatic tumor microenvironment and lymph node metastasis. Cells of the tumor 
microenvironment are essential contributors to tumor growth, perineural invasion, lymphatic 
vessel invasion, and lymph node metastasis. CAFs and TAMs secrete pro-lymphangiogenic 
factors and proteases needed for lymphangiogenesis and metastasis.  Lymphatic vessels act as 
conduits not only for tumor cell metastasis, but also for immunosuppressive cell and cytokine 
transport to lymph nodes.  Mutual tropism between nerves and cancer cells through secreted 
cytokines and direct receptor-ligand interactions instigate perineural invasion, another route of 
pancreatic tumor metastasis.  Vascularization of nerves and innervation of vessels may facilitate 
metastatic spread of tumor cells between these respective networks.  (This figure was 









One of the most striking features of PDAC is the robust desmoplastic reaction seen 
within the primary tumor.  Due to their abundance in the PDAC microenvironment, CAFs exert a 
strong influence over other microenvironmental cell types including the lymphatic endothelium 
(Hanahan and Coussens, 2012).  One of the main protein regulators of desmoplasia in PDAC is 
sonic hedgehog (Shh) (Bailey et al., 2008; Tian et al., 2009).  Bailey, et al. (2009), noted that Shh 
signaling in the CAFs of PDAC tumors led to the creation of a pro-angiogenic and pro-
lymphangiogenic stromal compartment.  When Shh signaling was inhibited in the CAFs, LVD 
decreased and lymph node metastasis was reduced.  Data such as these suggest that CAFs 
primarily influence the lymphatic endothelium via secretion of various effector proteins.  It has 
been demonstrated that CAFs of various tumor types, including PDAC, secrete a wide range of 
pro-lymphangiogenic factors such as VEGF-C, VEGF-D (Duong et al., 2012; Koyama et al., 2008), 
VEGF-A (Mace et al., 2013), epidermal growth factor (EGF) (Dadras, 2013), PDGF, and FGF (Feig 
et al., 2012).  CAFs also secrete chemokines, including CXCL12, which has been shown to 
correlate with increased tumor aggressiveness, LVD values, and lymph node metastases in PDAC 
patient tissues (Cui et al., 2011; Feig et al., 2013).  In addition to their direct action on lymphatic 
endothelia, many of these same secreted factors as well as pro-inflammatory cytokines allow 
CAFs to indirectly support lymphangiogenesis and lymphatic vessel invasion through the 
recruitment of pro-lymphangiogenic immune cells such as TAMs and DCs (Liao et al., 2009; 
Rasanen and Vaheri, 2010).  Lastly, CAFs secrete matrix metalloproteinases (MMPs) and other 
proteases that remodel the ECM of tumors (Kessenbrock et al., 2010).  This remodeling 
promotes tumor invasion of stroma and tumor vasculature and releases sequestered growth 
factors and cytokines from the ECM for tumor growth, angiogenesis, and lymphangiogenesis.  A 
recent study by Shi, et al., highlights an additional protease-related mechanism by which CAFs 
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may influence pancreatic cancer progression and lymphatic metastasis.  Specific pancreatic 
stromal compartment deletion of protease-activated receptor-2 (PAR-2), a GPCR highly 
expressed in PDAC, resulted in decreased primary tumor size (due to anti-angiogenesis effects) 
but increased LVD and lymph node metastases (Shi et al., 2014).   
Immune Cells and Immune Regulation 
One of the main functions of lymphatic vessels is to transport leukocytes to lymph 
nodes for immune response initiation, uniquely positioning LECs to modulate immune responses 
in ways that may support tumor progression.  As immune cell trafficking conduits, LECs are 
responsible for the transport of both antigens and antigen presenting cells, such as DCs, to the 
lymph nodes for immune response optimization (Tal et al., 2011).  By regulating the expression 
and secretion of various chemokines in response to inflammation, injury, or tumor 
development, LECs can alter the recruitment of immune cells to the lymph nodes, and, as a 
result, influence the ensuing immune response (reviewed in (Aebischer et al., 2014; Liao and von 
der Weid, 2015)).  Partially due to lymphatic-directed recruitment, tumor-draining lymph nodes 
demonstrate a more immunosuppressive environment as compared to normal lymph nodes 
with an increased presence of regulatory T cells (Tregs), myeloid-derived suppressor cells 
(MDSCs), immature and tolerogenic DCs, and immunosuppressive cytokines (Inman et al., 2014; 
Munn and Mellor, 2006; Podgrabinska et al., 2009; Shields et al., 2010).  These 
immunosuppressive cells and cytokines accumulate in the lymph as a result of increased 
lymphatic drainage from the tumor site (Harrell et al., 2007).  Within the lymph nodes TGF-β, a 
major driver of immune suppression, supports the differentiation and activation of Tregs as well 
as promoting tolerogenic and immature phenotypes of DCs (Ghiringhelli et al., 2005).  As Tregs 
differentiate and accumulate, they secrete more TGF-β to further drive immune suppression. 
Interleukin-10 (IL-10) is another factor that supports the accumulation of immunosuppressive 
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cells in the lymph nodes by promoting Treg activity (Seo et al., 2001b) and tolerogenic DC 
function (De Smedt et al., 1997; Seo et al., 2001b).  Indoleamine 2,3-dioxygenase increases the 
generation of Tregs in the lymph nodes (Fallarino et al., 2006; Munn and Mellor, 2007), while 
concurrently inhibiting effector T cell activity (Munn et al., 2005).  Other factors implicated in 
the accumulation of immunosuppressive cells in lymph nodes include interleukin-4 (IL-4), VEGF-
A, and prostaglandin E2 (Kim et al., 2006).  
In addition to cellular and cytokine transport, LECs also transport tissue antigens (and in 
the case of cancer, tumor antigens) from peripheral tissues to lymph nodes.  Studies have 
demonstrated that LECs, particularly those in the lymph nodes, are capable of scavenging these 
tissue and tumor antigens and cross-presenting them on major histocompatibility complex-I 
(MHC-I) (Hirosue et al., 2014; Lund et al., 2012).  This can lead to immune tolerance through 
deletion of naive CD8+ T cells as LECs lack co-stimulatory molecules needed to activate the T 
cells and instead express programmed death-ligand 1 (PD-L1), an inhibitory signal for T cells 
(Tewalt et al., 2012).  LECs can also present scavenged exogenous tissue/tumor antigens on 
MHC-II molecules and likely induce immune tolerance through interactions with the inhibitory 
lymphocyte activation gene-3 (LAG-3) protein on CD8+ T cells (Rouhani et al., 2015).  These 
studies shed light on the phenomenon that when tumor cells are denied lymphatic vessel 
experience, such as through direct implantation into lymph nodes, tumor immunity is impaired 
through a robust CD8+ T cell response (Preynat-Seauve et al., 2007).  LECs also modulate 
immune responses by inhibiting DC maturation (Podgrabinska et al., 2009).  Binding of DCs to 
the lymphatic endothelium via macrophage-1 antigen (Mac-1) and ICAM-1-mediated 
interactions during transendothelial migration can reduce the expression of co-stimulatory 
molecules on DCs needed for T cell activation.  Studies such as these inspire new ideas regarding 
increased lymphangiogenesis at the tumor periphery and draining lymph nodes, suggesting that 
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it may influence tumor progression in two ways:  1) increasing metastatic routes for 
dissemination and 2) immune suppression through increased antigen scavenging and decreased 
DC maturation leading to T cell inhibition and immune tolerance (Swartz, 2014).  Further 
investigation is needed to substantiate the immunosuppressive properties of the lymphatic 
endothelium and its specific contribution to disease progression as a component of the tumor 
microenvironment.  
A reciprocal concept in relation to the capacity of LECs to affect immunity is that of 
immune cells inducing effects on LECs.  One such tumor infiltrating immune cell type, TAMs, can 
be found in many tumor microenvironments, including PDAC (Condeelis and Pollard, 2006; 
Kurahara et al., 2013; Leek and Harris, 2002; Schoppmann et al., 2002), and their presence often 
correlates with poor patient prognosis (Jung et al., 2015; Kurahara et al., 2011; Sugimura et al., 
2015; Yuan et al., 2014).  TAMs promote tumor lymphangiogenesis through two mechanisms:  
paracrine secretion of pro-lymphangiogenic factors and transdifferentiation into LEC-like 
progenitor cells.  TAMs secrete high levels of VEGF-C and -D, which, in turn, increases LVD in and 
around tumors (Kurahara et al., 2013; Schoppmann et al., 2002; Schoppmann et al., 2006; Wu et 
al., 2012).  Indeed, TAM density has been shown to significantly correlate with increased LVD, 
lymphatic vessel invasion, and lymph node metastasis in many cancers (Ding et al., 2012; 
Kurahara et al., 2013; Schoppmann et al., 2006; Storr et al., 2012; Zhang et al., 2011).  Inhibition 
or depletion of TAMs from tumor microenvironments significantly reduced LVD values and 
decreased the incidence of lymph node metastases compared to tumors with TAMs present 
(Fischer et al., 2007; Yang et al., 2011b; Zumsteg et al., 2009).  However, depletion of TAMs did 
not completely inhibit lymph node metastasis as tumor cells were still able to invade pre-
existing lymphatic vessels.  These macrophages also secrete proteases such as MMP-2, MMP-9, 
and plasmin/urokinase plasminogen activator (uPA) that remodel the extracellular 
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microenvironment and release sequestered growth factors for lymphangiogenesis (Marconi et 
al., 2008; Ran and Montgomery, 2012).  The plasmin/uPA system is also important for the 
proteolytic maturation of VEGF-C and -D increasing their affinity for VEGFR-3 (McColl et al., 
2003).  It has yet to be determined if TAMs secrete any of the other factors known to promote 
lymphangiogenesis.  The second way TAMs contribute to lymphangiogenesis is by 
transdifferentiating into LEC-like progenitors both in inflammatory and tumor settings (Hall et 
al., 2012; Hunter et al., 2014; Schledzewski et al., 2006; Zumsteg et al., 2009).  
Transdifferentiated macrophages undergo genetic reprogramming (Hall et al., 2012) with 
increased expression of lymphatic markers Lyve-1, Prox-1, podoplanin, and VEGFR-3 (Hall et al., 
2012; Lee et al., 2010; Maruyama et al., 2005; Zumsteg et al., 2009).  Expression of LEC markers 
enables TAMs to physically incorporate into the newly developing lymphatic vasculature.  The 
percentage of transdifferentiated TAMs within these newly formed lymphatic vessels is often 
less than 10% (Lee et al., 2010; Zumsteg et al., 2009) suggesting the main mechanism by which 
TAMs promote tumor-associated lymphangiogenesis is through secretion of pro-
lymphangiogenic factors.  
Another Inflammation-Associated Paraneoplastic Effect of PDAC:  Cancer-Associated Cachexia 
Considerations of cancer often focus on the direct effects of primary tumor and 
metastatic deposits on involved organs.  However, cancer often results in systemic 
consequences beyond those directly attributable to compromised organ function.  One such 
paraneoplastic syndrome is cancer-associated cachexia.  Cancer cachexia negatively affects 
patient quality-of-life, decreases the efficacy of anti-tumor therapies either directly or by 
reducing patient tolerance for taxing treatment regimens, and may be responsible for shortened 
survival.  Cachexia has been assigned both causal and complicating roles in its status as a cancer 
comorbidity (Muscaritoli et al., 2015).  An international expert panel recently released a 
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consensus definition of cancer cachexia stating, “Cancer cachexia [is] a multifactorial syndrome 
defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot 
be fully reversed by conventional nutritional support and leads to progressive functional 
impairment” (Fearon et al., 2011).  The nature of cachexia as a progressive disease, beginning 
with understated and possibly reversible pre-cachexia symptoms and gradually advancing to a 
severe refractive state requiring specialized individual patient care is well recognized; although 
specific criteria for patient stratification differ among groups (Baracos, 2011; Fearon et al., 2011; 
Johns et al., 2014; Martin et al., 2015).  Cachexia has also been described as a disorder of 
metabolic flux (Penet et al., 2011), with decreased appetite, anorexia, and early satiety 
contributing to decreased nutritional intake, while increased proteolysis, lipolysis, and altered 
carbohydrate metabolism promote an imbalance in anabolic and catabolic processes and 
increased resting energy expenditure (Argiles et al., 2014; Baracos, 2011); together these 
processes result in net weight loss, decreased skeletal muscle mass, weakness, fatigue, and 
overall decreased patient quality-of-life.   
PDAC patients as a population are highly susceptible to cachexia.  Cancer cachexia has 
been estimated to affect over 80% of pancreatic cancer patients and to directly contribute to 
20% of cancer-related deaths (Argiles et al., 2014).  PDAC patients with muscle loss after 
treatment displayed decreased survival compared to patients with stable muscle mass or muscle 
gain (Fogelman et al., 2014).  Cachexia is also linked to disruption of the glucose-insulin axis 
often manifested in PDAC by the onset of type II diabetes mellitus.  Glucose intolerance and 
insulin resistance may be implicated in loss of muscle mass in cancer-associated cachexia (Asp et 
al., 2010) (Reviewed in (Honors and Kinzig, 2012)).  Treatment of C26 colon tumor-bearing mice 
with rosiglitazone ameliorated insulin resistance and began to reverse cachexia (Asp et al., 
2010).  Additionally, a large retrospective analysis of PDAC cases and controls has documented 
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an inverse relationship between fasting blood glucose (FBG) and body mass index (BMI) in the 
twelve months preceding PDAC diagnosis (Pannala et al., 2009) suggesting potential utility in 
early disease detection.  Glucose neurotoxicity is also linked to repeated or persistent 
hyperglycemia, as is the case in diabetic neuropathy (Reviewed in (Tomlinson and Gardiner, 
2008)).  High FBG is also significantly associated with increased PNI, neural density, NGF and 
receptor p75NTR (p75 neurotrophin receptor) expression, and PDAC death rates (Li et al., 2011a).  
Of special relevance to the present work are the contributions of perineural invasion 
and inflammation to cancer-associated cachexia.  Inflammation is consistently ranked among 
the most important driving forces behind the development and progression of cancer cachexia 
(von Haehling and Anker, 2014) and has been placed with weight loss as one of the defining 
features of this syndrome (Argiles et al., 2014).  Circulating factors secreted from tumor cells, 
supporting stromal cells, and activated immune cells in the tumor microenvironment contribute 
to the development of a systemic inflammatory profile.  Serum from PDAC patients or tumor-
bearing, but not tumor-resected, mice induced NFκB and downstream effector paired box 7 
(Pax7) to promote muscle wasting (He et al., 2013b).  Cachexia has been correlated with altered 
immune cell infiltrates in gastrointestinal tumors and increased levels of chemokines and 
inflammatory cytokines in tumor and adipose tissue compared to weight-stable cancer patients 
(de Matos-Neto et al., 2015).  NGF has been implicated in driving this process as well.  A unifying 
study by Ye and colleagues has suggested that NGF is a key regulator of tumor-associated 
inflammation and has shown that oral tumor progression, pain, and cachexia can all be 
ameliorated by NGF inhibition (Ye et al., 2011).  Interest is rising in the possible connection 
between perineural invasion and PDAC-associated cachexia with a recent study of PDAC patients 
and in a mouse model of PDAC PNI showing that PNI drives astrocyte activation resulting in 
decreased BMI and cachexia (Imoto et al., 2012).   
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Diagnosis of cachexia—particularly that associated with cancer—remains clinically 
challenging, and new approaches are needed for its recognition and management (Muscaritoli 
et al., 2015).  Rising obesity rates in the general populace and among cancer patients complicate 
detection.  Loss of skeletal muscle mass may be masked by subcutaneous and visceral fat 
deposits, and establishing the etiology and threshold percentage of clinically significant 
involuntary weight loss may be difficult in overweight or obese patients (Martin et al., 2013a).  A 
new use of routine abdominal CT scans originally ordered for PDAC diagnosis and staging is 
opening the door to objective determination of cachexia status.  Lumbar skeletal muscle index 
can be derived from CT imaging and used to detect occult muscle wasting masked by obesity to 
determine cachexia status independently of BMI (Martin et al., 2013a; Tan et al., 2009).  
Summary and Points Addressed 
 Nerves and lymphatic vessels are two tissue networks that both participate in and are 
influenced by changes in a microenvironmental tissue milieu.  The specific phenotypic and 
functional alterations of these networks and their regulation in acute inflammation, wound 
recovery, recurrent inflammation, and tumor-associated inflammation are not well defined.  We 
studied these changes in cornea and skin of mice under the described inflammatory states and 
in the context of melanoma or PDAC tumor microenvironments.  The involvement of lymphatics 
and nerves in PDAC disease progression is well established; presence of lymph node metastasis 
or perineural invasion negatively affects prognosis.  Another inflammation-related component 
of PDAC with negative implications for patient survival is the common co-morbidity cancer-
associated cachexia.  We aimed to address understudied areas of inflammation and PDAC 
biology, and the subsequent chapters detail our studies of the following points: (1) 
neurolymphatic remodeling during transitions between tissue microenvironmental states and a 
novel wound recovery-associated nerve phenotype, (2) connections between the lymphatic 
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vasculature and the peripheral nervous system and the regulation of neurolymphatic 
remodeling by the canonical nerve survival and patterning factor NGF, (3) distinctions in 
inflammation- and cancer-associated neurolymphatic remodeling identified through use of a 
novel live-imaging fluorescent mouse platform and implications of these neurolymphatic 
architecture signatures for PDAC detection and treatment, and (4) gene expression profiling of 








CHAPTER I.  Nerve Growth Factor Regulates 
Neurolymphatic Remodeling during Corneal 
Inflammation and Resolution2 
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Acute inflammation commonly results in either wound recovery or the development of 
a chronic inflammatory reaction.  The biologic mechanisms that direct these outcomes are not 
well understood, despite the negative clinical implications of chronic inflammation.  The concept 
that wound recovery and the resolution of inflammation are passive processes has been 
challenged by evidence that active processes trigger a switch from pro- to anti-inflammatory 
mediators in the tissue microenvironment that in turn resolve inflammation (Serhan and Savill, 
2005; Serhan et al., 2007; Serhan et al., 2008).   
Networks of nerves, blood vasculature, and lymphatic endothelia are strikingly similar in 
their anatomical organization and location.  Nerves and vasculature respond to overlapping or 
complementary environmental cues to direct their developmental patterning and maintenance 
(Adams and Eichmann, 2010; Bouvree et al., 2012b; Chauvet et al., 2013; Gelfand et al., 2009; 
Larrivee et al., 2009; Melani and Weinstein, 2010).  Signals elaborated by cells of one network 
may influence the behavior of cells in an adjacent network (Mukouyama et al., 2002).  There is 
evidence for shared neurovascular guidance pathways in conditions of tissue disruption, such as 
neurodegenerative disease or malignancy (Buchler et al., 2005; Entschladen et al., 2006; 
Entschladen et al., 2008; Quaegebeur et al., 2011).   
We hypothesized that common mechanisms regulated neurolymphatic remodeling 
during inflammation and wound recovery.   A corneal model of initial inflammation, wound 
recovery, and recurrent inflammation was developed to investigate mechanisms that regulate 
the structure and function of sensory nerves and lymphatic vessels, as these systems influence 
pain and swelling during the resolution of inflammation.  Accessibility and the neurovascular 
features unique to the cornea make it an ideal system in which to examine neurolymphatic 
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architecture and function during an inflammatory episode and wound recovery.  The cornea is 
densely innervated (Belmonte et al., 2004; McKenna and Lwigale, 2011; Muller et al., 2003; 
ZANDER and WEDDELL, 1951), primarily with sensory nerves derived from the ophthalmic 
branch of the trigeminal nerve (Marfurt et al., 1989).  Sympathetic nerves, from the superior 
cervical ganglion (Marfurt et al., 1989), and parasympathetic nerves, from the main and 
accessory ciliary ganglia (Marfurt et al., 1998) are less common.  During homeostasis, the 
corneal vasculature is limited to a peri-corneal limbal arcade.  Angiogenesis and 
lymphangiogenesis from the limbus can be stimulated experimentally using suture-induced 
inflammation (Kelley et al., 2011b; Kelley et al., 2013b).  In this work corneal sutures were used 
to induce initial inflammation; suture removal stimulated wound recovery; and replacement of 
corneal sutures induced recurrent inflammation.   
Examination of several candidate neurovascular guidance molecules for mRNA 
expression during initial inflammation, wound recovery, and recurrent inflammation in the 
cornea revealed that NGF gene expression was tightly correlated with these distinct physiologic 
states.  We therefore examined the contribution of NGF to alterations in lymphatic vasculature 
and neural structures during wound recovery.  We also evaluated pain—a clinically-relevant 
physiological measurement.  
These results reveal the capacity of NGF to inhibit neurolymphatic remodeling and the 
resolution of pain during wound recovery.  We show for the first time that NGF can induce 
lymphangiogenesis as an upstream driver of a hierarchical signaling pathway in which VEGF 
family members are downstream effectors.  These findings implicate NGF as a pathogenic factor 




Materials and Methods 
Mice 
All experimental procedures were approved by the Institutional Animal Care and Use 
Committees of Boys Town National Research Hospital and the University of Nebraska Medical 
Center in accordance with NIH guidelines.  Experiments were carried out in six- to ten-week-old 
female 129S2/SvPasCrl mice purchased from Charles River Laboratories (Wilmington, MA).   
Corneal Surgical Procedures 
Prior to all surgical procedures, mice were anesthetized by intraperitoneal 
administration of a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg).  Mice were 
euthanized by ketamine/xylazine overdose or by CO2 asphyxiation and cervical dislocation. 
 The corneal model of initial inflammation, wound recovery, and recurrent inflammation 
was described previously, as were the injection techniques for VEGFR-2/3 decoy receptors 
(Kelley et al., 2013b). 
Administration of NGF during Wound Recovery 
2.5S NGF (B.5017, Harlan Laboratories, Indianapolis, IN) was resuspended at 100 μg/mL 
in phosphate-buffered saline (PBS), pH 7.4.  Approximately 10 μL of suspension was delivered 
per subconjunctival injection with a 33 gauge needle.   
Micropellet Preparation and Micropocket Assay Procedures 
A 4 mm2 nylon mesh was used to mold a mixture of 12% (w/w) poly(2-hydroxyethyl 
methacrylate) (192066-10G, Sigma-Aldrich, St. Louis, MO) solution in 95% ethanol, sucrose 
octasulfate-aluminum complex (S0652-1G, Sigma-Aldrich), and cytokine into micropellets 
measuring approximately 305 μm x 305 μm x 460 μm.  Experimental micropellets contained 
approximately 200 ng of carrier-free recombinant mouse β-NGF (1156-NG-100/CF, R&D 
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Systems), recombinant human VEGF-C, CF (2179-VC-025/CF, R&D Systems), or PBS only.  A 20 or 
27 gauge needle was used to create a pocket in the center of the cornea, and a fine forceps was 
used to place a pellet under the corneal flap.   
Immunofluorescence Imaging of Whole Mount Corneas and Axial Sections and Data Collection 
Dissection and Staining 
Globes were enucleated and fixed in 1% paraformaldehyde (PFA) in PBS, pH 7.4, for one 
hour.  Corneas were dissected out and either hemi-sectioned or slit at each quadrant with a 
small incision.  Fixation was repeated for one hour.   Corneas were blocked and permeabilized in 
a sterile-filtered PBS, pH 7.4, solution containing 5.2% BSA, 0.3% Triton X-100, and 0.2% NaN3 
(blocking solution) for one hour shaking at room temperature.  Primary antibodies were diluted 
in blocking solution and applied to corneas overnight shaking at room temperature.  Corneas 
were washed in a sterile-filtered PBS, pH 7.4, solution containing 0.2% BSA, 0.3% Triton X-100, 
and 0.2% NaN3 (wash buffer) three times for one hour shaking at room temperature.  Secondary 
antibodies were diluted in blocking solution and applied to the corneas overnight shaking at 
room temperature.  After three one-hour washes in wash buffer, corneas were mounted on 
glass microscope slides with mounting medium containing DAPI and stored at 4°C.  Primary 
antibodies: pRb α-Ms β-III tubulin (ab18207, Abcam, Cambridge, MA), mRt α-Ms Lyve-1 (sc-
65647, Santa Cruz Biotechnology, Santa Cruz, CA), ArmHms α-Ms CD-31 (MAB1398Z, EMD 
Millipore, Billerica, MA), Rt α-Ms phospho-histone H3 (H9908, Sigma-Aldrich, St. Louis, MO).  
Secondary antibodies: 488 Dky α-Rb IgG (AlexaFluor A21206, Life Technologies, Carlsbad, CA), 
488 Dky α-Rt IgG (AlexaFluor A21208, Life Technologies), 549 Dky α-Rt IgG (DyLight 712-505-
150, Jackson ImmunoResearch Laboratories, West Grove, PA), 649 Gt α-ArmHms IgG (DyLight 
127-495-160, Jackson ImmunoResearch Laboratories).  
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Whole Mount Imaging 
Whole mount corneas were visualized on a Zeiss Axio A.1 epifluorescence microscope or 
a Leica stereoscope.  100X epifluorescence images were obtained using SPOT Advanced 
software (SPOT Imaging Solutions, Sterling Heights, MI).  32X stereofluorescence images were 
obtained using Leica Application Suite software (Leica Microsystems, Inc., Buffalo Grove, IL).  
200X and 400X z-stacks were obtained using a Zeiss 510META confocal microscope (Carl Zeiss 
AG, Oberkochen, Germany).  Images were compiled and analyzed using ZEN 2009, BioImageXD 
(Kankaanpaa et al., 2012) and ImageJ (Schneider et al., 2012) software packages. 
Quantification of Corneal Nerve Density 
Epifluorescence images were color-inverted and overlaid with a 25,000 pixels2 grid with 
random offset using ImageJ.  Portions of the grid lying outside of or overlapping the limbal 
arcade were excluded from the analysis.  β-III tubulin+ nerves intersecting grid line segments 
were manually counted in the X and Y directions.  To derive density from counted intersections, 
raw data were normalized to the number of grid squares counted in each image.  Both intact 
and hemisected whole mount corneas were included in the analysis.   
Corneal wound bed nerve density was derived by using ImageJ to superimpose a grid 
over β-III tubulin immunofluorescence photomicrographs.  A line was drawn around each 
wound bed and the area measured using ImageJ.  Nerves intersecting gridlines within the 
wound bed area were quantified and counts normalized to wound bed area. 
Quantification of Corneal Nerve Clusters 
Corneal nerve clusters were defined as tortuous nerve endings organized in a clustered 
pattern originating from a single larger nerve and extending in three dimensions.  Clusters were 
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identified and counted manually from epifluorescence images of intact and hemisected corneal 
whole mounts. 
Quantification of Nerve Density at Micropellet 
Epifluorescence or confocal images were overlaid with a 3,000 pixels2 grid with random 
offset using ImageJ.  Portions of the grid lying outside of the pellet were excluded from the 
analysis.  β-III tubulin+ nerves intersecting grid line segments were manually counted.  To derive 
density from counted intersections, raw data were normalized to the number of grid squares 
counted in each image. 
Quantification of Lymphatic Vessel Density and Length 
Epi- or stereofluorescence micrographs were imported into ImageJ and overlaid with a 
0.02 inches2 grid with random offset.  To determine lymphatic vessel density, grid squares 
displaying Lyve-1+ fluorescent signal were quantified using the Cell Counter feature of the 
ImageJ software.  Grid squares intersecting the limbal arcade were excluded from the 
quantification.  To quantify lymphatic vessel length, the ImageJ Freehand Line tool was used to 
trace along the length from origin at the limbus to tip of every-other Lyve-1+ lymphatic vessel in 
stereofluorescence micrographs and the length of each line measured using the ImageJ Measure 
feature. 
Quantification of Lymphatic Vessel Fragments 
A lymphatic vessel fragment was defined as a group of Lyve-1+ lymphatic endothelial 
cells present in the cornea that was no longer continuous with vessels sprouted from the limbal 
lymphatic vessel.  Following exogenous administration of NGF or PBS during wound recovery, 
Lyve-1 immunostained corneas were analyzed by epifluorescence microscopy.  The number of 
lymphatic vessel fragments per cornea was counted manually. 
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Quantification of Average Remaining Wound Size 
Light stereofluorescence micrographs were imported into ImageJ and the Freehand Line 
and Measure Area tools were used to trace around each of the four wound beds in each image 
and to quantify the areas.  The area of each wound bed was treated as an individual n in further 
analyses. 
Aesthesiometry 
A Luneau Cochet-Bonnet aesthesiometer (Ophthalmic Instrument Co., Inc., Stoughton, 
MA) was used to measure corneal sensitivity.  The nylon monofilament of the aesthesiometer 
was extended to its full length of 6.0 cm and touched to the corneal surface until first visible 
bending.  Monofilament length was decreased by 0.5 cm increments and touched to the cornea 
again until a blink response was elicited from the animal.  If an animal held its eye closed so as 
to prevent measurement, we assigned a reading of “7.0”.   
In Vitro and Biochemical Assays 
RNA Isolation, cDNA Library Construction, and qRT-PCR Characterization of Expression of 
Neurovascular Guidance Genes and NGF Receptors Genes 
Total RNA was isolated from mouse cornea, uninvolved human skeletal muscle obtained 
at rapid autopsy from pancreatic cancer patients, and adult human dermal lymphatic 
endothelial cells (Lonza, Walkersville, MD) by TRIzol (Life Technologies, Carlsbad, CA) or the 
RNeasy Mini Kit (Qiagen, Venlo, Netherlands) according to the manufacturers’ instructions.  10 
μL linear acrylamide (AM9520, 5 mg/mL, Life Technologies) was added to each corneal sample 
as a carrier prior to RNA isolation.  cDNA libraries were prepared using the SuperScript III First-
Strand Synthesis System (18080051, Life Technologies).  Mouse qRT-PCR reactions were 
performed in triplicate and assayed on the Applied BioSystems StepOnePlus Real-Time PCR 
System (Life Technologies).  Expression was normalized to GAPDH.  Data was analyzed using the 
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ΔΔCt method.  Gene expression levels in unmanipulated samples were set at 1.0.  Target gene 
expression levels in other tissue conditions are expressed as fold change relative to 
unmanipulated control levels. 
TaqMan Gene Expression Assays used for mouse qRT-PCR experiments:  GAPDH - 
4352339E, NGF - Mm00443039_m1, MMP10 - Mm00444630_m1, IL1-α - Mm00439620_m1, 
BDNF - Mm04230607_s1, Ntf3 - Mm00435413_s1, Nrp1 - Mm00435379_m1, Nrp2 - 
Mm00803099_m1, Sema3e - Mm00441305_m1, Plxnd1 - Mm01184367_m1, Ntn1 - 
Mm00500896_m1, Ntn4 - Mm00480462_m1, Unc5b - Mm00504054_m1, Slit2 - 
Mm00662153_m1, Robo4 - Mm00452963_m1, Robo1 - Mm00803879_m1, Efnb2 - 
Mm01215897_m1, Ephb4 - Mm01201157_m1, Notch1 - Mm00435249_m1, Cdk5 - 
Mm00432447_g1, FGF2 – Mm00433287_m1, Vegfa - Mm01281449_m1, Vegfc - 
Mm00437310_m1, Vegfd - Mm00438963_m1 (Life Technologies, Carlsbad, CA).   
Human qRT-PCR reactions were performed in triplicate and analyzed on a BioRad C1000 
Thermal Cycler CFX96instrument (Bio-Rad Laboratories, Inc., Hercules, CA).  TaqMan Gene 
Expression Assays used for human qRT-PCR experiments:  TBP - Hs00427521_m1, NTRK1 - 
Hs01021011_m1, NGFR - Hs00609977_m1 (Life Technologies).  Expression was normalized to 
TATA box binding protein (TBP).   Data was analyzed using the ΔΔCt method.  Average skeletal 
muscle expression levels of NTRK1 and NGFR were set at 1.0.  Average receptor gene expression 
levels in LEC samples were expressed as fold change relative to skeletal muscle levels.  Ct values 




Lymphatic Endothelial Cell Culture 
Adult human dermal lymphatic endothelial cells (LECs) were purchased from Lonza 
(Walkersville, MD) and cultured to the company’s specifications.  Media used to culture LECs 
was Endothelial Growth Media-2MV supplemented with recommended growth factors (EGM-
2MV).  For serum starvation Endothelial Basal Media-2 (EBM-2) was used.  
NGF and LEC Migration Assays 
Lower wells of 24-well (8.0 μm pore membrane) Boyden chambers (BD Biosciences, San 
Jose, CA) were loaded with 750 μL EGM-2MV media diluted 1:5 with serum-free EBM-2 and 
supplemented with increasing doses of  recombinant mouse NGF (0, 0.5, 1.0, 5.0 μg/ml).  2.5 x 
104 LECs diluted in EBM-2 were seeded into the upper inserts of the Boyden chamber and 
incubated for 24 hours.  After 24 hour migration, membranes were washed with PBS and non-
migratory cells were removed by mechanical force with a cotton-tipped applicator.  Cells were 
then fixed and stained using Differential Quik Staining Kit (Polysciences, Inc., Warrington, PA).  
Membranes were removed from the inserts and mounted on slides.  A Nikon Eclipse 90i 
microscope at 10X magnification was used to image four representative quadrants of the 
membrane and the number of migratory LECs was quantified.  
Treatment of LECs with Cytokines 
1.5 x 105 LECs were seeded into 60 x 15 mm tissue culture plates and allowed to adhere 
overnight.  Cells were then starved for 16 hours in EBM-2.  Following starvation, LECs were 
treated with either fresh EBM-2 or with EBM-2 containing either 4 μg/ml recombinant NGF or 
0.5 μg/ml recombinant VEGF-C for 1, 5, 15, or 30 minutes.  Cells were then washed twice with 
PBS and lysates collected with a radioimmunoprecipitation assay (RIPA) lysis buffer (150 mM 
sodium chloride, 1% IGEPAL, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 50 
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mM Tris buffer) containing a Roche mini PMSF tablet and phosphatase inhibitors  sodium 
fluoride, sodium pyrophosphate, and sodium orthovanadate all at 1 mM.  
Immunoblotting 
Lysates were prepared in RIPA buffer or RayBiotech Cell Lysis Buffer (RayBiotech, Inc., 
Norcross, GA) and were incubated with 4X SDS sample buffer and 2-mercaptoethanol and run 
on NuPAGE 10% Bis-Tris gels at 150 V for 75 minutes using the XCell SureLock Mini Cell 
electrophoresis system (Life Technologies, Carlsbad, CA).  Transfer was accomplished using the 
Mini Trans-Blot Electrophoretic Transfer Cell (BioRad Laboratories, Inc., Hercules, CA) at 100 V 
for 75 minutes onto Immobilon-FL or Immobilon-P polyvinylidene fluoride (PVDF) membranes 
(EMD Millipore, Billerica, MA).  Blots were blocked overnight shaking at 4°C in 5% BSA in PBS 
with 1X Halt Protease & Phosphatase Inhibitor Cocktail and ethylenediaminetetraacetic acid 
(EDTA) (Thermo Scientific, Rockford, IL) or in 5% non-fat dehydrated milk (NFDM) in tris-
buffered saline (TBS) containing 0.1% Tween-20 (TBS-T).  Primary antibodies were incubated in 
0.1% Tween in PBS (PBS-T) + 2.5% BSA or in TBS-T + 5% NFDM for 1 to 3.5 hours shaking at room 
temperature.  Blots were washed three times for 15 minutes in PBS-T or TBS-T.  Secondary 
antibodies were incubated in PBS-T + 2.5% BSA or TBS-T + 5% NFDM for 45 minutes to one hour 
shaking at room temperature.  Blots were washed three times for 15 minutes in PBS-T + 0.01% 
SDS or in TBS-T followed by a one minute wash in ddH2O.  Blots were imaged using the LI-COR 
Odyssey fluorescence imaging system and software (Lincoln, NE) or were incubated with 
chemiluminescence reagents and x-ray film developed with a Kodak X-OMAT 2000 processor. 
Tubulogenesis Assays 
Wells of a 96-well plate were coated with Matrigel Basement Membrane Matrix (BD 
Biosciences, Bedford, MA) according to manufacturer's specifications for growth in a three 
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dimensional matrix.  LECs were incubated with increasing doses of recombinant human NGF, 
VEGF-C, or a combination of NGF and VEGF-C diluted in EBM-2 as indicated for 30 minutes at 
4°C and then added to Matrigel-coated wells (1.2 x 104 LECs/well).  After four hours, LECs had 
formed tube-like networks and phase contrast images were collected.  Tubulogenesis was 
quantified by counting the number of tubes per image.  Each treatment was performed in 
triplicate.  
NGF ELISA 
Levels of NGF protein in unmanipulated and inflamed corneas were assayed by enzyme-
linked immunosorbent assay (ELISA) using the Mouse NGF/β-NGF ELISA Kit (EK0470, Boster 
Biotechnology Co., Ltd., Pleasanton, CA) according to the manufacturer’s instructions.  Individual 
corneal lysates were prepared in RayBiotech Cell Lysis Buffer (RayBiotech, Inc., Norcross, GA), 
homogenized with a plastic pestle homogenizer, and cleared by centrifugation.  Each sample 
was divided 90/10 into two wells of the ELISA plate and diluted accordingly with sample buffer.  
Right corneas from three animals made up each group.  Optical density (OD) absorbance 
readings were measured in triplicate using a Titertek Multiskan PLUS plate reader. 
VEGF-A Protein Quantification 
Levels of VEGF-A protein were quantified in corneas bearing either a PBS or NGF pellet.  
We performed a corneal pocket assay and prepared lysates as described above.  Lysates from 
two corneas were combined to make up each sample.  Six corneas comprised each group.  
VEGF-A content was assayed using the Quantibody Mouse Cytokine Array 1 (RayBiotech, Inc., 
Norcross, GA).  The array was scanned using the GenePix 4000B (Molecular Devices (Axon 
Instruments), Silicon Valley, CA) and data was collected using the GenePix Pro software at 
several PMT values ranging from 540 to 790 gain.  The PMT gain 590 scan generated the best 
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VEGF-A standard curve and data from this scan was analyzed using the Q-Analyzer Software for 
QAM-CYT-1 (RayBiotech, Inc.).   
Statistical Analysis 
Data were analyzed with GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, 
CA) using Student’s T-Test or One-Way ANOVA with Dunnett’s Multiple Comparison Post-Test or 
Bonferroni Post-Test.  An asterisk (*) denotes the control group.  A bracket between the control 
and experimental groups indicates statistical significance with p < 0.05.  In cases comparing two 






Characterization of Neural and Lymphatic Remodeling in a Corneal Model of Inflammation and 
Resolution 
We characterized structural and architectural changes in corneal lymphatic vessels and 
nerves through four distinct physiological conditions: healthy unmanipulated cornea, initial 
inflammation, wound recovery, and recurrent inflammation (Figure 2A).  In this model system, 
inflammation was induced by placement of a suture in each quadrant of the mouse cornea.  
Suture removal stimulated wound recovery.  Recurrent inflammation was induced by placement 
of a second set of four sutures.  DAPI-stained corneal axial sections demonstrated gross 
thickening of the visibly-wounded cornea during both initial and recurrent inflammation (Figure 
3A).  Wound-recovered cornea displayed an intact epithelium and decreased to normal 
thickness.  Levels of interleukin-1α (IL-1α) and matrixmetalloproteinase-10 (MMP-10) 
messenger RNA by qRT-PCR were consistent with inflammation and wound recovery.  IL-1α 
expression was approximately six-fold higher and MMP-10 eleven-fold higher during initial 
inflammation compared to unmanipulated controls.  During wound recovery, levels of IL-1α and 





Figure 2. Corneal model of initial inflammation, wound recovery, and recurrent inflammation.  
A.  Schematic depicts timing of corneal suture placement and removal to induce four distinct 
tissue microenvironmental conditions: healthy unmanipulated, initial inflammation, wound 
recovery, and recurrent inflammation. B. Schematics illustrate two corneal mounting styles:  
hemisected whole mount and whole mount.  Images are 100X epifluorescence 
photomicrographs of corneas immunostained for Lyve-1 (orange) and β-III tubulin (green) and 
harvested at the indicated time points. Top panel shows Lyve-1+ lymphatic vessels.  Bottom 
panel shows β-III tubulin+ corneal nerves.  Scale bars are 100 µm.  C.  Lymphatic vessel density 
was quantified from images like those shown in (B).  D.  Nerve density was quantified from 
images like those shown in (B).   E.  Corneal nerve clusters were quantified in wound-recovered 
tissue.  F.  A Cochet-Bonnet corneal aesthesiometer was used to measure corneal sensitivity.  










2: Initial Inflammation 
3: Wound Recovery 
4: Recurrent Inflammation 
 
Figure 2C - F  
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Figure 3. Induction of inflammation, wound recovery, and recurrent inflammation in the 
mouse cornea.  Corneal surgeries were performed as described in Figure 1A to induce initial 
inflammation, wound recovery, and recurrent inflammation.  Corneas were harvested and 
stained with DAPI for epifluorescence microscopy analysis or RNA was extracted for gene 
expression analysis.  A. Schematic depicts mount style of frozen corneal axial sections.  200X 
DAPI-stained corneal axial section epifluorescence micrographs.  Scale bar = 100 µm.  B. qRT-
PCR results showing levels of gene expression of inflammatory cytokines MMP10 (left panel) and 
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The lymphatic vessel remodeling that occurs in this system has been previously 
described (Kelley et al., 2013b).  We detected inflammatory lymphangiogenesis associated with 
initial inflammation, lymphatic vessel regression associated with wound recovery, and an 
accelerated lymphatic vessel response termed lymphatic vessel memory associated with 
recurrent inflammation (Figure 2B, C). 
We uncovered novel neuroremodeling events as we characterized the distinct tissue 
microenvironments generated in this model system.  Detection of nerves by β-III tubulin 
immunofluorescence revealed three distinct neural phenotypes corresponding to 
unmanipulated, inflamed, and wound-recovered tissue states, respectively (Figure 2B).  
Unmanipulated control corneas exhibited a very dense plexus of fine nerves organized in a 
regular swirled distribution present just below the epithelium.  These sub-epithelial nerves 
stemmed from thicker branched nerves lying deep within the corneal stroma and terminated in 
the epithelium.  During initial inflammation, the regular swirled pattern of sub-epithelial nerves 
was disrupted.  These nerves appeared grossly thickened and were present at a relatively low 
density.  Nerves tracked toward sites of injury, often exhibiting 90 degree bends and growing 
around and through suture knots.  Contrary to what we anticipated, nerves in wound-recovered 
tissue did not re-adopt their pre-morbid swirled morphology.  Instead, nerves displayed a novel 
phenotype characterized by their termination in tight tortuous groups, which we have termed 
clusters.   Quantification of these clusters showed their near-exclusive presence in wound-
recovered cornea (Figure 2E).  Recurrent inflammation resulted in a nerve phenotype very 
similar to that of initial inflammation with low nerve density and thickened nerves turning 
toward and knotting around sutures (Figure 2B, D). 
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Given the different nerve morphologies observed, we investigated the possibility that 
sensory nerve function was consequentially altered.  A Cochet-Bonnet aesthesiometer was used 
to quantify corneal sensitivity and revealed that inflamed corneas were significantly more 
sensitive than unmanipulated or wound-recovered corneas (Figure 2F).  This result suggested a 
connection between pain and the specific neuroremodeling events that accompany 
inflammation—both initial and recurrent.  Although the morphology of nerves in wound-
recovered tissue was greatly altered compared to normal cornea, nerves in wound-recovered 
tissue transmitted sensitivity signals at the same level as normal healthy nerves; only inflamed 
tissue was more sensitive. 
Expression Profiling of NGF and Other Neurovascular Guidance Family Members 
The dramatic changes in neurolymphatic anatomy during inflammation and wound 
recovery led us to profile expression of several families of neurovascular guidance genes.  RNA 
was extracted from corneas in the following conditions: unmanipulated, initial inflammation, 
wound recovery, and one-, three-, and seven-day recurrent inflammation.  We sampled the 
recurrent inflammation condition at three time points in order to better understand the kinetics 
of a second inflammatory response.  Of all of the molecules studied, we observed the most 
dynamic changes in the expression of NGF (Figure 4A).  NGF mRNA levels increased with 
inflammation about six-fold over control and decreased during wound recovery.  In recurrent 
inflammation, NGF levels were increased about seven-fold over control at days one and three, 
with a more modest increase of approximately four-fold observed at day seven.  The robust and 
rapid increase in NGF mRNA suggested that its expression was correlated with inflammation and 
wound recovery.  We examined the expression of several other neurovascular guidance 
molecules including two other members of the neurotrophin family: brain-derived neurotrophic 
factor (Bdnf) and neurotrophin-3 (Ntf3); four members of the semaphorin/plexin-neuropilin 
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signaling pathway: neuropilin-1 (Nrp1), neuropilin-2 (Nrp2), semaphorin 3e (Sema3e), and 
plexin-d1 (Plxnd1); three members of the netrin/unc family: netrin-1 (Ntn1), netrin-4 (Ntn4), and 
unc-5 homolog B (Unc5b); three members of the slit/robo family: slit-2 (Slit2), roundabout-4 
(Robo4), and roundabout-1 (Robo1); two members of the ephrin/eph family: ephrin-b2 (Efnb2), 
and Eph receptor B4 (Ephb4); as well as neurogenic locus notch homolog 1 (Notch1), cyclin-
dependent kinase 5 (Cdk5), and fibroblast growth factor 2 (Fgf2) (Figure 5).  Among these, 
members of the Netrin/Unc and Ephrin/Eph signaling axes were consistently downregulated 
during inflammation.  We did not detect consistent patterns of changes in expression of other 
neurovascular guidance gene families.   
We performed an ELISA for NGF in unmanipulated and initial inflammation corneal 
lysates to determine if NGF protein levels were upregulated during initial inflammation.  The 
results showed that NGF protein levels did not change with inflammation (Figure 4B).  These 
dramatic differences in transcriptional and translational regulation of NGF expression led us to 




Figure 4. NGF mRNA and protein expression during inflammation and wound recovery.  A.  
NGF expression (mRNA) in corneas was evaluated by qRT-PCR in healthy unmanipulated cornea 
and during initial inflammation, wound recovery, and days one, three, and seven of recurrent 
inflammation.  B.  NGF protein expression in corneal lysates was evaluated by ELISA.  (This figure 
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Figure 5. Changes in neurovascular guidance molecule gene expression during initial 
inflammation, wound recovery, and recurrent inflammation time course.  Corneal surgeries 
were performed as described to induce initial inflammation, wound recovery, and a recurrent 
inflammation time course.  RNA was extracted for qRT-PCR analysis of genes representing 
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Effects of Adding Exogenous NGF through Wound Recovery 
We sought to investigate the effect of adding exogenous NGF during wound recovery.  It 
was necessary to first establish the baseline kinetics of neural and lymphatic remodeling during 
wound recovery, a process that involves the resolution of inflammation.  A wound recovery time 
course experiment was performed in which sutures were removed and corneas were harvested 
at several time points throughout the course of an extended 21-day wound recovery (Figure 
6A).  Concomitantly, corneal sensitivity was evaluated by aesthesiometry as inflammation 
resolved.  We found that lymphatic vessel density decreased gradually throughout the wound 
recovery period, while nerve density remained at a constant and relatively low level as 
compared to controls from previous experiments (Figure 6B).  Nerve distribution and 
morphology showed changes throughout the time course.  Nerves in early wound recovery 
(days one through four) displayed features similar to those observed in initial inflammation, i.e. 
tracking toward sites of injury, low density, and overall thickening.  Nerves at these time points 
were also very densely associated with healing wound beds.  By day seven of wound recovery, 
nerves no longer tracked toward wound beds, but rather appeared as loose clusters or 
individually following tortuous paths.  Nerve thickness decreased, approaching that seen in the 
normal condition.  By day ten, the dense networks at wound beds were no longer evident, and 
clusters were the predominant nerve phenotype visible within the corneal tissue.  These clusters 
persisted through day twenty-one.  Assessment of corneal sensitivity by aesthesiometry 
revealed a steady decrease in the corneal hypersensitivity created by inflammation with a return 




Figure 6. Wound recovery time course.  Wound recovery was stimulated by suture removal and 
corneas were harvested at the indicated time points, immunostained for Lyve-1 and β-III 
tubulin, and analyzed by epifluorescence microscopy.  A. 100X immunofluorescence 
micrographs of Lyve-1+ lymphatic vessels (top panel) and β-III tubulin+ nerves (bottom panel).  
Scale bars = 100 µm.  B.  Quantification of corneal nerve density from images like those in (A).  C.  
Measurements of corneal sensitivity through extended wound recovery time course.  (This 
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This better understanding of the dynamic anatomical and physiological events that 
accompany a period of wound recovery allowed us to test the effects of NGF administration on 
specific features of wound recovery.  Following suture removal to induce wound recovery, 
mouse β-NGF or PBS control was administered subconjunctivally every other day for fourteen 
days with commensurate aesthesiometer readings.  Lymphatic vessel density remained 
significantly higher in mice treated with NGF (Figure 7A, B), and there was a significant reduction 
in lymphatic vessel fragmentation (Figure 7A, E), a hallmark of normal lymphatic regression 
during wound recovery (Figure 7H).  We measured remaining corneal ulcers from control and 
NGF-treated corneas and found no difference in average remaining wound size with NGF 
administration (Figure 7A, C).  While nerves did form clusters under both treatment conditions 
(Figure 7A, F), mice treated with NGF showed nerves organized in dense mesh-like networks 
that encompassed the wound bed (Figure 7A, D).  NGF-treated corneas were significantly more 




Figure 7. Effects of NGF administration during wound recovery on lymphatic vessel regression, 
nerve density at corneal wounds, and corneal sensitivity.  After removing sutures to stimulate 
wound recovery, mouse β-NGF or PBS control was injected subconjunctivally every other day for 
two weeks.  Corneas were harvested, immunostained for Lyve-1 and β-III tubulin, and analyzed 
by whole mount microscopy.  A.  Epifluorescence images of Lyve-1+ lymphatic vessels (left panel, 
scale bar = 100 µm, 100X), bright field images showing remaining wound beds at sites of suture 
placement (center panel, scale bar = 200 µm, 32X), epifluorescence images of β-III tubulin+ 
nerves (right panel, scale bar = 200 µm, 32X).  Expanded detail shows confocal analysis of β-III 
tubulin+ nerves at wound beds (offset panel far right, scale bar = 100 µm, 200X).  B.  Analysis of 
effects of exogenous NGF administration on corneal lymphatic vessel density during wound 
recovery from images like those in (A).  C.  Quantification of average remaining wound size 
following administration of NGF or PBS.  D. Nerve density at remaining wound beds quantified 
from confocal immunofluorescence images.  E.  Quantification of lymphatic vessel fragments 
discontinuous with limbal lymphatic vessel.  F.  Quantification of nerve clusters in wound-
recovered cornea following administration of NGF or PBS.  G.  Measurements of corneal 
sensitivity throughout wound recovery period with administration of NGF or PBS.  H.  200X 
confocal immunofluorescence micrograph showing lymphatic vessel fragments (arrowheads).  
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NGF Stimulates Lymphangiogenesis 
Given the inhibition of lymphatic vessel regression by NGF, we sought to determine if 
NGF was capable of inducing lymphangiogenesis in the cornea.  A corneal micropocket assay 
was used to test this hypothesis.  Micropellets loaded with PBS control, VEGF-C, or NGF were 
placed in a corneal micropocket for seven days, after which corneas were harvested and 
analyzed using immunofluorescence microscopy (Figure 8A).  β-III tubulin staining showed 
corneal nerves tracking toward pellets in all three conditions. Nerve density did not change at 
pellets loaded with cytokine (Figure 8A, B).  VEGF-C and NGF stimulated lymphangiogenesis 
(Figure 8A).  Measurement of lymphatic vessel density (Figure 8C) and length (Figure 8D) 
confirmed that VEGF-C and NGF significantly increased lymphangiogenesis over PBS control.  
NGF-induced lymphatic vessels were significantly longer than those induced by VEGF-C (Figure 
8D).  Analysis of lymphatic endothelial cell proliferation in newly synthesized lymphatic vessels 
by quantification of phosphorylated histone H3 staining in Lyve-1+ cells showed an increased 




Figure 8. NGF induces lymphangiogenesis.  Micropellets loaded with PBS, VEGF-C, or NGF were 
positioned in a corneal micropocket.  Corneas were harvested seven days after pellet 
implantation, immunostained for Lyve-1, β-III tubulin, and phosphorylated histone H3 and 
analyzed by whole mount and confocal microscopy.  A.  Epifluorescence images of β-III tubulin+ 
corneal nerves (top panel, scale bar = 100 µm, 100X), confocal detail images of β-III tubulin+ 
nerves at micropellets embedded in cornea (middle panel, scale bar = 100 µm, 100X), 
epifluorescence images of Lyve-1+ lymphatic vessels (bottom panel, scale bar = 100 µm, 100X), 
and confocal detail images of Lyve-1+ lymphatic vessel tip cells (bottom panel, inset, scale bar = 
100 µm, 200X).  B.  Quantification of corneal nerve density at micropellets loaded with PBS, 
VEGF-C, or NGF from confocal images like those shown in (A).  C.  Quantification of lymphatic 
vessel density in response to cytokine micropellets from images such as those shown in (A).  D.  
Quantification of length of lymphatic vessel outgrowth from limbus.  E. Proliferation of Lyve-1+ 
lymphatic endothelial cells as quantified by positive staining for phosphorylated histone H3.  
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We also examined the gene expression of NGF and known lymphangiogenic cytokines 
VEGF-A, -C, and -D in corneas with a PBS or NGF pocket as well as in the unmanipulated and 
initial inflammation conditions.  NGF gene expression increased during initial inflammation and 
did not change with PBS or NGF pellet placement (Figure 9A).  VEGF-A gene expression displayed 
the same pattern as NGF with an increase in initial inflammation and no change in the presence 
of a PBS or NGF pellet (Figure 9B).  VEGF-C gene expression trended toward an increase during 
initial inflammation and was significantly higher than the unmanipulated condition in the 
presence of an NGF pellet (Figure 9C).  VEGF-D gene expression remained unchanged in all 
conditions (Figure 9D).  We also assayed VEGF-A and -C protein levels in corneas with a PBS or 
NGF pellet.  Quantification of VEGF-A protein levels by cytokine microarray showed no change 
with an NGF pellet (Figure 9E).  Western blotting detected an increase in three isoforms of 
VEGF-C in the presence of an NGF pellet (Figure 9F).  These results show an increase in both 
VEGF-C mRNA and protein in the presence of an NGF pellet, but not VEGF-A or -D, and suggest 
that NGF may induce expression of VEGF-C, the canonical lymphangiogenic cytokine, in the 




Figure 9. mRNA and protein expression profiling of lymphangiogenic cytokines.  Conditions of 
initial inflammation, PBS pellet, or NGF pellet were created by placement of sutures or 
appropriate pellet as described.  A.  NGF gene expression from corneal RNA from 
unmanipulated, initial inflammation, PBS pellet, and NGF pellet conditions.  B.  VEGF-A gene 
expression.  C.  VEGF-C gene expression.  D.  VEGF-D gene expression.  E.  VEGF-A protein 
quantification from cytokine array from corneas with PBS pellet or NGF pellet.  F.  VEGF-C 
protein quantification by western blot from corneas with PBS pellet or NGF pellet.  β-actin was 
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In Vitro Interrogation of NGF Activity on Adult Human Dermal Lymphatic Endothelial Cells 
Considering that NGF stimulated corneal lymphatic vessels and VEGF-C mRNA and 
protein expression in vivo, we investigated whether NGF acted directly on lymphatic endothelial 
cells (LECs).  We examined the potential of NGF as a chemoattractant in Boyden-chamber 
migration assays.  NGF induced a modest but statistically significant increase in migration of 
LECs (Figure 10A).  Because of the low numbers of migratory cells in these assays, we postulated 
that NGF might have activity only on a subpopulation of cells or that VEGF-C might be required 
for robust migration.  We also examined the potential of NGF to stimulate tube formation in 
LECs.  Two concentrations of NGF, positive control VEGF-C, and the two cytokines in 
combination were equally capable of increasing tubulogenesis in LECs cultured in Matrigel at 
four hours (Figure 10B). 
LECs were evaluated for expression of mRNA for canonical NGF receptors TrkA and 
p75NTR by qRT-PCR.  Human skeletal muscle was used as a positive control for expression of 
these receptors.  Gene expression of TrkA was 11.2-fold lower in LECs than in skeletal muscle 
(Figure 10C).  Expression of p75NTR was 317.1-fold lower in LECs than in skeletal muscle (Figure 
10D).  These results suggested that these receptors were not expressed on these cells.   
We studied the expression of signaling phosphoproteins downstream of receptor 
tyrosine kinases that are known to induce LEC proliferation and migration.  Levels of 
phosphorylated mitogen-activated protein kinase 3/1 (pERK1/2) and phosphorylated AKT (pAKT) 
were examined in LEC lysates treated with NGF or positive-control VEGF-C for 1, 5, 15, or 30 
minutes.  As expected, VEGF-C induced phosphorylation of pERK1/2 and pAKT at 15 and 30 




Figure 10. In vitro experiments examining the effects of NGF on LECs.  A. Adult human dermal 
lymphatic endothelial cells (LECs) were seeded in the upper inserts of Boyden chamber 
migration plates.  NGF was added to the lower wells at the indicated concentrations.  Migratory 
cells were quantified.  B.  Matrigel was placed in tissue culture plate wells.  LECs were incubated 
with the indicated cytokines and then added to wells.  Tubes were quantified at four hours.  C. 
RNA was extracted from LECs or positive control adult human skeletal muscle and cDNA was 
synthesized.  Gene expression levels of NGF receptor TrkA were quantified by qRT-PCR.  D.  
Gene expression levels of p75NTR in human skeletal muscle and LECs.  E. RIPA lysates were made 
from LECs treated with the indicated cytokines for 1, 5, 15, or 30 minutes.  Western blot analysis 
was performed for the indicated proteins using β-actin as a loading control.  (This figure was 




Figure 10  
91 
 
Taken together, these results suggest that NGF does not act through its canonical 
receptors or through typical receptor tyrosine kinase signaling pathways on populations of LECs 
in culture. 
VEGFR-2/3 Decoy Receptors Block NGF Pellet-Mediated Corneal Lymphangiogenesis 
A combinatorial experimental approach was taken to investigate the hierarchical nature 
of NGF/VEGF-C signaling in vivo.  An initial set of experiments showed that subconjunctival 
injection of VEGFR-2/3 decoy receptors during initial inflammation blocked suture-mediated 
lymphangiogenesis while having no effect on overall corneal nerve density (Figure 11A, B).  This 
result confirmed the efficacy of ablating VEGFR-2/3 signaling on inflammatory 





Figure 11. VEGFR-2/3 decoy receptor treatment ablates suture-mediated lymphangiogenesis 
and does not affect neural remodeling.  Corneas were inflamed with four sutures on 
experimental day zero.  Fc control or a solution of VEGFR-2/3 decoy receptors was administered 
subconjunctivally on days zero, two, and four.  Corneas were harvested on day seven, 
immunostained for Lyve-1 and β-III tubulin, and analyzed by whole mount epifluorescence 
microscopy.  A.  100X immunofluorescence micrographs of Lyve-1+ lymphatic vessels (top panel) 
and β-III tubulin+ nerves (bottom panel).  Scale bar = 100 µm.  B.  Quantification of corneal nerve 











We investigated the effects of VEGFR-2/3 signaling blockade on NGF-mediated 
lymphangiogenesis.  Micropellets loaded with PBS or NGF were placed in the cornea to induce 
lymphangiogenesis followed by subconjunctival injection of VEGFR-2/3 decoy receptors or Fc 
control (Figure 12A).  PBS control pellet paired with Fc control subconjunctival injection 
stimulated minimal lymphangiogenesis.  NGF-laden pellet and Fc control injection induced 
robust lymphangiogenesis.  NGF-laden pellet coupled with blockade of VEGFR-2/3 signaling by 
decoy receptor injection ablated lymphangiogenesis.  Lymphatic vessel density was significantly 
higher in the NGF pellet and Fc injection condition, while the addition of VEGFR-2/3 decoy 
receptors to the system significantly reduced lymphatic vessel density and length (Figure 12B).  
These results suggest that the capacity of NGF to induce lymphangiogenesis in the cornea is 
largely mediated through indirect effects (stimulation of production of VEGF-C) on cell types 




Figure 12. VEGFR-2/3 decoy receptors ablate NGF pellet-mediated corneal lymphangiogenesis.  
Micropellets loaded with PBS or NGF were positioned in a corneal micropocket on experimental 
day zero.  Fc control or a solution of VEGFR-2/3 decoy receptors was administered 
subconjunctivally on days zero, two, and four.  Corneas were harvested on day seven, 
immunostained for Lyve-1 and β-III tubulin, and analyzed by whole mount microscopy.  A.  100X 
epifluorescence images of β-III tubulin+ corneal nerves (top panel) and Lyve-1+ lymphatic vessels 
(bottom panel).  Scale bars = 100 µm.  B.  Quantification of lymphatic vessel density (left panel) 
and length of outgrowth from limbus (right panel).  (This figure was previously published in Fink 














Our studies investigated the mechanistic basis for the resolution of two of the cardinal 
features of inflammation—pain and tissue edema—during wound recovery.  We characterized 
the behavior of two classes of tissue microenvironmental structures in the cornea, the nerves 
and the lymphatic vessels, during episodes of inflammation and wound healing.  We show 
synchronized neurolymphatic remodeling during inflammation and wound recovery that is 
regulated by NGF and its downstream effectors, including VEGF-C.  These studies demonstrate 
that NGF stimulates lymphangiogenesis and increases pain, and they implicate NGF as a 
pathogenic factor that inhibits the neural and lymphatic vascular remodeling processes 
associated with wound recovery. 
Neurolymphatic Remodeling and Wound Recovery 
A corneal model of initial inflammation, wound recovery, and recurrent inflammation 
was used to explore mechanisms that coordinately regulate neurolymphatic remodeling.  This 
study features experimental results from wound recovery and recurrent inflammation 
conditions, two understudied physiologic states with significant clinical relevance.  Histological 
and biochemical results supported our conclusion that this model represents these physiologic 
states.  
We and others have previously shown that sutures induce lymphangiogenesis from the 
corneal limbus and that suture removal stimulates wound recovery and lymphatic vessel 
regression (Kelley et al., 2011b).  Suture placement may transect or induce neuropraxia in a 
subset of corneal nerves.  However, the data presented here reveal new aspects of neural and 
lymphatic responses to inflammation and injury, processes similar to severe clinical corneal 
infection or direct trauma.   
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During initial inflammation, we observed synthesis of new Lyve-1+ lymphatic vessels and 
remodeling of β-III tubulin+ neural structures to wound-centric tracking with sharp directional 
turns.  Nerves also displayed thickening and a decrease in density, similar to previous 
observations (Donaghy, 2003; Ferrari et al., 2013).  We visualized regressed Lyve-1+ lymphatic 
vessels and β-III tubulin+ neural clusters during wound recovery.  Recurrent inflammation 
accelerated the development of a lymphatic vessel network (Kelley et al., 2013b) and induced 
neural remodeling, changing nerve clusters to a wound-centric organization.  We also detected 
marked changes in corneal sensitivity that represented a physiological consequence of neural 
remodeling events.  Among several classes of neurovascular guidance molecules, we identified 
NGF mRNA to have increased expression during inflammation compared to unmanipulated 
control and wound recovery conditions.  Surprisingly, NGF protein levels were similar in control 
compared to conditions of initial corneal inflammation.   Expression of immature or alternately 
processed biologically active forms of NGF, such as proNGF or other cleavage or post-
translationally modified products, may not have been detected by the ELISA we performed.   
It is well known that several cell types present in the cornea including epithelium, 
endothelium, keratocytes, and nerves express NGF and/or the NGF receptors TrkA and p75NTR 
(Blanco-Mezquita et al., 2013; Lambiase et al., 1998a; Lambiase et al., 2000b; Sornelli et al., 
2010; Woo et al., 2005; You et al., 2000).  Here we show that NGF inhibited the normal 
processes of wound recovery by inhibiting lymphatic vessel regression, maintaining high nerve 
density in wounds, and increasing pain.  Interestingly, NGF did not appear to affect epithelial 
wound closure.  Previous studies have described conflicting results related to the effects of 
manipulating the NGF pathway.  Administration of NGF to the cornea has been shown to 
increase presence of corneal nerves and increase rates of epithelial proliferation (Blanco-
Mezquita et al., 2013; Esquenazi et al., 2005; You et al., 2000), improve corneal healing after 
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capsaicin administration and epithelial scraping (Lambiase et al., 2012), and increase wound 
closure (Lambiase et al., 2000b).  Other studies have shown that NGF has no effect on wound 
closure (Woo et al., 2005).  Administration of an NGF blocking antibody has been shown either 
to slow epithelial wound healing (Lambiase et al., 2000b) or to have no effect (Woo et al., 2005).  
These different observations may reflect model-to-model variability and possibly the pan-
regulatory functions of NGF. 
NGF Induced Lymphangiogenesis 
In our studies with micropellets loaded with NGF, we documented the unexpected 
finding of stimulating new lymphatic vessel growth.  We considered the possibility that NGF 
acted directly on LECs that expressed the canonical receptors for NGF, TrkA and p75NTR, or a 
non-canonical receptor tyrosine kinase.  The data did not support this hypothesis, as we did not 
detect TrkA and p75NTR expression or phosphorylation of two known downstream signaling 
mediators, Erk and Akt, in LECs treated with NGF.  The results of LEC migration and 
tubulogenesis assays were intriguing and suggested that NGF may bind to a non-canonical 
receptor and transduce migratory signals via effectors other than Erk or Akt.  We explored an 
alternative but non-exclusive hypothesis that NGF stimulated LECs indirectly through effects on 
other cell types. 
Members of the VEGF family have been shown to induce lymphangiogenesis directly by 
interacting with VEGF receptors expressed by LECs (Cao et al., 2004c; Jeltsch et al., 1997; Oh et 
al., 1997b; Sweat et al., 2014).  We explored this in vivo and showed that NGF-laden pellets 
stimulated expression of VEGF-C mRNA and protein and that lymphangiogenesis stimulated by 
NGF pellets was dependent upon the  VEGF-A and -C signaling axes.  
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This is the first report describing that NGF stimulates lymphangiogenesis, indirectly via 
VEGF family members.  Blocking VEGF-A and -C signaling with decoy receptors ablated both 
VEGF-C- and NGF-induced lymphangiogenesis and did not affect neural remodeling.  NGF pellets 
have also been shown to induce angiogenesis in rat corneas (Seo et al., 2001a), and other 
studies have defined a relationship between the VEGF and NGF signaling axes.  Production of 
VEGF-A has been documented in several models of neural development, disease, or injury and 
has been shown to be stimulated by NGF administration under certain conditions, presenting 
the possibility that corneal nerves are the source of one or more VEGF family members (Calza et 
al., 2001; Li et al., 2013; Mukouyama et al., 2005; Nakamura et al., 2011; Samii et al., 1999; 
Saygili et al., 2011).  Studies with bevacizumab, which binds VEGF-A (Bock et al., 2007; Bock et 
al., 2009), provide further support for crosstalk between these two signaling pathways including 
changes in NGF levels (Jee and Lee, 2012; Kim et al., 2010a; Rossi et al., 2012) and nerve activity 
(Bock et al., 2009; Li et al., 2011b; Yu et al., 2008a).  The results of the in vivo studies presented 
here support a similar model of NGF and VEGF-C cross regulation to coordinately regulate neural 
structures and lymphatic vessel growth.  These findings are consistent with a model in which 
NGF functions as an overarching regulatory molecule with primary neural targets and 
downstream secondary targets regulating lymphangiogenesis via VEGF family members. 
Facilitating Wound Recovery 
The resolution of inflammation and wound recovery are universally important biological 
processes.  Here we investigated these processes in two basic physiologic systems, the 
lymphatic vasculature and the nervous system in the cornea.   The distribution, density, and 
functions of the lymphatic vessels and nerves vary considerably from organ to organ presumably 
to meet the unique physiologic and pathologic challenges presented in specific 
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microenvironments.  Whether the operational mechanisms that we have defined in the cornea 
can be generalized to other organs systems is unclear. 
Other preclinical and clinical studies have investigated the contribution of NGF to 
corneal disease.  Consistent with the findings reported here, TrkA-/- mice display decreased 
innervation of corneal stroma and epithelium and decreased corneal sensitivity (de Castro et al., 
1998), and clinical studies have shown that topical NGF treatment generally increased corneal 
sensitivity (Joo et al., 2004; Lambiase et al., 2000a).  In other clinical studies, topical 
administration of NGF eye drops has been perceived as generally favorable by observations of 
decreased healing time and increased epithelial closure in refractive disease (Bonini et al., 2000; 
Cellini et al., 2006; Lambiase et al., 1998b; Lambiase et al., 2003; Lambiase et al., 2011; Mauro et 
al., 2007; Tan et al., 2006), presumably by stimulating epithelial migration (You et al., 2000).  The 
findings presented here suggest that NGF serves as part of a signaling hierarchy that regulates 
neurolymphatic remodeling in the cornea, and that clinical strategies to block NGF function may 







CHAPTER II.  Defining Tumor-Induced Alterations to 
Microenvironmental Neurolymphatic Networks by Live 
Imaging3 
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 Portions of the material presented in this chapter have been previously published under the following 




We previously used a corneal model to characterize neurolymphatic remodeling events 
during inflammation, wound recovery, and recurrent inflammation and identified common 
regulatory mechanisms shared by both tissue networks.  Here, we extended these studies to 
investigate neurolymphatic remodeling dynamics and tumor-lymphatic interactions in 
nonmalignant and tumor-associated inflammatory microenvironments in real time with a novel 
live imaging platform. 
During acute inflammation, new lymphatic vessels sprout from the existing lymphatic 
vasculature in the direction of the inflammatory stimulus.  This process is directed by 
lymphangiogenic cytokines and requires extensive coordination as the cells migrate through the 
tissue and form new lymphatic capillaries.  These newly-synthesized lymphatic vessels are 
functional and can traffic inflammatory immune cells such as macrophages to and from an 
inflamed area.  Tissue nerve networks also undergo structural and functional changes in the 
presence of inflammation.  Nerves track toward and engulf stimuli and display altered 
nociceptive properties.   
Lymphatic vessels and nerves are two types of tissue microenvironmental networks 
often invaded by tumor cells during metastatic spread.  Despite the clinical importance of 
lymphatic vessel invasion, lymph node status, and perineural invasion in cancer staging, 
treatment decisions, and patient outcomes, neurolymphatic remodeling in malignancy remains 
an understudied biological process.  Little is known about how structural changes to these 
networks may be associated with the earliest events of metastasis or exploited to facilitate early 
detection of malignancy.   
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We used real-time live imaging microscopy to study lymphatic vessel remodeling and 
tumor-lymphatic dynamics in a novel transgenic murine model and used immunostaining to 
extend our studies to nerve networks.  In the Lyve1CreERT2tdT mouse, tamoxifen-inducible 
tdTomato fluorescent protein is expressed in Lyve-1+ cells—lymphatic, but not blood vascular, 
endothelia and a subset of macrophages.  This approach, coupled with the development of 
customized fluorescent stereomicroscopy techniques, allowed us to visualize tdTomato-
expressing lymphatic vasculature in remarkable detail in live mice.  We focused our studies on 
two tissues:  pinna and cornea.  The respective anatomical features of the pinna and cornea 
made them ideal platforms for live imaging microscopy studies of nascent and steady-state 
lymphatic vessels, surgical manipulations, and delivery of tumor cells.  Two-color imaging 
allowed us to simultaneously track tumor cells at single-cell resolution and morphologic changes 
in lymphatic vessels.  We clearly visualized and documented several key behaviors of 
metastasizing tumor cells including tumor-lymphatic interactions, presence of tumor cells in 
vessels, clearing from vessels, and the accumulation of tumor cells in draining lymph nodes.   
We also found differences in nerve and lymphatic architectures in suture- and tumor-
associated inflammatory microenvironments.  Local nerve and lymphatic remodeling behaviors 
unique to malignant inflammation were induced in the vicinity of both minimal and large tumor 
burdens and tracked over time; field effects extended beyond sites of tumor residence to alter 
structures in adjacent regions.  Tumor- and suture-associated remodeling signatures could be 
induced simultaneously in either pinna or cornea at the positions of tumor cells and sutures.  
These characteristic neurolymphatic architecture signatures generated in the presence of a very 
small number of tumor cells and distinct from those associated with acute nonmalignant 
inflammation could represent a target for early detection of malignancy.  
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Materials and Methods 
Lyve1CreERT2tdT Mouse Model 
All experimental procedures were approved by the Institutional Animal Care and Use 
Committees of Boys Town National Research Hospital or the University of Nebraska Medical 
Center in accordance with NIH guidelines.  Representative Images are presented; in general, 
observations were confirmed three times.  The generation of this transgenic mouse model, 
validation of fluorescent protein expression in the appropriate cell type, and back-crossing to 
C57BL/6 has been previously described (Connor et al., 2016).  In short, administration of 4-
hydroxytamoxifen (4-OHT) drives expression of tdTomato fluorescent protein in Lyve-1+ cells, 
including the lymphatic endothelium and a subset of macrophages.  Conversion of nearly all 
Lyve-1+ cells is possible with high-dose 4-OHT administration, while immunofluorescence co-
staining for Lyve-1 shows that conversion penetrance can be titrated down to minor populations 
of cells by modifications of 4-OHT dose and schedule.  Fluorescent protein is most concentrated 
in the nuclei of cells with diffuse cytoplasmic expression.  We have shown tdTomato fluorescent 
protein expression in the lymphatic vasculature present in and around several organs including 
cornea, pinna, lymph node, spleen, pancreas, stomach, and intestine by live imaging and 




Figure 13. Lyve1CreERT2tdT transgenic mouse model displays tdTomato fluorescent protein 
expression in lymphatic endothelium.  Administration of 4-hydroxytamoxifen as described 
induces tdTomato fluorescent protein expression in cells expressing the Lyve-1 promoter.  Bright 
field and Texas Red (TR) stereofluorescence microscopy live imaging (A, B) or imaging at 
necropsy (C-G) shows tdTomato expression in lymphatic vessels in several tissues and organs.    
A. Newly synthesized corneal lymphatic vessels growing out from limbal arcade in response to 
sutures are tdTomato+.  B. Lymphatic vessel networks present in mouse pinna under steady 
state conditions express tdTomato.  C. Lymph nodes (here, submandibular; magnification 
greater in right panel) express tdTomator.  D.  Lyve-1+ cells of spleen express tdTomato.  E-G. 
Lymphatic tissue associated with digestive organs including pancreas, stomach, and intestine are 
tdTomato+.  H. Whole mount pinna.  Endogenous tdTomato protein is present in nucleus, 
cytoplasm, and cellular projections of lymphatic endothelial cells and survives 





Figure 13  
Greater magnification than at left 
108 
 
Induction of Fluorescence with 4-hydroxytamoxifen 
 Expression of tdTomato protein in Lyve-1+ cells of the Lyve1CreERT2tdT mouse model 
was induced by administration of 4-hydroxytamoxifen (4-OHT) suspended in sunflower oil.  As 
described above, this transgenic mouse was engineered to allow titration of tdTomato 
expression by varying the level of 4-OHT administered to each individual animal.  For all of the 
experiments described in this work, expression of tdTomato fluorescent protein in all cells 
expressing Lyve-1 was desired.  To achieve this high level of expression, 1 mg of 4-OHT was 
injected intraperitoneally each day for three days with a fourth booster dose administered as 
needed.  
Cell Lines 
 The Lyve1CreERT2tdT mouse has been back-crossed to the C57BL/6 genetic background, 
enabling tumor studies with syngeneic cell lines.  We used the following cell lines:  B16 
melanoma, KPC pancreatic adenocarcinoma, and E0771 medullary breast carcinoma.  The B16 
melanoma cell line was a kind gift from Dr. James E. Talmadge at the University of Nebraska 
Medical Center, Omaha, NE.  The KPC cell line used in these experiments was derived in our 
laboratory from a KPC mouse tumor (mouse #WT6012).  KPC mice (LSL-KrasG12D/+;LSL-
Trp53R172H/+;Pdx-1-Cre) are genetically engineered to develop spontaneous pancreatic 
adenocarcinoma (Hingorani et al., 2005).  E0771 is an aggressive estrogen receptor+ (ER) 
medullary breast cancer cell line (Ewens et al., 2005); it was a kind gift from Dr. Rakesh Singh at 
the University of Nebraska Medical Center, Omaha, NE. 
Surgical Procedures:  Cornea 
Surgeries were performed on the right eye of each animal.  Prior to all surgical 
procedures, mice were deeply anesthetized by intraperitoneal administration of a mixture of 
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ketamine (100 mg/kg) and xylazine (10 mg/kg).  Topical anesthetic proparacaine was applied to 
the corneal surface before surgery.  Mice were euthanized by ketamine/xylazine overdose or by 
CO2 asphyxiation and death ensured by cervical dislocation.   
Establishment of Inflammatory and Wound Recovered Corneal Microenvironments 
 The corneal model of initial inflammation, wound recovery, and recurrent inflammation 
was described in detail in Chapter I.  Briefly, to establish initial inflammation a 10-0 nylon 
monofilament suture was placed in each quadrant of the mouse cornea and left in residence for 
seven days.  In experiments comparing pre-sutured, simultaneously-sutured, and unsutured 
environments, the pre-sutured condition was defined as placement of sutures three days prior 
to tumor pellet implantation.  The simultaneously-sutured condition consisted of sutures placed 
immediately prior to pellet placement on the same day.  For the unsutured condition, pellets 
were placed in previously unmanipulated corneas. 
Micropellet Preparation, Tumor Loading, and Corneal Implantation 
Micropellet preparation was described in detail in Chapter I.  Briefly, nylon mesh was 
used to mold a mixture of 12% (w/w) poly(2-hydroxyethyl methacrylate) solution in 95% ethanol 
and a sucrose octasulfate-aluminum complex into micropellets.  Tumor cells were labeled with 
CFSE (carboxyfluorescein diacetate, succinimidyl ester, Vybrant CFDA SE Cell Tracer Kit, 
Invitrogen) or CMRA (CellTracker Orange CMRA, ThermoFisher) live cell tracker dye according to 
the manufacturers’ instructions and loaded in suspension onto a micropellet ex vivo.  A tumor-
bearing pellet was placed into a micropocket in the cornea by making a slit with a 20 or 27 
gauge needle and using fine forceps to tuck the pellet under the corneal flap.  Presence of CFSE-
labeled cells in the cornea was confirmed immediately following implantation via live imaging 
fluorescence microscopy.   
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Tumor Cell Injection 
 Labeled tumor cells were delivered to the cornea by either:  injection with a 33 gauge 
needle into a micropocket made with a 20 or 27 gauge needle or by pulling a 10-0 nylon 
monofilament suture through a suspension of tumor cells on the surface of the cornea. 
Immunofluorescence Imaging of Whole Mount Corneas 
Dissection and Staining 
These procedures were described in detail in Chapter I.  Briefly, corneas were dissected 
out of PFA-fixed globes, fixed a second time, blocked, and permeabilized. Primary antibodies 
were diluted in BSA blocking solution and applied to corneas overnight shaking at room 
temperature.  Corneas were washed three times.  Secondary antibodies were diluted in blocking 
solution and applied to the corneas overnight shaking at room temperature.  After three 
washes, corneas were mounted and stored at 4°C.  Primary antibodies: pRb α-Ms β-III tubulin 
(ab18207, Abcam, Cambridge, MA), mRt α-Ms Lyve-1 (sc-65647, Santa Cruz Biotechnology, 
Santa Cruz, CA).  Secondary antibodies: 488 Dky α-Rb IgG (AlexaFluor A21206, Life Technologies, 
Carlsbad, CA), 488 Dky α-Rt IgG (AlexaFluor A21208, Life Technologies), 549 Dky α-Rt IgG 
(DyLight 712-505-150, Jackson ImmunoResearch Laboratories, West Grove, PA).  
Whole Mount Imaging 
Whole mount corneas were visualized on a Zeiss Axio A.1 epifluorescence microscope or 
a Leica stereoscope.  100X epifluorescence images were obtained using SPOT Advanced 
software (SPOT Imaging Solutions, Sterling Heights, MI).  32X stereofluorescence images were 
obtained using Leica Application Suite software (Leica Microsystems, Inc., Buffalo Grove, IL).  
200X and 400X z-stacks were obtained using a Zeiss 510META confocal microscope (Carl Zeiss 
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AG, Oberkochen, Germany).  Images were compiled and analyzed using ZEN 2009, BioImageXD 
(Kankaanpaa et al., 2012) and ImageJ (Schneider et al., 2012) software packages. 
Surgical Procedures:  Pinna 
Prior to all surgical procedures, mice were deeply anesthetized by intraperitoneal 
administration of a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg).  Pinna was 
depilated by application of Nair Hair Removal Lotion (Church and Dwight Co, Inc., Ewing, NJ) 
according to the manufacturer’s instructions.  Mice were euthanized by ketamine/xylazine 
overdose or by CO2 asphyxiation and death ensured by cervical dislocation.   
Establishment of Local Inflammatory Microenvironment 
 Dissolvable (5-0 chromic gut) or nylon monofilament (10-0) sutures were placed in the 
pinna.  Sutures passed through both layers of ear skin.  Duration of residence, number, and 
location of sutures varied depending on experimental conditions and are described below as is 
appropriate. 
Tumor Cell Delivery 
 CFSE- or CMRA-labeled tumor cells were delivered to the pinna by either:  end-on 
injection of a large or small bolus dose of cells into and between the two layers of ear skin with a 
33 gauge needle or injection at a specific location with a 33 gauge needle or pulled glass pipette 
attached to a compressed gas-powered microinjector (Model PLI-100A Basic Pico-Injector 64-
1735, Warner Instruments, Hamden, CT).    
Immunofluorescence Imaging of Whole Mount Pinnae 
Dissection and Staining 
Intact pinnae were removed and fixed in 1% paraformaldehyde in PBS, pH 7.4, shaking 
at room temperature.  Sections were washed in PBS and then blocked and permeabilized in a 
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sterile-filtered PBS, pH 7.4, solution containing 5.2% BSA, 0.3% Triton X-100, and 0.2% NaN3 
(blocking solution) for two days at 4°C.  Primary antibodies were diluted in blocking solution and 
applied to pinnae overnight shaking at room temperature.  Tissue was washed in a sterile-
filtered PBS, pH 7.4, solution containing 0.2% BSA, 0.3% Triton X-100, and 0.2% NaN3 (wash 
buffer) three times for one hour shaking at room temperature.  Secondary antibodies were 
diluted in blocking solution and applied overnight shaking at room temperature.  After three one 
hour washes, tissue was mounted for imaging and stored at 4°C.   
Whole Mount Imaging 
Whole mount pinnae were visualized on a Zeiss Axio A.1 epifluorescence microscope or 
a Leica stereoscope.  100X epifluorescence images were obtained using SPOT Advanced 
software (SPOT Imaging Solutions, Sterling Heights, MI).  32X stereofluorescence images were 
obtained using Leica Application Suite software (Leica Microsystems, Inc., Buffalo Grove, IL).  
200X and 400X z-stacks were obtained using a Zeiss 510META confocal microscope (Carl Zeiss 
AG, Oberkochen, Germany).  Images were compiled and analyzed using ZEN 2009, BioImageXD 
(Kankaanpaa et al., 2012) and ImageJ (Schneider et al., 2012) software packages. 
Live Imaging Microscopy:  Mouse Cornea and Pinna 
Mice were deeply anesthetized as described above.  Imaging was performed using GFP 
(Green Fluorescent Protein) and TR (Texas Red) filter sets on a Leica MZ10F modular stereo 
microscope for fluorescent imaging with a Fluo III rapid filter changer, a Leica Planap × 1.0 
objective, and a Leica DFC310FX camera using the Leica Application Suite software version 
4.0.0.8777 (Leica Microsystems, Inc., (Buffalo Grove, IL).  Imaging was performed using FITC 
(fluorescein isothiocyanate) and TRITC (tetramethylrhodamine) filter sets on a Zeiss Axio 
Zoom.V16 fluorescence stereo zoom microscope with a Zeiss Plan-NeofluarZ 1.0 × 0.25 NA 
113 
 
objective and a Zeiss AxioCam MRm camera using ZEN 2012 Blue Edition software version 
1.1.1.0 (Carl Zeiss AG, Oberkochen, Germany). 
 Cornea was imaged by using fine forceps to position and stabilize the globe; focus on 
either limbal vasculature or central cornea was achieved in this way.  Extraneous vibration from 
respiratory motions was minimized by gently stabilizing the head with a large forceps. 
 Pinna was immobilized and mounted for imaging for up to one hour by loosely securing 
it in a customized mounting apparatus consisting of small glass plates and adjustable clamps.  
Positioning the pinna on this platform effectively brought the tissue into one plane and 
decreased movement due to respiration.  Lymphatic vessel landmarks within the tissue allowed 





Sutures Induce Inflammatory Neurolymphatic Remodeling in Mouse Pinna  
 We studied alterations in lymphatic vessel and nerve morphology in mouse pinna in 
response to placement of sutures in live animals over several days.  Lymphatic vessels are 
normally present in the homeostatic mouse pinna in two plexuses within the tissue.  These 
plexuses are defined by uniform distribution of blind-ended lymphatic capillaries throughout the 
pinna in stochastic conformations and with frequent anastomoses.  We placed dissolvable 
(Figure 14A, B lower panel) or nylon (Figure 14B upper panel) sutures through the pinna of 
Lyve1CreERT2tdT mice in which tdTomato fluorescence had been induced by administration of 4-
OHT.  Changes in tdTomato+ lymphatic vessel architecture were characterized over several days 
following suture placement.  With either suture type, we observed a local decrease in lymphatic 
vessel density at the site of suture placement.  Development of a “zone-of-clearing” in which no 
tdTomato+ lymphatic endothelial cells were present resulted at every suture site individually, 
while normal lymphatic vessel architecture as seen in homeostasis was maintained in areas 
away from and between sutures (Figure 14B right panel).  Several days after suture placement 
we observed local lymphangiogenic sprouting into the site of wounds (Figure 14C).  Single 
tdTomato+ cells infiltrated areas previously devoid of lymphatic vessels around sutures.  Newly 
synthesized lymphatic vessel sprouts branched off of existing lymphatic vessels into wounded 
regions. 
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Figure 14. Sutures induce local pinna lymphatic vessel remodeling.  A.  Live imaging.  
Dissolvable or nylon sutures were placed through the depilated Lyve1CreERT2tdT mouse pinna.  
B.  Live imaging.  Suture placement resulted in local decrease in lymphatic vessel density and 
formation of “zone-of-clearing” (dashed lines) around suture sites (*).  C.  Live-imaging of 
mounted ear several days after suture placement (left panel, Texas Red filter; right panel, bright 
field); Local sprouting into previous suture site zone-of-clearing (dashed lines higher 





Figure 14  
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We also studied the behavior of nerves in response to suture placement in the mouse 
pinna (Figure 15).  As with vascular supply, each layer of ear skin is independently innervated.  In 
homeostasis, large nerve trunks enter the base of the pinna and fan out toward the edges with 
extensive branching and anastomoses forming dense plexuses.  Upon stimulation with a suture, 
neuroremodeling in the pinna was similar to that observed in the cornea.  A dramatic increase in 
nerve density was observed at the margins of wounds.  Nerve bundles tracked in an organized 
manner toward the site of injury, encircled and penetrated it forming a dense net-like structure.  
Sprouting lymphatic vessel tips maintained distance from the injury, while nerves were present 




Figure 15. Sutures induce local pinna neuroremodeling.  Two 5-0 chromic gut sutures were 
placed through the depilated Lyve1CreERT2tdT mouse pinna.  Maximum intensity projections of 
100X confocal micrographs are shown.  Size bars = 100 μm.  Pinna nerves (β-III tubulin-
immunolabeling, green) and lymphatic vessels (endogenous tdTomato+, red).  A.  Networks of 
nerves and lymphatic vessels in homeostasis in a region away from sutures.  B.  Local increase in 
nerve density and altered morphology in immediate vicinity of suture (*).  Lymphatic vessels are 




Figure 15  
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Very Small Tumor Burden Induces Lymphatic Vessel Remodeling and Is Cleared from Tissue 
 We studied tumor behavior and lymphatic vessel response to presence of tumor cells in 
the mouse pinna.  We delivered varied loads of tumor cells, ranging from less than a hundred 
cells to more than a million, to the pinna with and without sutures.  We used live imaging 
microscopy to investigate tumor-associated lymphatic vessel remodeling, to track tumor cells 
through pinna tissue, and to evaluate lymph node status at necropsy. 
 We found that the presence of a very small tumor burden was sufficient to induce 
localized lymphatic vessel remodeling (Figure 16).  Lymphatic vessels in the immediate vicinity of 
a group of tumor cells displayed stochastic sprouting at the site of tumor residence after seven 
days.  Tips of growing lymphatic vessels were often multi-sprouted, and anastomosis occurred 
to form lymphatic vessel ring structures.  Vessels farther away from tumor cells did not display 
any alterations in morphology, likely demonstrating the localized effects of lymphangiogenic 
cytokines secreted from these very small groups of cells.   
We found that tumor cells disappeared from sites of residence in the tissue.  By day 
seven, no tumor cells were visible at their previous locations.  This could indicate clearance by 
activated immune cells, intravasation into blood or lymphatic vessels and transport away, or cell 




Figure 16. Tumor cells induce local unsutured pinna lymphatic vessel remodeling and are 
cleared from tissue.  A-F.  CFSE-labeled B16 melanoma cells were injected into the 
Lyve1CreERT2tdT unsutured depilated mouse pinna.  Live stereofluorescence microscopy was 
used to track CFSE-labeled tumor cells (green) and tdTomato-expressing lymphatic endothelial 
cells (red) over seven days.  Lymphatics are visible with both the Texas Red (TR) and Green 
Fluorescent Protein (GFP) filter sets due to the brightness and broad fluorescence emission 
spectrum of tdTomato protein.  A, D.  Site of CFSE-labeled B16 tumor cell residence in pinna 
(arrow) on imaging day 1.  B, E.  Return to site of tumor cell residence on imaging day 7.  Tumor 
cells are no longer present.  Local lymphangiogenic sprouting and anastomosis can be visualized.  
C, F.  Higher magnification view of lymphatic endothelial sprouts and ring anastomosis. 













Tumor Cells Enter Lymphatic Vessels and Traffic to Lymph Nodes 
We designed experiments to investigate possible trafficking of tumor cells through 
lymphatic vessels.  This would represent a mechanism of clearance from tissue and mimic 
metastasis to lymph nodes.  We injected a large bolus dose of CFSE-labeled B16 melanoma cells 
into the edge of the Lyve1CreERT2tdT pinna.  One day after injection, lymphatic vessels half the 
distance of the pinna away from the injection site and distinct from the circular region of 
injected cell suspension harbored CFSE+ tumor cells.  Both groups of cells and single cells could 
be visualized in the lumen of lymphatic vessels (Figure 17A, top panel).  Cells resident in the 
extravascular pinna tissue could also be visualized in these regions, suggesting possible 
intravasation/extravasation activity at these sites, although we did not directly observe these 
behaviors. 
The relatively stable nature of the pinna lymphatic vasculature architecture facilitated 
returning to landmark vessel structures in the tissue for sequential imaging over time.  We 
returned to the areas of tumor-bearing lymphatic vessels on day two after injection, or 24 hours 
after first observing this phenomenon.  We detected no CFSE signal in the vessels that had 
housed tumor cells the previous day and did not find similar groups of cells in vessels within the 
neighboring tissue (Figure 17A, bottom panel).  This suggested that the tumor cells had been 
cleared from the pinna lymphatic vasculature and transported to the lymph nodes. 
At necropsy on day seven, we examined lymph nodes for the presence of CFSE+ cells 
(Figure 17B).  Across experiments we found tumor cells in lymph nodes in several locations 




Figure 17. Tumor cells enter unsutured pinna lymphatic vessels, are cleared from vessels, and 
are present in lymph nodes at necropsy.  CFSE-labeled B16 melanoma cells (green) were 
injected into the periphery of the depilated Lyve-1CreERT2tdT mouse pinna.  Tumor cells and 
tdTomato+ lymphatic vessels (orange) were followed by live imaging stereofluorescence 
microscopy.  A. Tumor cells are visible in groups in lymphatic vessels on imaging day 1 (arrows, 
top panel).  Identification of landmark lymphatic vessel structures facilitated imaging of the 
same regions 24 hours later.  Tumor cells are no longer present at their previous locations 
within lymphatic vessels (arrows, bottom panel).  B.  CFSE+ cells are present in draining lymph 
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Spatially Localized Suture- and Tumor-Associated Lymphatic Vessel Remodeling  
 We established that placement of a suture or delivery of a minimal tumor burden 
results in two distinct patterns of skin lymphatic remodeling.  We next studied these remodeling 
behaviors in different contexts:  first, we investigated lymphatic remodeling in the presence of a 
much larger tumor burden, and second, we created distinct suture- or tumor-associated 
microenvironments within the same pinna.   
 We first established local zones of nonmalignant inflammation with the placement of 
chromic gut sutures in the Lyve1CreERT2tdT mouse pinna; one suture was placed in the center of 
the pinna and another in the upper quadrant, leaving a large area free of inflammatory stimuli 
(Figure 18A).  After three days, a medium dose of CFSE-labeled B16 melanoma cells was injected 
into the margin of the pinna opposite the sutures.  Sutured locations displayed the characteristic 
loss of lymphatic capillaries immediately adjacent to stimuli with some sprouting into wounded 
area (Figure 18A, E).  Lymphatic vessels in the area of tumor challenge appeared grossly 
enlarged; closer examination at necropsy on day seven revealed dramatic hypersprouting 
morphology in the tumor-associated microenvironment (Figure 18A-C).  Single sprouts budded 
off existing vessels in all directions; single cells not incorporated into the vascular network 
infiltrated spaced between vessels; single and elongated cells lined up in thin extended chains 
among larger lymphatic capillaries (Figure 18C).   
 Tumor cells were in close association with lymphatic vessels of both ear skin layers as 
revealed by dissection at necropsy (Figure 18B).  Single and groups of cells were present at 
various distances from the bolus injection site within the tissue (Figure 18A-C).  Lymph nodes at 




Figure 18. Establishment of wound- and tumor-associated inflammatory microenvironments 
in separate regions of the mouse pinna results in distinct patterns of lymphatic remodeling.   
Sutures were placed in the depilated Lyve1CreERT2tdT mouse pinna.  Three days later, a large 
bolus dose of CFSE-labeled B16 melanoma cells in suspension was injected into the margin of 
the pinna.  Tumor cells and lymphatic vessels were tracked for seven days by live imaging.  At 
necropsy on day seven, the two layers of ear skin were separated to reveal the intact lymphatic 
vessel plexuses, and the draining lymph nodes were examined for the presence of CFSE+ cells.  A.  
Intact pinna shows CFSE signal at site of tumor cell injection and sites of suture placement (*).  
B.  Two layers of ear skin are separated at necropsy.  Tumor cells have moved through tissue 
away from injection site.  C.  Higher magnification of designated area from B.  Lymphatic vessels 
display hypersprouting morphology in immediate vicinity of tumor cells.  In the right panel, 
three images taken at different focal depths were stitched together to form this micrograph.   
Black lines indicated by arrows demarcate transitions between the images.  D.  CFSE+ cells are 
present in draining lymph node.  E.  Higher magnification images of sites of suture placement.  
Characteristic “zone-of-clearing” is present around wound.  Some sprouting is present at lower 








Delivery of Tumor Cells to Cornea is Feasible and Cells Are Viable 
 To this point, all of our work had been done in the context of an orthotopic model of 
melanoma, i.e. study of B16 melanoma cells in the syngeneic murine skin.  To better address 
tumor-associated neuroremodeling and to track inflammatory new lymphatic vessel synthesis in 
a setting normally devoid of lymphatic vessels, we transitioned our studies to a corneal live 
imaging platform.  Our previous work had established the utility of micropellet implantation as a 
means to administer cytokine to the cornea, and we now tested this method for tumor cell 
delivery.  As there was some uncertainty about whether or not the corneal microenvironment 
would be hospitable to tumor cells, we also tested tumor cell viability after implantation. 
 Several methods of loading tumor cells onto micropellets were tested, and allowing 
tumor cells in high cell numbers in suspension to adhere to the pellet matrix was suitable (Figure 
19A).  Pellets were implanted into a pocket made by a small incision as described for cytokine 
pellets, and we determined that pocket placement either in the center of the cornea or at the 
midpoint between the corneal apex and temporal limbal arcade was feasible and facilitated the 
desired experiments.  Pellets could be placed in tissue with or without sutures without excessive 
disruption of ocular globe integrity (Figure 19B, C).  We also tested direct injection of tumor cell 
suspension into a corneal pocket and found this to be a reasonable alternative delivery method 
(Figure 19D).  The most notable difference in the two techniques was the dissemination of 
tumor cells from the injection site. 
 To ascertain tumor cell viability following injection we observed cell morphology by live 
imaging and followed CFSE+ cells in culture derived from harvested corneal explants previously 
injected with tumor cells.  Injected tumor cells often displayed spindle shaped morphology and 
cell-cell interactions visible by live imaging microscopy.  CFSE-labeled cells grew out of corneal 
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explants and could be subcultured and grown on coverslips for confocal microscopy (Figure 
19E).  CFSE signal was clearly present in cells; cells displayed expected morphology; nuclei were 




Figure 19. Tumor cells are viable after corneal implantation.  A.   CFSE-labeled B16 melanoma 
(shown here), E0771 breast cancer, or KPC pancreatic cancer cells were loaded onto a 
micropellet ex vivo.  B.  Sutured mouse cornea before tumor administration.  Size bar = 250 μm.  
C.  A tumor-bearing pellet was placed into a micropocket in the center of the cornea.  Presence 
of tumor cells was confirmed by live imaging immediately following pellet implantation.  Size bar 
= 250 μm.  D.  CFSE-labeled B16 melanoma cells (green) in suspension were directly injected into 
the Lyve1CreERT2tdT cornea and visualized by live imaging (endogenous tdTomato fluorescence, 
red).  Size bar = 250 μm.  E.  Five days after administration of tumor cells, corneal explants were 
placed in tissue culture.  CFSE+ cells grew out of explants onto coverslips and were imaged by 
confocal microscopy.  400X maximum intensity projection shown (CFSE, green; DAPI, blue).  Size 









Tumor Cells Induce Local Corneal Neuroremodeling 
Presence of tumor cells in the cornea had both local and field effects on nerve 
architecture.  In the presence or absence of sutures, delivery of a modest dose of tumor cells 
resulted in localized decreases in nerve density in the immediate vicinity of tumor cells (Figure 
20A, B).  This local effect was seen regardless of tumor position within the tissue.  Nerve density 
was decreased around cells located in the center or periphery of the cornea; proximity of tumor 
cells to sutures also did not affect this remodeling.  All classes of corneal nerves were affected, 
including large stromal trunks, subepithelial leashes, and epithelial nerve endings.  Local 
neuroremodeling was accompanied by broader effects.  In cases in which only a few tumor cells 
remained resident in the cornea after injection, we saw local nerve cluster formation and 
transition of the surrounding tissue to a more wound recovery-like phenotype.  Nerves 
displayed a more tortuous morphology and often terminated in small clusters (Figure 20C-E). 
Addition of tumor cells to an inflammatory microenvironment attenuated typical 
inflammatory neuroremodeling.  As characterized in Chapter I, in suture-mediated 
nonmalignant inflammation thickened nerves drive toward stimuli and are present at extremely 
high density at suture sites, often engulfing the foreign body (Figure 20F).  Here, nerve 
morphology was more variable and included nerves terminating in clusters typically only seen in 
wound recovery (Figure 2E), though large diameter sprouting lymphatic vessels confirmed that 




Figure 20. Tumor cells induce local neuroremodeling in the presence or absence of sutures.  A, 
D.  B16 melanoma cells were labeled with CMRA Orange CellTracker dye and injected into the 
uninflamed cornea.  Size bar = 250 μm.  A.  Tumor cells are resident at several locations within 
the tissue (arrows).  Corneas were harvested on day three and nerves stained for β-III tubulin.  
Size bar = 250 μm.  B.  Corneas were sutured and CMRA-labeled B16 melanoma cells were 
injected the same day.  Arrows indicate positions of tumor residence.  Tissue was harvested and 
stained as in A.  Size bar = 250 μm.  C.  CFSE-labeled B16 melanoma cells were injected into the 
cornea; tissue was harvested on day nine.  Size bar = 250 μm.  E.  Confocal micrograph of Lyve-1-
stained lymphatic vessels and β-III tubulin-stained nerves in the sutured cornea in the presence 
of injected CFSE-labeled B16 melanoma cells (arrows).  Size bar = 100 μm.  F.  Confocal 












Tumor Cells Induce Lymphangiogenesis 
 Our studies in the pinna were limited by the nature of that tissue’s lymphatic 
vasculature.  The dense regularly distributed lymphatic vessels present in homeostasis were 
capable of only minor localized remodeling events after suture placement or tumor challenge.  
We used the corneal platform to investigate tumor-directed new lymphatic vessel synthesis; this 
was facilitated by the lack of vascularization under steady state conditions.   
 We injected tumor cells into micropockets in unsutured corneas.  By day two (Figure 
21A, upper panel), some tumor cells had migrated away from the micropocket and spread 
through the corneal tissue.  Many of these cells had moved to the limbal region, where nerve, 
lymphatic, and blood vessel arcades are located.  The majority of injected cells remained at the 
injection site.  By day six (Figure 21A, middle panel), new lymphatic vessels had sprouted from 
the limbal vessels and were growing toward the tumor cells.  Most of the cells that had migrated 
away from the injection site were no longer visible in the tissue.  Marked lymphangiogenesis 
occurred by day eight (Figure 21A, lower panel).  New lymphatic vessel growth was more 
pronounced from limbal locations nearer the tumor cells, but sprouting occurred from limbal 
lymphatic vessels in each corneal quadrant (Figure 21B).  Single tdTomato+ cells also migrated 
through the tissue toward the tumor burden.  These results support the hypothesis that there is 
a secreted chemotactic factor gradient emanating from tumor cells that directs lymphatic vessel 





Figure 21. Tumor cells alone stimulate new lymphatic vessel growth.  CFSE-labeled B16 
melanoma cells were injected into a Lyve1CreERT2tdT mouse corneal micropocket placed near 
the temporal limbus.  A.  Tumor cells and lymphatic vessels were monitored by fluorescence live 
imaging microscopy for eight days at 32X, 50X, and 80X.  Size bar = 100 μm.  B.  Each quadrant of 
harvested tissue was imaged at 100X by epifluorescence microscopy and images were compiled 
to form composite images shown.  Tumor injection site is bright focus in bottom right image of 
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Unique Lymphatic Structures Arise in Inflammatory Lymphangiogenesis in the Presence of 
Tumor Cells  
 We identified several types of unique lymphatic vessel behavior and architecture in 
tissues bearing both sutures and tumor cells (Figure 22, Figure 23, Figure 24).  We previously 
established that in corneal tissue inflamed by sutures alone, lymphatic vessels adopted a 
chalice-like morphology as they neared the location of a suture and did not penetrate within the 
immediate vicinity of the suture (Figure 2B, Figure 20F).  This did not change in the presence of a 
tumor pellet in the center of the cornea with sutures in each quadrant (Figure 22A).  Conversely 
however, hypertrophic lymphatic vessels with activated multi-sprouted tips approached and 
invaded tumor pellets from all directions, completely taking them over in some cases (Figure 
22A, B, Figure 24A).  Tumor cells interacted with newly synthesized lymphatic vessels (Figure 
22C), and single tdTomato-expressing cells could be seen in close contact with tumor cells as 
well near tumor pellets (Figure 22D).  Although blood vessels do not express Lyve-1 and do not, 
therefore, express tdTomato fluorescent protein in the Lyve1CreERT2tdT mouse model, we were 
able to visualize the contrast of dark blood flowing in these vessels against the autofluorescence 
of the eye lens.  Angiogenesis also occurred in these corneas, and sprouting blood capillaries 
invaded tumor pellets along with lymphatics (Figure 22B, Figure 24A).  
We also identified disorganized lymphatic vessels sprouting from the corneal limbus in 
response to both a large injected tumor burden and tumor bearing pellets (Figure 24) in sutured 
tissue.  Highly irregular lymphatic endothelial sprouts with no discernable organized vascular 
architecture grew out of the limbus near tumor pocket placement (Figure 23).  This occurred in 
tissue that was sutured the same day as tumor injection.  In tissue that was pre-sutured six days 
before tumor pellet placement, two types of lymphatic vessels were present (Figure 24C).  
Large, well-organized vessels with both sprouting and bulbous termini typical of suture-
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mediated lymphangiogenesis were present alongside thin, disorganized, discontinuous 
structures that appeared to be immature or incompletely synthesized.  Many single cells were 
present in these regions, many of which were elongated.  Live imaging of these structures over 
time with the aid of tissue landmarks highlighted their disorganized nature and suggested that 
some of the larger, more typical lymphatics in these regions were well-established prior to 
tumor implantation and had originally been stimulated by suturing, while the more disorganized 
structures emerged in the presence of tumor burden (Figure 24B). 
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Figure 22. Lymphatic vessels respond differently to suture and tumor stimuli.   CFSE-labeled 
B16 melanoma cells were loaded onto micropellets and placed in pockets in the center of 
Lyve1CreERT2tdT corneas that had been sutured with four 10-0 nylon sutures six days earlier.  
Tumor cells (green) and tdTomato+ lymphatic vessels (red) were tracked by live imaging 
microscopy for several days.  A.  Sutures are indicated by asterisks (*).  Pellets are outlined with 
dashed lines.  Size bar = 100 μm.  B.  Blood vessels are visible as dark structures against lens 
autofluorescence alongside lymphatic vessels and tumor cells.  Size bar = 100 μm.  C.  Tumor cell 
interactions with newly-synthesized lymphatic vessels (arrows).  Size bar = 100 μm.  D.  Single 
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Figure 23. New lymphatic vessels growing in the presence of sutures and large tumor burden 
are disorganized.  Lyve1CreERT2tdT corneas were sutured with four 10-0 nylon sutures and 
injected with a large dose of CFSE-labeled B16 melanoma cells on the same day.  A.  Tumor cells 
(green) and lymphatic vessels (red) were tracked for eight days by live imaging microscopy.  
Dashed line indicates limbus.  Size bar = 100 μm.  B.  100X epifluorescence micrograph of 
endogenous tdTomato signal in lymphatic vessels sprouting from limbus (dashed line) in fixed 
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Figure 24. Presence of lymphatic vessels of two distinct morphologies in corneas bearing 
sutures and tumor cells.  CFSE-labeled B16 melanoma cells were loaded onto micropellets and 
placed in pockets in the center of Lyve1CreERT2tdT corneas that had been sutured with four 10-0 
nylon sutures six days earlier.  A, B.  Tumor cells and tdTomato+ lymphatic vessels were tracked 
by live imaging microscopy for several days.  A region of interest was identified for closer 
monitoring over time with landmarks (A, Day 6, dashed box).  Blue dot indicates suture 
landmark.  Yellow star indicates hooked lymphatic vessel landmark.  Time course of images of 
this region make up B.  Size bar = 100 μm.  C.  100X epifluorescence micrograph of tdTomato+ 
lymphatic vessels co-immunostained for Lyve-1 with a 549 nm emission wavelength (overlaps 














Simultaneous Establishment of an Inflammatory Microenvironment Prolongs Tumor 
Residency in Cornea 
 In several of our previous experiments, we noted an effect of the inflammatory status of 
corneal tissue on success of prolonged tumor imaging after tumor delivery.  To further study this 
effect, we established three microenvironmental conditions in the cornea prior to tumor cell 
injection by placing sutures at different time points and following tumor cell signal over time by 
live imaging.  Corneas were unsutured, sutured three days before injection of tumor cells (pre-
sutured), or sutured immediately prior to tumor injection on the same day.  We performed 
these experiments with two different cell lines syngeneic to C57BL/6 mice:  E0771 estrogen 
receptor+ medullary breast carcinoma cells and KPC pancreatic adenocarcinoma cells.  Similar 
results were seen with both cell lines.  By day two after injection, cells were distributed 
throughout the cornea in all conditions.  By day four, the groups had separated.  Unsutured 
corneas had only a few cells remaining; these were concentrated at the injection site and near 
the limbal vascular arcade.  The few cells remaining in the pre-sutured corneas were resident at 
the injection site and near sutures.  By contrast, corneas that had been sutured the same day as 
tumor injection had tumor cells distributed throughout—at the injection site, sites of sutures, 
near the limbus, and in the corneal parenchyma away from any of these structures.  These 
results suggested that aspects of the earliest events in the establishment of a suture-mediated 
inflammatory response in the cornea (before day three) affected tumor biology such that cells 




Figure 25. Timing of inflammatory microenvironment establishment influences tumor cell 
behavior in tissue.  E0771 breast cancer or KPC pancreatic cancer cells were labeled with CFSE 
(green) and injected into a micropocket of a C57BL/6 mouse cornea in one of the following 
conditions:  unsutured, sutured three days prior to tumor injection, or sutured the same day as 
tumor cell administration.  Live imaging was performed on days two and four post tumor 
injection and corneas were harvested on day four.  Harvested tissue was fixed and lymphatic 
vessels were immunostained for Lyve-1 (orange).  Live imaging: 32X.  Epifluorescence: 100X.  









Distinct Stimulus-Dependent Neurolymphatic Remodeling Signatures and Mini-
Microenvironments 
 We used live imaging microscopy to visualize kinetics and dynamics of lymphatic vessel 
remodeling in physiologically distinct microenvironmental conditions induced by physical injury 
or tumor burden.  Sutures caused directional lymphangiogenic sprouting from existing vessels, 
but nascent lymphatics did not enter a “zone-of-clearing” immediately surrounding each suture.  
Tumor-associated lymphangiogenesis was quite different.  The presence of a very small number 
of tumor cells resulted in a disorganized multi-directional hypersprouting lymphangiogenic 
phenotype.  This effect was even more pronounced in the presence of a larger tumor burden.  
Lymphatic vessels were not inhibited from entering the tissue immediately adjacent to tumor 
cells; sprouting lymphatics contacted and invaded tumor-bearing pellets and interacted directly 
with tumor cells.  These two distinct stimulus-dependent modes of new lymphatic vessel growth 
were not mutually exclusive.  Placing sutures and tumor cells in the same pinna or cornea 
resulted in localized lymphangiogenesis responses commensurate with stimulus type.  This 
intra-tissue variability, even in a region as small as one quadrant of the mouse cornea, 
demonstrated the true micro nature of a microenvironment.  Regardless of inflammatory status 
or presence of malignancy, “tissue microenvironments” are inherently hypervariable and plastic 
and are composed of an infinite number of stochastically shifting mini-microenvironments 
responding to changes in local complements of cytokines, resident cell types, tissue pressure, 
metabolite flux, etc.   
 We also found stimulus-dependent differences in neuroremodeling.  Similar to the 
effect on lymphatic vessels, placement of a suture resulted in a directional shift in nerve 
organization, with nerves bending to track toward the stimulus.  Nerves grew into and around 
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suture knots at very high density.  Addition of tumor cells to a sutured environment resulted in 
both local and broader neuroremodeling effects.  Tumor cell presence in an inflamed tissue 
caused local decreases in density of nervous structures of all sizes; this was in contrast to the 
effect seen upon tumor placement in unsutured tissue in which tumor cells caused local nerve 
cluster formation.  A transition toward a more tortuous phenotype and the presence of small 
nerve clusters was also broadly seen in sutured tissue with tumor cells.  The appearance of 
nerve clusters in these two tissue states—unsutured + tumor and sutured + tumor—was striking 
given our previous characterization of this phenotype as a feature restricted to wound-
recovered tissue (sutures placed to induce inflammation, then removed to stimulate healing).   
Simultaneous Inflammation Prolongs Tumor Residency 
 We unexpectedly found that placement of tumor cells and sutures in the cornea on the 
same day prolonged tumor residency.  This was an incidental finding of several preliminary 
experiments with B16 melanoma cells and was confirmed using both the E0771 medullary 
breast carcinoma cell line and a KPC pancreatic adenocarcinoma cell line.  The majority of tumor 
cells injected into the unsutured mouse cornea were no longer visible by live imaging or 
epifluorescence microscopy of fixed tissue after several days.  Pre-inflammation of tissue by 
placement of sutures three days before tumor injection resulted in a similar loss of tumor signal, 
although some cells remained near sutures and at the injection site.  In striking contrast to these 
two conditions, signal from tumor cells injected into the cornea on the same day as suturing was 
visible for several days by live imaging as well as in fixed whole mount corneas.   
 We considered the possibility that in the same-day sutured condition, lymphatic vessel 
sprouts (and sprouting blood vessels) would not have had sufficient time to extend and mature 
as may be required for tumor cell trafficking away from the injection site.  In our live imaging 
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experiments we documented the simultaneous presence of “typical” large newly-synthesized 
lymphatic vessels and disorganized incomplete atypical lymphatic structures in pre-sutured 
tissue.  The presence of larger suture-induced lymphatics in pre-sutured tissue may have 
provided a means of migration out of the cornea for tumor cells in the pre-sutured condition 
that was not yet available to tumor cells in the same-day sutured group.  While this may be true, 
we also saw loss of tumor cell signal in the unsutured condition.  We showed that injection of 
tumor cells is sufficient to induce lymphangiogenesis in unsutured tissue, but it seems that the 
low level of lymphangiogenic sprouting in response to tumor cells in the early days of 
implantation would not be sufficient to quickly clear a large injected tumor burden.  If this were 
the case, it would also be reasonable to assume a similar tumor-lymphangiogenesis effect in 
same-day sutured tissue.  Taken together, this suggested that another mechanism must explain 
the extended residency of cells in the same-day group.   
 We also considered attack of tumor cells by phagocytic immune cells as an explanation 
for loss of tumor signal.  Again, however, the similarity in tumor behavior between the 
unsutured and pre-sutured conditions was confounding.  Infiltrating immune cells would 
presumably travel through lymphatic and/or blood vasculature to reach the tumor site and 
enter the corneal parenchyma.  This could explain the difference between the pre-sutured and 
same-day sutured conditions, but not the unsutured group.  Relative immune privilege is a well-
described characteristic of the unmanipulated cornea.  Additionally, were phagocytic immune 
cells responsible for clearing of tumor cells, we would still expect to see CFSE signal in these 
cells. 
 While the answer to this question remains unclear, we suggest that aspects of the 
earliest events of inflammation predispose tumor cell residence in the cornea.  These may, in 
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fact, be considered either positive or negative regulators of tumor cell behavior, depending on 
point of view.  Inflammatory factors in the tissue may, for example, down regulate cell migration 
and proliferation causing them to stay resident at their point of injection with little diminishing 
of signal.  Contrariwise, factors may promote cell survival in this condition while cells without 
the benefit of a new inflammatory reaction undergo cell death and signal diffuses away.  It is 
also possible that two different mechanisms govern loss of cell signal in the unsutured and pre-
sutured conditions.  Dissecting these nuances will require more careful study, however, these 
results demonstrate the importance of inflammation in the establishment and progression of a 
tumor.  
Additional Uses for Lyve1CreERT2tdT Live Imaging Platform 
The Lyve1CreERT2tdT cornea and pinna live imaging platforms we have described here 
could be used in the future to study many other aspects of basic lymphatic biology and tumor-
lymphatic interactions.  Some key questions to be addressed might include:  How does a tumor 
cell intravasate into a lymphatic vessel?  Do specific features of lymphatic vessel architecture or 
physical properties of tumor cells affect this process?  How do circulating tumor cells in 
lymphatic vessels pause, extravasate, and enter tissues to form metastases?  Do these processes 
differ from mechanisms used by leukocytes?  Might putative druggable targets be identified that 
regulate physical lymphatic remodeling?  Do other characteristics of organ-specific 
microenvironments affect the biology of metastasis for tumor cells that arise there?  Inflamed 
corneal lymphatic vessels may be activated to facilitate immune cell trafficking.  Do these 
activation properties also equip lymphatic vessels to support tumor cell trafficking, or are they 
not required by tumor cells?  What role do Lyve-1-expressing macrophages play in lymphatic 
vessel remodeling and interactions with tumor cells?  Does “flipping the switch” from 
inflammation to wound recovery in the tumor microenvironment affect tumor cell proliferation 
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and metastasis?  How does the presence of specific cytokines affect tumor-lymphatic 
interactions?  What molecular features distinguish tumor- and suture-associated lymphatic 
vessels?  Intravascular tumor cells from those that remain resident in tissue?  Can these features 







CHAPTER III.  Pancreatic Cancer Cachexia in Rapid 





Pancreatic ductal adenocarcinoma patients are often plagued with the paraneoplastic 
syndrome cachexia.  This progressive disease has been linked to low-grade systemic 
inflammation and as such has broad effects on several aspects of patient quality-of-life.  
Cachexia results in unintentional weight loss, loss of muscle mass, weakness, and increased 
frailty.  Cancer-associated cachexia may cause reduced tolerance for chemotherapy and has 
been implicated in decreased overall survival.  Despite the importance of this disease for 
outcomes and quality-of-life, little is known about the effects of cachexia on skeletal muscle of 
PDAC patients.  The KPC mouse model of PDAC, designed to develop spontaneous pancreas 
tumors, does show a cachexia phenotype (Hingorani et al., 2005), but while animal models can 
provide some insight into human disease, these artificial systems often fall short in their 
attempts to mirror the intricacy of the human condition.   
We studied PDAC-associated cachexia in skeletal muscle samples taken from patients 
within hours of death at rapid autopsy and normal control samples from cancer-free donors.  
We isolated total muscular RNA and examined the expression levels of six genes reported to be 
important in cachexia, involved in muscle atrophy or wasting, or activated in exercise.  The 
genes we studied were:  Fibroblast activation protein alpha (FAP), follistatin (FST), 
calcium/calmodulin-dependent protein kinase type II subunit beta (CAMK2B), tyrosine kinase 
with immunoglobulin-like and EGF-like domains 1 (TIE1), tripartite motif containing 63 (TRIM63), 
and F-box protein 32 (FBXO32).   
FAP-α expression has been reported in cancer-associated fibroblasts (CAFs) and stromal 
cells of other tissues including skeletal muscle.  Cachectic KPC mice displayed decreased skeletal 
muscle mass and reduced levels of Fap and Fst gene expression (Roberts et al., 2013).  We 
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expected to find similar decreases in FAP and FST expression levels in our human cachexia 
samples.  CAMK2B and TIE1 were identified as possible biomarkers of cancer-associated 
cachexia in a study of upper gastrointestinal cancer (including pancreatic) patient muscle 
samples (Stephens et al., 2010).  We expected to see increased expression of these exercise-
activated genes in cachexia patients over non-cachectic or normal controls.  TRIM63 and 
FBXO32 are E3 ubiquitin ligases important in the ubiquitin-proteasome pathway of protein 
degradation.  Studies in rat models of muscle atrophy first described the importance of the E3 
ubiquitin ligase family of proteins in muscle disease.  Animal homologs of human TRIM63 and 
FBXO32 were consistently upregulated across models; loss of either of these enzymes resulted 
in resistance to muscle wasting (Bodine et al., 2001).  We expected to detect increased levels of 






Materials and Methods 
Rapid Autopsy Procedures 
Local patients diagnosed with pancreatic cancer voluntarily enrolled in a Rapid Autopsy 
Pancreas (RAP) program.  Trunk-only autopsies were performed within approximately three 
hours of death by a pathologist, pathology resident, and research volunteer sample collection 
team at the University of Nebraska Medical Center.  All abdominal organs were removed and 
analyzed for presence of pancreatic adenocarcinoma grossly and by microscopic histology.  
Organs typically examined and collected included:  pancreas, spleen, liver, stomach, gall bladder, 
adrenal gland, kidney, small bowel, large bowel, rectum, prostate, diaphragm, lung, heart apex, 
omentum, nerve, lymph node, and skeletal muscle.  Organs were sliced into approximately 
0.75” thick sections and each section was macrodissected and annotated with regard to disease 
presentation according to the following pathologic designations:  primary tumor (pancreas 
only), metastatic lesion, margin of primary or metastatic tumor and uninvolved parenchyma, or 
uninvolved parenchyma.  Dissected specimens were flash frozen in liquid nitrogen, transferred 
to dry ice, and stored long-term at -80°C.  Skeletal muscle was customarily collected from psoas 
or pectoral muscle. 
Skeletal Muscle Specimens from Normal Patients 
 Normal control human skeletal muscle samples were obtained from the Comparative 
Human Tissue Network or the National Disease Research Interchange.  Only fresh frozen muscle 
from donors without a previous cancer diagnosis was accepted.  Muscle samples were received 
after shipment on dry ice and stored at -80°C.  Demographic information for PDAC patients and 











Mean Age 68.03 54.73
Sex (M/F) 38/20 14/1
Race
     White 57 14
     Hispanic 0 1
     Black 1 0
 Table 1. Muscle Donor Characteristics 
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Designation of Cachexia Status 
 Cachexia status (Yes or No) was assigned at autopsy by a pathologist at the University of 
Nebraska Medical Center in Omaha, NE.  These two groups were further stratified into the 
following categories based on weight loss, BMI, and other clinical or pathology notes:  yes, 
severe cachexia (S); yes, weight loss (YWL); yes, normal or overweight BMI (YN); no, weight loss 
(NWL); no, normal or overweight BMI (NN); and no, obese (NOB).  Patients included in group S 
were of normal or underweight BMI and presented with significant weight loss of greater than 
14 kg, or were of normal or underweight BMI and had a specific pathology note such as “severe 
cachexia” or “emaciated; presented with extreme weakness”.  YWL inclusion criteria were 
normal or overweight BMI at autopsy and weight loss of greater than 3 kg.  YN patients were of 
normal or overweight BMI and did not have weight loss.  The NWL group was composed of 
patients who were not cachectic and had weight loss of greater than 3 kg.  NN patients did not 
have cachexia and were of normal or overweight BMI.  Patients in the NOB category were not 
cachectic and had a BMI in the obese range at autopsy. 
Pancreatic Cancer Collaborative Registry 
 The Pancreatic Cancer Collaborative Registry is a database maintained by the University 
of Nebraska Medical Center in Omaha, NE.  This database contains demographic data about 
pancreatic cancer patients as well as treatment histories, information about family members, 
and lifestyle data such as alcohol and tobacco use.  We had access to data from the first 50 rapid 
autopsy patients, or 74% of the population included in our other analyses. 
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RNA Isolation Procedure, Reagents, and Quality Control 
Total RNA was isolated from muscle specimens of approximately 0.3 g in mass according 
to our modified TRIzol extraction protocol optimized for skeletal muscle4.  RNA concentration 
and presence of contaminants was tested using a NanoDrop 1000 spectrophotometer and ND 
1000 V3.6.0 software (ThermoFisher Scientific).  RNA quality was tested by Fragment Analyzer 
(Advanced Analytical Technologies, Inc., Ames, IA) or BioAnalyzer (Agilent Technologies, Inc., 
Santa Clara, CA).  Data was analyzed using the ProSize 2 software (Advanced Analytical 
Technologies, Inc., Ames, IA) or 2100 Expert software (Agilent Technologies, Inc., Santa Clara, 
CA).  RNA quality value of 6.0 was set as the minimum threshold for gene expression analysis.  
The average quality score for our normal control sample set was 6.8 and that of our 
experimental RAP sample set was 7.6. 
cDNA Library Construction and qRT-PCR 
cDNA libraries were constructed using the Verso cDNA kit (Cat. #AB1453A/B, 
ThermoFisher Scientific) according to the manufacturer’s instructions.  An additional digestion 
with RNase H (Cat. #18021071, ThermoFisher) to remove RNA-DNA duplexes was performed at 
37°C for 20 minutes following cDNA synthesis.  cDNA was stored at -20°C.   
Gene expression was quantified by qRT-PCR using 20X TaqMan Gene Expression Assay 
hydrolysis probes (Applied Biosystems) as shown in Table 2 at 1X (900 nM) in each 20 μL 
reaction.  Reactions were performed in triplicate using 2X Universal PCR Master Mix (Applied 
Biosystems) and analyzed on a BioRad C1000 Thermal Cycler CFX96 instrument (Bio-Rad 
Laboratories, Inc., Hercules, CA).  Automated reaction conditions were as follows:  Initial hold 
                                                          
 
4
 Full protocol provided in Appendix A. 
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50°C 2 minutes; Initial denaturation 95°C 10 minutes; 40 cycles of denaturation (95°C 15 
seconds), annealing and extension (60°C 1 minute); Final hold 4°C. 
Data Analysis and Statistics 
 Gene expression data were analyzed using the standard curve method.  Plasmids 
containing genes of interest were purchased from Open Biosystems and DNA isolated by 
QIAprep Miniprep (Qiagen) according to the manufacturer’s instructions.  Standard curves were 
generated by serial ten-fold dilution of plasmid DNA and amplification by qRT-PCR using TaqMan 
Gene Expression Assays.  R2 values and amplification efficiencies were within accepted ranges.  
Standard curves were used to calculate experimental copies per reaction.   These values were 
normalized to housekeeping gene TBP expression levels.  Standard curve regression equations 
and other calculations are shown in Table 2. 
Data were analyzed using statistical software GraphPad Prism 5 (GraphPad Software, 
Inc., La Jolla, CA).  Groups were compared using 1 way ANOVA and Tukey’s Multiple Comparison 
Test post-hoc.  (* indicates p < 0.05.  ** indicates p < 0.01.  *** indicates p < 0.001.)  Pearson 
correlation coefficient and associated p values were calculated for the Pancreatic Cancer Clinical 
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% Efficiency 108.34 100.07 89.28 95.26 95.40 92.76 107.34




Differences in Gene Expression in Pancreatic Cancer Patients vs. Normal Controls 
 We found significant differences in gene expression levels between PDAC patient 
skeletal muscle samples regardless of cachexia status and normal control skeletal muscle for all 
genes analyzed except FST (Figure 26).  FAP expression was lower in cancer patients compared 
to normal controls.  The same was true of CAMK2B expression.  TIE1 levels were also decreased 
in PDAC patients.  TRIM63 was expressed at a higher level in both cachectic and non-cachectic 
PDAC patients compared to normal controls.  FBXO32 gene expression was also higher in cancer 
patients than normal donors. 
Differences in Gene Expression in Cachectic vs. Non-Cachectic Pancreatic Cancer Patients 
 There were no significant differences in the expression of any of the genes we analyzed 
in skeletal muscle samples of cachectic and non-cachectic PDAC patients based on the original 
Yes/No cachexia status designations.  We decided to further stratify patients into subgroups 
based on additional clinical and pathology notes, weight loss history, and BMI at time of death.  
Cachectic and non-cachectic patients were reclassified into the following six subgroups:  yes, 
severe cachexia (S); yes, weight loss (YWL); yes, normal or overweight BMI (YN); no, weight loss 
(NWL); no, normal or overweight BMI (NN); and no, obese (NOB).  Specific inclusion criteria for 
each group are described above.   
Subgroup Gene Expression Analysis 
 There were no significant differences in gene expression between PDAC patient 
subgroups for any of the genes analyzed.  Gene expression in some subdivided groups was 
significantly different than normal controls.  YWL and NWL groups had lower expression of FAP 
than controls, but the other subgroups were no longer significantly different (Figure 27).  As 
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with the Yes/No analysis, no subgroups showed differential FST expression compared to normal 
controls (Figure 28).  Expression levels of CAMK2B (Figure 29) and TIE1 (Figure 30) were 
significantly lower in all subgroups compared to control levels.  For TRIM63, subgroups S, YN, 
NN, and NOB displayed higher expression than controls (Figure 31).  S, NWL, NN, and NOB 
samples had higher levels of FBXO32 than normal control muscle samples (Figure 32).   
PDAC Cachexia and Alcohol Use, Tobacco Use, and Diabetes Status 
 We analyzed Pancreatic Cancer Collaborative Registry data on alcohol use, tobacco use, 
and diabetes mellitus status of the majority of the PDAC patients included in this study (Table 3).  
We found no correlation between alcohol use, tobacco use, or diabetes status with cachexia 
status in our patient population.  There was also no correlation of any of these variables with 




Figure 26. Cachexia gene expression normalized to TBP.  Gene expression of putative cachexia-
associated genes in skeletal muscle samples from cachectic and non-cachectic pancreatic ductal 
adenocarcinoma patients and normal donor controls that had no history of cancer.  Data 
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Figure 27. FAP-α gene expression based on modified cachexia status.  Gene expression in 
skeletal muscle samples from cachectic and non-cachectic pancreatic ductal adenocarcinoma 
patients and normal donor controls that had no history of cancer.  Data normalized to TBP.   
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Figure 28. FST gene expression based on modified cachexia status.  Gene expression in skeletal 
muscle samples from cachectic and non-cachectic pancreatic ductal adenocarcinoma patients 
and normal donor controls that had no history of cancer.  Data normalized to TBP.  (Ns = not 
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Figure 29. CAMKIIβ gene expression based on modified cachexia status.  Gene expression in 
skeletal muscle samples from cachectic and non-cachectic pancreatic ductal adenocarcinoma 
patients and normal donor controls that had no history of cancer.  Data normalized to TBP.   
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Figure 30. TIE-1 gene expression based on modified cachexia status.  Gene expression in 
skeletal muscle samples from cachectic and non-cachectic pancreatic ductal adenocarcinoma 
patients and normal donor controls that had no history of cancer.  Data normalized to TBP.   
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Figure 31. TRIM63 gene expression based on modified cachexia status.  Gene expression in 
skeletal muscle samples from cachectic and non-cachectic pancreatic ductal adenocarcinoma 
patients and normal donor controls that had no history of cancer.  Data normalized to TBP.  





Figure 31  
182 
 
Figure 32. FBXO32 gene expression based on modified cachexia status.  Gene expression in 
skeletal muscle samples from cachectic and non-cachectic pancreatic ductal adenocarcinoma 
patients and normal donor controls that had no history of cancer.  Data normalized to TBP.   









Table 3. Cachexia Status Does Not Correlate with Alcohol or Tobacco Use or Diabetes 
Status 
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Previous Studies of Cachexia Gene Expression 
 We studied expression levels of genes previously reported to have a role in cachexia, 
muscle wasting, or exercise using skeletal muscle samples taken at rapid autopsy from 
pancreatic ductal adenocarcinoma patients and normal control muscle samples.  We found 
upregulation of FAP, TRIM63, and FBXO32 in PDAC samples irrespective of cachexia status 
compared to controls.  We found no significant difference in FST expression in PDAC samples 
with and without cachexia and compared to normal controls.  CAMK2B and TIE1 were 
downregulated in cachectic and non-cachectic PDAC skeletal muscle compared to controls.  We 
found no significant differences in gene expression between PDAC patients with and without 
cachexia.  Cancer cachexia is a progressive disease; further stratification of PDAC patients 
according to severity of cachexia, however, did not reveal additional differences in gene 
expression among cachectic and non-cachectic subgroups.   
Several studies have examined the role of FAP-α in cancer-associated cachexia and its 
relationship to FST, TRIM63, and FBXO32.  Depletion of FAP+ fibroblasts by genetic ablation or 
chimeric antigen receptor (CAR) T cell targeting caused muscle wasting and cachexia (Roberts et 
al., 2013; Tran et al., 2013).  KPC mice bearing spontaneous PDAC and mice with C26 colon 
tumors developed cancer-associated cachexia and concomitant decreases in FAP-expressing 
fibroblasts (Roberts et al., 2013).  These cells are the major source of FST, and their loss resulted 
in decreased FST levels.  Decreased FST was accompanied by concomitant increases in atrogin15 
and MuRF-1 (muscle RING finger protein-1) expression in cachectic mice only (Roberts et al., 
                                                          
 
5
 As much of the previous work in cancer cachexia was done in mouse models, alternative nomenclature 
is often used in referring to genes.  Atrogin-1 and MAFbx are alternative names for FBXO32.  MuRF-1 is 
another name for TRIM63. 
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2013).  Our findings of increased FAP expression and no change in FST levels in stand in contrast 
to these mouse data.  We also found parallels in gene expression of PDAC patient skeletal 
muscle samples regardless of cachexia status compared to cancer-free controls, while in the KPC 
mouse study, littermates and non-cachectic KPC gene expression profiles were consistently 
similar while cachectic KPC samples displayed a different pattern of expression.  A study of 
gastric cancer patients also found no change in FST expression across patient and control 
skeletal muscle samples.  That group, however, did not find increased ubiquitin ligase pathway 
genes; they reported no significant difference in levels of MuRF1 and atrogin-1 between cancer 
patient samples and controls (D'Orlando et al., 2014).  A study of several rat models of muscle 
atrophy reported increased expression of MuRF1 and muscle atrophy F-box (MAFbx) (Bodine et 
al., 2001).  A study of human upper gastrointestinal cancers, including PDAC, found no increases 
in ubiquitin ligase pathway genes TRIM63 and FBXO32 or exercise-activated genes CAMK2B and 
TIE1 expression, but these genes were upregulated in mouse models (Gallagher et al., 2012).  
Another study of human tissue found correlations between weight loss and the levels of 
CAMK2B and TIE1, but not MuRF1 or MAFbx (Stephens et al., 2010).  These discrepancies 
illustrate the limitations of animal models in recapitulating human disease and heterogeneity 
among cancer types and in human patient populations.   
Study Limitations 
Our study had several limitations.  First, we had a small sample size.  Nearly all of our 
patients and controls were white, and the age and gender distributions of normal tissue donors 
were different than those in the PDAC population.  Second, normal control samples in many 
cases were not derived from disease-free donors.  Tissue was excluded in the event of patient 
history of cancer, but many of the samples were taken from diseased limbs.  Co-morbidities 
associated with our control samples included gangrene, ischemia, vascular disease, and 
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osteomyelitis.  Finally, we profiled only gene expression.  Many levels of regulation lie between 
message levels and functional output of a specific protein. 
The universal differences in gene expression between RAP PDAC skeletal muscle 
samples and normal control samples raise the question of whether a fundamental difference in 
sample sets (such as tissue handling conditions) could be responsible rather than a biological 
effect.  There are several reasons why we do not believe that to be the case.  We used standard 
nucleic acid spectrophotometry and fragmentation analysis procedures to confirm RNA quality 
of each sample.  The average RNA quality score for the RAP cohort was 7.6, and that of the 
normal control group was 6.8, both of which were above the established lower threshold value 
of 6.0 for quantitative gene expression analysis.  Samples for which minimum quality thresholds 
could not be achieved after two extraction attempts were excluded from our study.  We also 
confirmed equal expression of housekeeping gene TBP across groups.  The mean TBP threshold 
cycle in the RAP group was 26.27, and that of the normal control group was 27.28; two outliers 
in the normal group with threshold cycle values of 31.43 and 32.65, respectively, were 
responsible for this shift, and their exclusion resulted in a normal group average of 26.48.  
Additionally, the bidirectional nature of the differences in experimental gene expression did not 
support the notion that one sample set was universally of poorer quality than the other.  Three 
of the genes studied were more highly expressed in normal control samples compared to RAP 
samples, one gene’s expression was not significantly different between groups, and two genes 
were present at lower levels in normal samples.  If the levels of all genes were lower in normal 
controls than RAP samples, we might conclude that the difference in RNA quality between the 
two cohorts (7.6 vs. 6.8) accounted for this difference, but that was not the case here.  
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Additional Studies with RAP Tissues Based on Cachexia Status 
Despite the relatively small number of patients who have been studied in the PDAC 
rapid autopsy program (nearly 100), the tissue samples in our repository are some of the most 
comprehensive and well-annotated in the world.  We routinely collect primary pancreas tumor, 
metastatic lesions from all involved organs, tumor margins, adjacent normal organ parenchyma, 
and other sites not directly infiltrated by carcinoma but that may nevertheless be affected by 
the systemic consequences of end-stage PDAC, such as skeletal muscle.  Clinical records are also 
available for these patients.  Future studies extending the work done here in pancreatic cancer 
cachexia could include evaluation of circulating inflammatory factors in patient serum samples, 
analysis of cardiac muscle for cachexia-associated pathology, studies of how the various 
pancreatic cancer treatment regimens affect cancer cachexia and vice versa, and examination of 
how cachexia impacts disease progression and overall survival.  Patient CT scans routinely 
performed in PDAC diagnosis and staging could also be used to track development of cachexia 
over time as it relates to disease progression and to include a quantifiable metric (lumbar 
skeletal muscle index) in the process of assigning cachexia status (Martin et al., 2013b; Tan et 
al., 2009).  Finally, although diabetes status did not correlate with cachexia in this analysis, 
evidence suggests a connection between diabetes mellitus and cachexia (Asp et al., 2010; 
Honors and Kinzig, 2012; Pannala et al., 2009).  Further studies with these unique tissues could 
more carefully dissect the interplay of insulin resistance, glucose neurotoxicity, pancreatic 







DISCUSSION AND FUTURE DIRECTIONS6 
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 Portions of this chapter have been published under the following references:  (Fink et al., 2014a), (Fink 
et al., 2015a) 
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Through the exploration of three aspects of inflammation—nonmalignant- and tumor-
associated neurolymphatic remodeling and crosstalk and cancer-associated cachexia—work 
presented in this dissertation has:  discovered a novel role of NGF in lymphatic vessel regulation 
in inflammation and wound recovery; identified distinct neurolymphatic architecture signatures 
present in inflammatory, wound-recovered, and tumor-associated microenvironments; 
characterized distinct spatiotemporal tumor cell behaviors dependent on timing of 
establishment of tissue microenvironmental inflammatory conditions; and challenged some 
previous findings regarding expression of muscle atrophy and exercise-associated genes in the 
paraneoplastic inflammatory syndrome PDAC cancer cachexia. 
NGF and Neurolymphatic Remodeling   
We first studied the resolution of two cardinal signs of non-malignant inflammation—
pain and swelling—by investigating molecular mechanisms that regulate neural and lymphatic 
vessel remodeling during the resolution of corneal inflammation.  A mouse model of corneal 
inflammation and wound recovery was developed to study this process in vivo.  We showed for 
the first time activity of NGF, the prototypical nerve survival and guidance molecule, on the 
lymphatic endothelium.  NGF influenced the two major lymphatic vessel remodeling events that 
accompany shifts in microenvironmental inflammatory status—lymphangiogenesis and 
lymphatic vessel regression.  The corneal micropocket assay revealed that NGF-laden pellets 
stimulated lymphangiogenesis and increased protein levels of VEGF-C.  Adult human dermal 
lymphatic endothelial cells did not express canonical NGF receptors TrkA and p75NTR or activate 
downstream MAPK- or Akt-pathway effectors in the presence of NGF, although NGF treatment 
increased their migratory and tubulogenesis capacities in vitro.  Blockade of the VEGFR-2/3 
signaling pathway ablated NGF-mediated lymphangiogenesis in vivo.  Administration of NGF also 
increased pain sensation and inhibited neural remodeling and lymphatic vessel regression 
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processes during wound recovery.  These findings suggested a hierarchical relationship with NGF 
functioning upstream of the VEGF family members, particularly VEGF-C, to stimulate 
lymphangiogenesis.  Taken together, these studies showed that NGF stimulates 
lymphangiogenesis and that NGF may act as a pathogenic factor that negatively regulates the 
normal neural and lymphatic vascular remodeling events that accompany wound recovery. 
Microenvironment-Specific Neurolymphatic Architecture Signatures:  
Implications for Therapy  
A major theme throughout this work has been the identification and characterization of 
novel neurolymphatic remodeling signatures present under distinct microenvironmental 
conditions.  We studied neurolymphatic remodeling in two mouse organ systems with distinct 
nerve and lymphatic architectures in homeostasis—cornea and pinna.  The cornea is one of the 
most densely innervated tissues in the body but is devoid of lymphatic vessels in homeostasis.  
Each skin leaflet of the pinna houses separate uniformly-distributed nerve and lymphatic vessel 
plexuses under normal physiological conditions.  We used these complementary systems to 
study neurolymphatic remodeling in non-malignant and tumor-associated inflammation and the 
resolution of inflammation, or wound recovery.  Suture or tumor stimuli were used to induce 
inflammatory conditions, and the removal of sutures stimulated wound recovery.  Growing 
evidence suggests that the resolution of inflammation is not, however, a passive process merely 
allowed by loss of inflammatory mediators as they diffuse away upon stimulus removal (Serhan 
and Savill, 2005; Serhan et al., 2007; Serhan et al., 2008), and our neurolymphatic remodeling 
results supported that idea.  We identified distinct neurolymphatic architecture signatures 
present in inflammatory, wound-recovered, and tumor-associated microenvironments.  We 
characterized non-malignant inflammatory lymphangiogenesis and neuroremodeling both in 
initial and recurrent inflammation, and we discovered three novel rapid neuroremodeling 
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phenotypes that characterized transitions into initial inflammation, from initial inflammation to 
wound recovery, and from wound recovery to recurrent inflammation.  We also identified novel 
neurolymphatic remodeling events that accompany malignancy.  We found distinct differences 
in nerve and lymphatic penetration into the site of a suture stimulus as compared to the site of a 
tumor including a dramatic hyper-sprouting phenotype in nascent tumor-associated lymphatic 
vessels.  These findings show that neurolymphatic architecture is highly responsive to 
microenvironmental conditions, and further organ-specific study of tumor-associated 
neurolymphatic signatures may identify targetable aspects of these remodeling events that are 
suitable for early detection imaging or treatment. 
PDAC Treatments:  Emphasis Lymphatics and Nerves 
Due to advanced stage at diagnosis and its complex microenvironmental organization, 
pancreatic ductal adenocarcinoma has proven to be very difficult to treat.  Surgical removal of 
the tumor is the most effective option, but only approximately 15% of cases are considered 
resectable (Yeo and Cameron, 1998; Zuckerman and Ryan, 2008).  Of those cases in which 
resection is an option, incomplete removal of microscopic disease (R1 residual margin status) 
only slightly improves patient survival over those cases presenting with unresectable metastatic 
disease (Chang et al., 2009; Konstantinidis et al., 2013).  Non-surgical options for pancreatic 
cancer include radiation, chemotherapy, or a combination of both.  Some approved 
chemotherapies for the treatment of pancreatic cancer are the use of FOLFIRINOX (combination 
of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin), gemcitabine, albumin-bound paclitaxel, 
and cisplatin (as well as others) (Gresham et al., 2014; Tempero et al., 2014).  However, these 
drugs have had limited success in prolonging patient survival.  Development of targeted 
therapies that specialize in blocking crucial molecular pathways of the pancreatic tumor and its 
microenvironment is becoming an increasingly attractive therapeutic option.   
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Pancreatic Tumor Resection, Lymphadenectomy, and Nerve Plexus Removal 
Surgical resection of pancreatic adenocarcinoma was first brought to clinical practice by 
Walther Kausch in Berlin in 1909 (Gerdes et al., 2005).  Beginning in the mid-1930s, American 
surgeon Allen O. Whipple further employed and modified the pancreat(ic)oduodenectomy (PD) 
procedure that would bear his name; he eventually condensed the surgery into a single 
operation, the first of which was successfully performed in 1940 (Whipple, 1941).  In a 
traditional PD the head of the pancreas is removed along with the duodenum, gall bladder, and 
end of the common bile duct (Bhatti et al., 2010; Doi et al., 2007; Duanmin et al., 2013; Henne-
Bruns et al., 1998; Henne-Bruns et al., 2000; Hirono et al., 2012; Kanda et al., 2011; Kocher et al., 
2007; Murakami et al., 2010; Sergeant et al., 2013; Zacharias et al., 2007).  Several timely 
surgical advances facilitated increased success of the PD as performed by Whipple and his 
contemporaries including the first successful duodenectomy in a canine, the discovery that 
direct immediate restoration of biliary and pancreatic secretions into the gastrointestinal tract 
was not necessary for survival of patients, and the use of non-dissolvable silk suture rather than 
the more temporary catgut (Howard, 1999; Whipple, 1941).  Additional scientific breakthroughs 
critical for decreased perioperative morbidity and mortality included the discovery and synthesis 
of vitamin K, the discovery of insulin, and the description of human blood types and subsequent 
establishment of blood banks (Howard, 1999; Whipple, 1941).  Today, a broad range of similar 
pancreatic resection procedures are in use in modern surgical practices around the world.  
Differences in primary tumor placement within the pancreas—head/neck vs. body/tail—and 
tumor invasion into surrounding tissues and organs often necessitate customization of resection 
(Cui et al., 2011; Dansranjavin et al., 2006; Formentini et al., 2009; Kamisawa et al., 1995; 
Kurahara et al., 2004; Liu et al., 2015a; Ohta et al., 1994; Pignatelli et al., 1994; Sergeant et al., 
2009; Tempia-Caliera et al., 2002; Wang et al., 2012; Yamamoto et al., 2014) beyond the 
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traditional PD to such procedures as distal pancreatectomy with or without splenectomy 
(Duanmin et al., 2013; Nagai et al., 2011), pancreaticogastrostomy (Zacharias et al., 2007), 
pylorus-preserving PD (Doi et al., 2007; Hirono et al., 2012; Murakami et al., 2010), pylorus-
resecting PD (Hirono et al., 2012), subtotal stomach-preserving PD,  pancreatojejunostomy, 
duodenum-preserving head resection, wedge resection of inferior vena cava, and total (Kocher 
et al., 2007) or regional (Tao et al., 2006) pancreatectomy (Kobayashi et al., 2010; Shimada et 
al., 2006).   
As with surgical treatment of other malignancies, one of the most controversial aspects 
of modern pancreatic ductal adenocarcinoma resection has been the extent to which 
surrounding connective tissue, lymph nodes, and neural tissue should be removed.  Evidence 
suggests that metastasis to lymph nodes is an early event in pancreatic cancer progression, and 
presence of tumor cells in lymph nodes represents one of the most negative prognostic factors 
with respect to patient outcomes (Benassai et al., 1999; Chen et al., 2010; Doi et al., 2007; Fujita 
et al., 2010; Kanda et al., 2011; Nakagohri et al., 2006; Winter et al., 2006; Yamamoto et al., 
2004).  Conservative surgical views support the standard PD with loco-regional 
lymphadenectomy (Evans et al., 2009; Farnell et al., 2005; Farnell et al., 2008; Gerdes et al., 
2005; Henne-Bruns et al., 1998; Henne-Bruns et al., 2000; Hirata et al., 1997; Kanda et al., 2011; 
Michalski et al., 2007; Murakami et al., 2010; Nagai et al., 2011; Nimura et al., 2012; Pawlik et 
al., 2005; Pederzoli et al., 1997; Pissas, 1984; Samra et al., 2008; Sergeant et al., 2013; Shimada 
et al., 2006; Yeo et al., 2002), while others, most notably numerous Japanese groups, advocate 
that a more radical PD with extensive removal of retroperitoneal soft tissue and extended 
lymphadenectomy (Fernandez-Cruz et al., 1999; Henne-Bruns et al., 1998; Ishikawa et al., 1988; 
Kanda et al., 2011; Katuchova et al., 2012; Kocher et al., 2007; Manabe et al., 1989; Masui et al., 
2013; Meriggi et al., 2007; Nakao et al., 1995; Ohta et al., 1993; Pedrazzoli et al., 1998; Riall et 
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al., 2005; Sergeant et al., 2013) results in better patient outcomes.  Collected studies in Table 4 
(Benassai et al., 1999; Bittner et al., 1989; Dasari et al., 2015; Doi et al., 2007; Evans et al., 2009; 
Farnell et al., 2005; Farnell et al., 2008; Fernandez-Cruz et al., 1999; Fujii, 2013; Gerdes et al., 
2005; Henne-Bruns et al., 1998; Henne-Bruns et al., 2000; Hirata et al., 1997; Hirono et al., 2012; 
Imai et al., 2010; Iqbal et al., 2009; Ishikawa et al., 1988; Jang et al., 2014; Kanda et al., 2011; Ke 
et al., 2014; Kocher et al., 2007; Manabe et al., 1989; Masui et al., 2013; Meriggi et al., 2007; 
Michalski et al., 2007; Nakao et al., 1995; Nguyen et al., 2003; Nimura et al., 2012; Ohta et al., 
1993; Pawlik et al., 2005; Pederzoli et al., 1997; Pedrazzoli et al., 1998; Pedrazzoli, 2015; 
Peparini, 2015; Pissas, 1984; Riall et al., 2005; Roche et al., 2003; Samra et al., 2008; 
Schoellhammer et al., 2015; Sergeant et al., 2013; Shimada et al., 2006; Svoronos et al., 2014; 
Tol et al., 2014; Yeo et al., 1999; Yeo et al., 2002) demonstrate the broad range of study designs 
and conclusions that have fueled this debate.  A recent set of randomized, controlled clinical 
trials from several centers around the world and a mathematical model of outcomes prediction 
have concluded that extended lymphadenectomy does not improve survival over traditional, 
more conservative resection and that quality-of-life may be decreased with more radical surgery 
(Farnell et al., 2005; Farnell et al., 2008; Jang et al., 2014; Michalski et al., 2007; Nguyen et al., 
2003; Nimura et al., 2012; Pawlik et al., 2005; Pedrazzoli et al., 1998; Riall et al., 2005; Yeo et al., 
1999; Yeo et al., 2002).  Leading international surgical groups have also applied their expertise to 
the ongoing conversation in this field.  They have recently identified lymph node stations to be 
included in standard lymphadenectomy for head (5, 6, 8a, 12b1, 12b2, 12c, 13a, 3b, 14a, 14b, 
17a, and 17b) and body/tail (10, 11, 18) pancreatic cancer resections (Tol et al., 2014) and have 
released recommendations suggesting discontinued use of extended lymphadenectomy for 
treatment of PDAC (Evans et al., 2009; Sergeant et al., 2013; Tol et al., 2014).  The occasional 
case report continues to demonstrate the biological diversity of pancreatic malignancy and 
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challenge these recommendations.  In 2013 a Japanese group reported that extended 
lymphadenectomy in a well-differentiated, chemotherapy-responsive PDAC with para-aortic 
lymph node metastases resulted in patient survival of over ten years (Masui et al., 2013).  
Peparini, et al., addressed para-aortic lymph node involvement (stations 16a2 and 16b1), stating 
that involvement of these lymph nodes may be due to direct invasion of the primary pancreatic 
tumor as opposed to dissemination and seeding of migratory cancer cells in the traditional 
definition of metastasis and that their removal may favorably impact R margin status (Peparini, 
2015).  Clinical trials and expert consensus recommendations consistently recommend standard 
lymphadenectomy over more radical resection strategies, but, as each case of pancreatic cancer 
is truly a unique disease, circumstances in which extended lymph node removal is beneficial 
may be more clearly defined in the future. 
Controversy also exists with regard to the amount of nervous tissue that should be 
removed as part of pancreatic tumor resection (Reviewed in (Fernandez-Cruz et al., 1999; Samra 
et al., 2008)).  Nerve invasion by PDAC cells occurs both in intrapancreatic nerves as well as 
extending to peripancreatic nerve plexuses.  As with lymphadenectomy, the concept of nervous 
tissue removal is founded on the principle that in order to prevent recurrence, all local 
reservoirs of tumor cells must be surgically eradicated.  And as with other radical resection 
procedures, aggressive surgical strategy must be balanced with undesirable side effects 
attributable to tissue removal as peripancreatic nerve plexus removal often results in severe 
diarrhea.   
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Table 4. Standard (sLE) vs. Extended (eLE) Lymphadenectomy for Treatment of PDAC:  





Results/Conclusions Supported LE Type 
Masui 2013 CR 
In selected cases eLE can result in long-term patient survival:  here 
well-differentiated, chemotherapy-responsive pancreatic cancer 





Survival trends toward an increase in node positive patients with 
PD + eLE and retroperitoneal tissue removal over sLE; No increase 
in operative morbidity/mortality Extended 
Riall 2005 P 
Survival trends toward an increase in pylorus-preserving PD with 
retroperitoneal LE and distal gastrectomy in PDAC patients, but 
this may be due to increased positive resection margins in 




Survival increased with eLE but may be due to patient selection; 




eLE and connective tissue removal is recommended for regional 




Survival increased with radical pancreatectomy including soft 




Extended peripancreatic and locoregional LE including removal of 
nerve and connective tissue reduces local recurrence in tumors < 4 
cm in diameter Extended 
Nakao 1995 R 
eLE including PALNs should be performed in patients with pancreas 
head cancer Extended 
Ohta 1993 R 
eLE and removal of retroperitoneal connective tissue is 
recommended for curative resection  in tumors macroscopically 




Removal of primary tumor as well as eLE and removal of nerve 
plexus, soft tissue, and portions of nearby blood vessels are 
necessary to prevent tumor recurrence and spread Extended 
Samra 2008 Rv 
Modified en bloc resection (including removal of lymphatics and 
neural tissue associated with superior mesenteric artery and 
retropancreatic tissue) may be best for PDAC of pancreas head 
Modified radical/ 
Intermediate 
Tol 2014 Exp 
International Group on Pancreatic Surgery accepted Japanese 
Pancreas Society lymph node classification system, defined 
standard and extended LE procedures, and recommended 





Quality-of-life is decreased in patients following eLE with no 
survival benefit; No further trials should be performed comparing 
these two surgical methods Standard 
Gerdes 
2005 
P Radical LE not recommended in cases of pylorus-preserving PD Standard 
Jang 2014 P 
Prospective randomized clinical trial found no improvement in 




No difference in 5-year or disease-free survival or number of 
involved lymph nodes; Local recurrence higher and quality-of-life 
lower with eLE; eLE not indicated based on trials Standard 
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Pissas 1984 P 
Describes pancreatic lymphatic drainage patterns and involved 
lymph nodes with discussion of appropriate surgical procedures to 
remove specific lymph node clusters; eLE may not be beneficial 
because of close proximity of pancreatic lymphatics and thoracic 
duct allowing early circulation of tumor cells Standard 
Yeo 2002 P 
Extending pylorus-preserving PD with retroperitoneal LE and distal 
gastrectomy does not improve survival and increases morbidity in 
patients with periampullary carcinomas; eLE may show some 




Retroperitoneal eLE does not improve survival over regional LE for 





Survival after partial PD does not improve with eLE and 
retroperitoneal tissue removal over regional LE Standard 
Hirata 1997 R 
eLE does not always improve PDAC outcomes and may be 
responsible for increased post-operative mortality 
Standard 
Kanda 2011 R 
A thorough but not radical degree of LE is recommended with 
differential dissections indicated for head vs. body/tail tumors Standard 
Pawlik 2005 R 
eLE may only benefit 0.3% of patients; Too large of a population 
size would be necessary to sufficiently power a prospective trial 




eLE does not improve outcomes in the presence of positive PALNs 
and is not recommended Standard 
Dasari 2015 Rv 
Meta-analysis of randomized clinical trials; eLE does not improve 
survival over sLE but increases morbidity Standard 
Evans 2009 Rv 
Survival is not improved with eLE over sLE; Recommend sLE during 




Recommends standard PD without eLE based on survival and 
quality-of-life outcomes of four randomized clinical trials Standard 
Fujii 2013 Rv 
Title somewhat misleading; Advocates LE with sufficient removal of 
LNs to provide accurate prognosis (to include lymph node ratio 
metric) but does not recommend extensive eLE 
Standard 
Iqbal 2009 Rv 
Meta-analysis 1988-2005; eLE is associated with increased patient 
morbidity including delayed gastric emptying with no increase in 
survival 
Standard 
Ke 2014 Rv 
eLE is associated with poor post-operative quality-of-life; sLE is 




Survival not improved and quality-of-life decreased with eLE; Not 






Current data does not show benefit of extensive LE; Additional 




Lymph node stations 6, 8a, 8p, 12a, 12b, 12c, 13a, 13b, 14a, 14b, 
14c, 14d, 16b1, 17a, and 17b should be removed as part of a sLE to 





Lymph node stations 16a2 and 16b1 (PALNs) should be included in 





eLE should not be implemented for PDAC patients due to lack of 




Sufficient evidence does not exist to indicate eLE over sLE for 




Five-year overal survival was not improved with eLE and eLE 
patients experienced a significant increase in post-operative 
diarrhea; sLE with PD should be used to treat PDAC of pancreas 
head 
Standard 
The studies below do not directly support one type of LE over another but provide pertinent results that 




Intraoperative physiological fluorescence imaging identified 7 lymphatic drainage pathways from 
pancreatic uncinate process; Removal of PALNs and skeletonization of superior mesenteric artery 
may both be beneficial 
Imai 2010 P 
CT, MRI, and FDG-PET cannot accurately detect presence or absence of lymph node metastases; 




Sentinel pancreas lymph nodes were not identified intraoperatively; Prediction of positive lymph 




There is no difference in quality-of-life metrics in standard vs. radical resection 2.2 years following 
surgery 
Roche 2003 P 
Preoperative CT does not accurately predict positive lymph nodes especially in the case of 
micrometastasis and should not preclude curative resection or direct LE decisions 
Yeo 1999 P 
Extending pylorus-preserving PD with retroperitoneal LE and distal gastrectomy does not increase 
morbidity and mortality over standard resection; More time and greater numbers of patients are 




Surgery for pancreatic cancer does not increase morbidity or mortality over other abdominal 
oncologic surgeries; Resection only benefits TNM stage I population 
Doi 2007 R 
PALN metastasis correlated with increased mortality; Upon intraoperative confirmation of PALN 
metastasis alternative treatment strategies should be considered due to short survival duration 
even with eLE 
    
CR: Case report, Exp: Expert consensus statement, LE: Lymphadenectomy--(e) Extended, (s) Standard, P: 
Prospective study, PALN: Para-aortic lymph node, PD: Pancreat(ic)oduodenectomy, PDAC: Pancreatic 
ductal adenocarcinoma, R: Retrospective study, Rv: Review 
 




Outcomes Prediction:  Lymphatic-Specific Metrics 
Outcomes prediction for pancreatic cancer patients has traditionally been based on 
stage classification according to the TNM (tumor, node, metastasis) system at diagnosis (Santi et 
al., 2011).  Pancreatic cancer is rarely diagnosed in a pre-metastatic state.  Unlike perineural 
invasion, which is nearly universally accepted to negatively impact survival, the utility of 
lymphatic-specific metrics in predicting patient outcomes is less well understood and 
appreciated.  Comprehensive examination of lymph node and lymphatic vessel involvement 
would provide clinicians with important information about the progression characteristics of an 
individual patient’s tumor such as its pattern and route of spread, likelihood of local/distant 
recurrence, and potential immunomodulatory effects.  Four outcomes predictive metrics 
specifically address lymph node/lymphatic vessel involvement:  lymph node disease (LND), 
lymph node burden (LNB), lymph node ratio (LNR), and lymphatic vessel invasion (LVI).  Each of 
these measures provides distinct information regarding disease pathology and may be useful in 
refining prognoses.  LND is defined as the confirmed presence of metastatic tumor cells in at 
least one lymph node.  The total number of positive lymph nodes confirmed at resection 
constitutes LNB.  LNR is the ratio of the number of positive nodes to the total number of nodes 
examined (John et al., 2013).  LNR has been shown to be an effective tool to further stratify the 
TNM stage N1 patient population for outcomes prediction while decreasing likelihood of 
understaging and stage migration (Berger et al., 2004; Pawlik et al., 2007; Slidell et al., 2008).  
LVI may refer to lymphatic vessel invasion as determined by immunohistochemical staining of 
tissue sections or more broadly, to lymphovascular invasion, which may or may not distinguish 
between invaded hematogenous and lymphogenous vessels (Chen et al., 2010; Safuan et al., 
2012).  The relative prognostic value of each of these lymph node-/lymphatic vasculature-
specific metrics is controversial.  Prospective and retrospective clinical studies evaluating the 
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utility of these criteria are collected in Table 5 (Ausborn et al., 2013; Berger et al., 2004; Bhatti et 
al., 2010; Chen et al., 2010; House et al., 2007; John et al., 2013; Konstantinidis et al., 2010; La 
Torre et al., 2011; Murakami et al., 2010; Nakagohri et al., 2006; Pawlik et al., 2007; Riediger et 
al., 2009; Robinson et al., 2012; Schwarz and Smith, 2006; Sergeant et al., 2009; Sierzega et al., 
2006; Slidell et al., 2008; Smith and Mezhir, 2014; Tol et al., 2015; Yamamoto et al., 2014).  
Contradictory conclusions from these studies highlight the remaining need for additional work 




Table 5. Lymphatic-Specific Outcomes Metrics:  Lymph Node Disease (LND), Lymph Node 
Burden (LNB), Lymph Node Ratio (LNR), Lymphatic Vessel Invasion (LVI)
 
 
    Analyzed/Significant Metrics7 
Citation Conclusions/Recommendations LND LNB LNR LVI 
Ausborn 2013 
High LNR is associated with decreased overall survival of 
PDAC patients only when 53BP1 expression is low         
Berger 2004 
LNR > 0.15, not number of LNs examined, predicts 
overall survival and disease-free survival in patients with 
PDAC         
Bhatti 2010 
LNR is a better predictor of overall survival than LNB or 
LND in PDAC 
        
Chen 2010 
Lymphovascular invasion (may be blood or lymphatic 
vessels) predicts 5-year survival in periampullary cancer 
and PDAC patients 
        
House 2007 
Presence of LND predicts survival in PDAC patients; In 
node positive disease, LNB and LNR are good predictors 
of survival 
        
John 2013 
LNB and LNR can be used to predict cancer-specific 
survival in patients with PDAC of pancreas head 
regardless of resection margin status 
        
Konstantinidis 
2010 
Regional lymph node metastasis and direct lymph node 
invasion equally negatively impact survival; LNR ≥ 0.2, 
LNB, and LVI are useful predictors of prognosis of PDAC 
patients         
La Torre 2011 
LND and LNR are both predictive of prognosis in PDAC 
patients; LNR maintains significance on multivariate 
analysis 
        
Murakami 
2010 
LND and LNB, not LNR, predict overall survival in PDAC 
patients; LNR also significant in univariate analysis 
        
Nakagohri 
2006 
LND and LVI are predictors of 3-year survival; LND is best 
predictor of all analyzed for PDAC patients 
        
                                                          
 
7
 White: metric not analyzed; Light gray: metric analyzed but not statistically significant; Dark gray: 




LNR predicts prognosis and disease-specific survival in 
PDAC patients 
        
Riediger 2009 
LNR, not LND or LNB, predicts overall survival in PDAC 
patients 
        
Robinson 2012 
LND and LNR are good predictors of 5-year survival of 
PDAC patients; LNR better when > 0.15         
Schwarz 2006 
Number of lymph nodes examined and number of 
negative lymph nodes identified predict survival for 
exocrine pancreatic cancer patients 
        
Sergeant 2009 
Extracapsular LNR predicts overall survival as does 
overall LNR; LNB predicts disease-free survival in PDAC 
patients 
        
Sierzega 2006 
LND predicts prognosis in patients with PDAC of 
pancreas head; In node positive disease, LNR > 0.2 
predicts survival; Specifically, Group 8 and 12 lymph 
nodes were prognostic         
Slidell 2008 
Number of positive LNs, presence of LND, and LNR are 
significantly associated with survival in PDAC patients 
        
Smith 2014 
New predictive tool available for LNR and survival that 
incorporates specific patient metrics and includes 
population characteristics          
Tol 2015 LNR above 0.18 predicts 3-year survival in PDAC patients         
Yamamoto 
2014 
LNB and LNR are predictors of PDAC patient prognosis, 
not LVI; LNR is best predictor of all metrics examined 
        
      




A major challenge in pancreatic cancer biology and treatment is the presence in lymph 
nodes of single or small clusters of tumor cells that are not detected by routine 
histopathological staining techniques (Bogoevski et al., 2004; Demeure et al., 1998; Katuchova 
et al., 2012; Milsmann et al., 2005; Ridwelski et al., 2001).  Similar to insufficient surgical 
removal of primary lymph nodes (Berger et al., 2004; House et al., 2007; Meriggi et al., 2007; 
Pawlik et al., 2007; Schwarz and Smith, 2006; Slidell et al., 2008), failure to detect occult 
micrometastatic deposits in nodes may result in patient misclassification, understaging, and 
improperly informed outcomes prediction.  Descriptions of “skip metastases” in which primary 
lymph nodes are negative but metastases are established in secondary nodes or distant organ 
sites (Farnell et al., 2005; Golse et al., 2013; Mao et al., 1995) may be attributable, at least in 
part, to this phenomenon.  Emerging immunohistochemical and molecular techniques such as 
epithelial cell adhesion molecule (EpCAM/Ber-EP4) (Bogoevski et al., 2004; Milsmann et al., 
2005), cytokeratin (Katuchova et al., 2012; Ridwelski et al., 2001), and carbohydrate antigen 19-
9 (CA19-9; sialyl-Lewis A) staining (Ridwelski et al., 2001), and polymerase chain reaction for 
mutant KRAS (Demeure et al., 1998) have demonstrated efficacy in occult tumor cell detection 
in nodes, but their adaptation from the research laboratory to practical clinical application will 
require more extensive study. 
Targeting Tumor Vasculature 
Anti-angiogenic therapies were originally developed to starve tumors of important 
nutrients and oxygen and to reduce the number of potential routes for dissemination.  However, 
clinical trials demonstrated that, when used alone, anti-angiogenic therapy was not sufficient to 
improve patient survival.  Unexpectedly though, the results indicated that anti-angiogenic 
therapy significantly improved survival of patients with solid tumors when used in combination 
with conventional chemotherapies (Hurwitz et al., 2004; Saltz et al., 2008; Sandler et al., 2006).  
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These findings led to the evolution of the current vascular normalization theory:  the use of anti-
angiogenic therapy to block aberrant tumor angiogenesis and alleviate vessel dysfunction (Goel 
et al., 2012).  By restoring the balance between pro- and anti-angiogenic factors, anti-angiogenic 
therapies improved vessel organization, stabilized cell-to-cell junctions, increased pericyte 
coverage, and, consequently, reduced fluid leakage.  All these factors, in turn, relieved blood 
flow irregularities resulting in improved delivery of chemotherapy to all parts of the tumor (Goel 
et al., 2011).  Unfortunately, in the setting of pancreatic cancer, anti-angiogenic therapies have 
had either no effect or only transient effects on improving patient survival even when used in 
combination with standard chemotherapies (Bergers and Hanahan, 2008; Kindler et al., 2010; 
Sahora et al., 2014; Sohal et al., 2013; Van Cutsem et al., 2009).  PDAC tumors are unusually 
hypovascular and desmoplastic negating the ability of even normalized vessels to deliver 
therapy (Tamburrino et al., 2013).  The failure of anti-angiogenic therapy in PDAC may also be 
the result of tumor cells circumventing the VEGF-A/VEGFR-1 blockade through autocrine or 
paracrine secretion of alternative angiogenic  factors, such as the prototypical lymphangiogenic 
factors which have overlapping angiogenic functions (Bergers and Hanahan, 2008; Cao et al., 
1998; Chien et al., 2009; Scavelli et al., 2004).   
Targeting the tumor lymphatic vasculature as a treatment for cancer is beginning to gain 
interest among both basic and clinical research groups with the primary focus on anti-
lymphangiogenic therapies.  Lymphangiogenic growth factors are not critical for the 
maintenance of adult lymphatic vessels in homeostasis.  This allows for extended treatment 
with anti-lymphangiogenic therapies in tumor settings without disruption of pre-existing vessels 
and with minimal drug-induced toxicities (Karpanen et al., 2006; Lin et al., 2005).  Numerous 
pre-clinical in vivo studies have demonstrated that blocking pro-lymphangiogenic factors VEGF-C 
and VEGF-D and their receptor VEGFR-3 significantly reduces tumor lymphangiogenesis and 
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lymph node metastases in many tumor types including pancreatic (Koch et al., 2009), breast (He 
et al., 2008; Karpanen et al., 2001; Krishnan et al., 2003; Roberts et al., 2006), melanoma (Lin et 
al., 2005), renal (Stacker et al., 2001), lung (He et al., 2002; He et al., 2005), gastric (Chen et al., 
2005; Shimizu et al., 2004), prostate (Burton et al., 2008), hepatocellular (Thelen et al., 2008), 
and bladder (Yang et al., 2011a).  Other protein targets of lymphangiogenesis that have shown 
promise in inhibiting lymphatic metastasis in vivo include the VEGFR-3 co-receptor Nrp-2 (Caunt 
et al., 2008; Ou et al., 2015) and the angiopoietins Ang-1 and -2 (Holopainen et al., 2012; Neal 
and Wakelee, 2010).  Currently, two humanized neutralizing antibodies are in clinical trials for 
patients with solid tumors:  VGX-100, which inhibits VEGF-C (NCT01514123) and IMC-3C5, which 
inhibits VEGFR-3 (NCT01288989). 
The blockade of a single VEGF/VEGFR pathway will likely be insufficient to inhibit tumor 
lymphangiogenesis and lymph node metastasis due to the multiple compensatory and 
overlapping roles of the VEGF ligands and receptors (Alitalo and Detmar, 2012; Bjorndahl et al., 
2005b; Da et al., 2008; Scavelli et al., 2004).  Other growth mechanisms outside of VEGF/VEGFR 
signaling may also regulate lymphangiogenesis in the tumor setting, such as PDGF-BB/PDGFR 
(Cao et al., 2004a) and FGF/FGFR(Cao et al., 2012).  Receptor tyrosine kinase inhibitors (RTKIs) 
often target multiple receptors allowing them to inhibit several signaling pathways 
simultaneously—including the VEGFR pathways.  Both pre-clinical comparative studies and 
clinical trials have determined the safety and efficacy of numerous anti-angiogenic/-
lymphangiogenic RTKIs for the treatment of cancer including foretinib (Chen et al., 2015), 
cediranib (Heckman et al., 2008; Padera et al., 2008), and axitinib (Grunwald and Merseburger, 
2012; Rixe et al., 2007; Spano et al., 2008).  Some of these RTKIs have also been approved for 
clinical use.  Sorafenib, which inhibits VEGFR-1 and -3, PDGFR-β, FGFR-1, and Raf proteins, has 
been approved for renal cell (RCC) and hepatocellular carcinomas (Procopio et al., 2012; Reataza 
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and Imagawa, 2014; Wilhelm et al., 2004); sunitinib, which inhibits VEGFR-1 and -3, and PDGFR-
α and -β, has been approved to treat pancreatic neuroendocrine tumors, RCC, and 
gastrointestinal stromal tumors (Detry et al., 2013; Khagi and Saif, 2015; Kodera et al., 2011; 
Mankal and O'Reilly, 2013); and pazopanib, which inhibits VEGFR-1 and -3, PDGFR-α and -β, and 
FGFR, has been approved to treat RCC and soft tissue sarcoma (Ahn et al., 2013; Schutz et al., 
2011; Verweij and Sleijfer, 2013) (RTKIs further reviewed in (Stacker et al., 2014)).  Vatalanib, 
which inhibits VEGFR-1, -2, and -3, and PDGFR-β, is currently in clinical trials for the treatment of 
various solid tumors including pancreatic, ovarian, and breast cancers.  This RTKI has been 
shown to directly inhibit angiogenesis, lymphangiogenesis, and tumor growth in pre-clinical 
models of pancreatic cancer as well as other cancer models (Baker et al., 2002; Drevs et al., 
2000; Lin et al., 2002; Sini et al., 2008; Solorzano et al., 2001).  In a recent clinical trial, vatalanib 
resulted in a partial or stable response for some metastatic pancreatic cancer patients who had 
initially failed gemcitabine treatment (Dragovich et al., 2014).  Many of these lymphangiogenic 
receptor-targeting RTKIs hold promise for the treatment of early-diagnosed and resectable 
cancers (Alitalo and Detmar, 2012).   Unfortunately, these are not typical characteristics of 
pancreatic cancer, and, consequently, many of these drugs have failed to significantly improve 
pancreatic cancer patient survival (Cardin et al., 2014; Goncalves et al., 2012; Kindler et al., 
2011; Spano et al., 2008).  
Lymphangiogenesis is not the only manner by which the lymphatic vasculature can 
promote tumor progression.  As discussed previously, pre-existing lymphatic vessels can directly 
facilitate metastasis by transporting tumor cells to distant sites.  Lymphatic endothelia may also 
contribute to immune suppression by altering DC and T cell responses.  However, these 
functions are poorly understood and much more work needs to be done to determine if these 
functions can be specifically targeted in lymphatic vessels for the treatment of cancer.  
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Using Lymphatic Vessels to Deliver Therapies to Lymph Nodes 
In pancreatic cancer, metastasis to lymph nodes and distant sites has often already 
occurred by the time of diagnosis.  Anti-lymphangiogenic therapies may inhibit further tumor 
cell dissemination but will do little to reduce the growth of metastatic tumors that have already 
seeded at distant sites (He et al., 2005; Hoshida et al., 2006; Padera et al., 2008).  Successful 
treatment of tumor-invaded lymph nodes has been particularly difficult to achieve.  Resection of 
invaded lymph nodes would intuitively seem to be a promising strategy; however, as discussed 
above, current clinical imaging technologies cannot reliably detect single cell or microscopic 
lymph node metastases (Nune et al., 2011; Sevick-Muraca et al., 2014), and excision of an 
excessive number of lymph nodes is controversial due to conflicting evidence regarding its 
survival benefits and concerns about post-operative quality-of-life (Michalski et al., 2007; Witte 
et al., 2011).  Also, conventional intravenously-administered therapies display poor access to 
lymphatic vessels and lymph nodes resulting in sub-optimal drug concentrations within lymph 
nodes (O'Hagan et al., 1992).  This enables tumor cells present within lymph nodes to evade 
treatment and potentiate future recurrence.  Using the lymphatic vasculature as a delivery 
system for cancer therapies to the lymph nodes has gained increasing interest.  For therapies to 
be effectively taken up by lymphatic vessels and not blood capillaries requires specific 
characteristics of drug formulations such as being of a particular size and molecular weight, 
lipophilicity and surface charge of the drug carrier, and concentrations of the drug and carrier 
(reviewed in (Ali Khan et al., 2013; Singh et al., 2014)).  A few anti-cancer drugs have been 
formulated to target the lymphatic system and have shown promise in vivo:  a methyl 
poly(ethylene glycol)-distearoylphosphatidylethanolamine micelle containing doxorubicin re-
duced the size of lymph node metastases in a melanoma model (Li et al., 2015); addition of 
polyethylene glycol (PEGylation) to interferon-α2 demonstrated anti-tumor efficacy in the lymph 
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nodes of rats with breast cancer (Kaminskas et al., 2013); cisplatin conjugated to a copolymer 
block of poly(ethylene oxide)-block-poly(lysine) successfully treated lymph node metastases in a 
model of squamous cell carcinoma (Dunne et al., 2007); and gemcitabine loaded onto magnetic 
multiwalled carbon nanotubes resulted in better uptake of gemcitabine in the lymph nodes and 
regression of lymph node metastases in a subcutaneous model of pancreatic cancer (Yang et al., 
2011a).  The field of lymphatic-based drug delivery is still in its infancy and more studies are 
required to demonstrate efficacy and feasibility in patients.   
New Murine Platforms for Real-Time Live Imaging Studies of PDAC-Associated 
Neurolymphatic Remodeling 
 Translation of the findings presented here to clinically-meaningful therapies or imaging 
signatures would require considerable additional development.  The live imaging 
neurolymphatic remodeling studies presented in this dissertation were performed in mouse 
cornea and pinna—two accessible tissues housing neurolymphatic networks with distinct 
properties in homeostasis and inflammation.  We used B16 melanoma cells for the majority of 
our experiments and in so doing created an orthotopic system in the mouse skin and a pseudo-
orthotopic environment in the mouse cornea mimicking corneal melanoma.  We tracked tumor 
cells over time through cornea and pinna lymphatic vessels by real time live imaging microscopy 
and showed that they entered lymphatic vessels, were cleared from sites identifiable for several 
days by tissue landmarks, and eventually trafficked to draining lymph nodes.  Entry of tumor 
cells into lymphatic vessels was a relatively rare event, and properties of tumor cells trafficking 
through the cornea could be influenced by the inflammatory status of that tissue at the time of 
cell delivery.  These systems have provided insight into many aspects of neurolymphatic 
remodeling and tumor metastasis, but extrapolation of these microenvironment-dependent 
principles to PDAC requires study under more appropriate organ-specific conditions.  An 
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interesting intermediate step in the transition to the pancreas would be the use of PDAC 
organoids (Boj et al., 2015) in skin or corneal live imaging experiments.  Organoids better 
represent the complexity of a tumor microenvironment and would likely be amenable to use in 
both of our established platforms. 
Of interest for future work is the development of an intravital imaging system 
specifically designed to track pancreatic tumorigenesis, tumor-lymphatic/-nerve/-blood vessel 
interactions, and pancreatitis- and malignancy-associated neurolymphatic and blood vascular 
remodeling in the pancreas.  Development of such a platform would first require the generation 
of a multi-color mouse model in which nerves, lymphatics, and blood vessels expressed distinct 
fluorescent reporter proteins.  Pancreatitis studies could be performed in these triple-transgenic 
reporter animals by one or more previously established methods such as cerulein injection or 
Coxsackie virus challenge.  Traditional orthotopic surgery protocols could be used with 
syngeneic fluorescent reporter cell lines to study tumor-associated neurovascular remodeling 
and tumor-neurovascular interactions.  An alternative strategy in lieu of cell line implantation 
that would also enable studies of premalignant PanIN lesions would be use of the PKCY (Rhim et 
al., 2012) or KPCT (Stopczynski et al., 2014) modifications of the original autochthonous KPC 
PDAC model which include fluorescent reporter proteins in cells of the pancreas.  Live imaging 
could be accomplished by implantation of a pancreas window as has been previously described 
(Ritsma et al., 2013).  This platform could also be used to identify subgroups of tumor cells that 
preferentially migrate to/through one of the tissue networks of interest—nerves, lymphatics, or 




 We have performed preliminary proof-of-concept experiments to demonstrate the 
feasibility of deep tissue imaging reconstruction of vasculature networks in fixed pancreas.  
tdTomato fluorescent protein was constitutively expressed in Tie-2+ cells using Cre recombinase 
technology.  This enabled visualization of both blood and lymphatic endothelium by live imaging 
and in fixed tissue.  We developed a modified CLARITY protocol in which cellular lipids were 
removed to facilitate 2-photon microscopy of intact organs or thick sections up to approximately 
500 μm.  Figure 33 shows one example of 3D blood and lymphatic vasculature reconstruction 
performed in Tie2CretdT mouse pancreas.  Both large vessels and capillary structures can be 
visualized, and we are confident that inflammation- or malignancy-induced vascular architecture 
changes could be identified using this technology.  We have also optimized immunostaining 
protocols for CLARITY hydrogel-perfused organs, which would enable hypothesis-driven 




Figure 33. Tie2CretdT pancreatic blood and lymphatic vessel network revealed by CLARITY and 
2-photon microscopy.  TdTomato fluorescent protein is expressed under the control of the Tie-2 
promoter.  Tie-2 is expressed in blood and lymphatic endothelial cells.  Tie2CretdT mice were 
perfused with CLARITY hydrogel monomer solution as described (Chung and Deisseroth, 2013; 
Chung et al., 2013b) to facilitate penetration of hydrogel deep into body organs.  Pancreases 
were harvested and further clarified according to the CLARITY protocol.  2-photon confocal 
imaging was performed on approximately 500 μm thick pancreas sections.  A. 100X maximum 









 This multi-fluorescent imaging platform would enable at least two other lines of 
experimental investigation.  First, live fluorescent neurovascular cells could be sorted out of 
pancreas (or adjacent lymph nodes or neural plexuses) with or without 
orthotopic/autochthonous PDAC tumor to identify tumor-dependent distinctions in biological 
processes and molecular characteristics of these cells, i.e. by in vitro assays such as migration, 
tubulogenesis, proliferation, cytokine stimulation, signaling, neurite outgrowth, etc., or by RNA-
sequencing.  Similarly, tumor cells found in pancreatic lymphatic vessels or nerves could be 
extracted by laser capture microdissection; or these experiments could be carried out in the 
absence of tumor cells to interrogate pancreas-specific differences in homeostatic, non-
malignant inflammatory, and wound-recovered microenvironments.  Second, identification of 
pancreas-specific neurovascular remodeling events that accompany premalignant PanIN lesions 
or very small tumors could be used in early detection of PDAC.  We have demonstrated in this 
work that very small numbers of tumor cells induce local neurolymphatic remodeling signatures 
that are distinguishable from those caused by non-malignant inflammation and that these local 
remodeling events are sometimes accompanied by broader field effects outside the immediate 
“mini-microenvironment” of a group of tumor cells.  These tenets of neurolymphatic remodeling 
may hold true in the pancreatic microenvironment and may be targetable for imaging. 
Objective Measurement of PDAC Patient Cachexia Status and Correlation with 
Other Metrics 
 Determination of cachexia status of patients enrolled in the pancreatic cancer rapid 
autopsy (RAP) program remains somewhat subjective.  Designation of cachexia status at autopsy 
is not based solely on measurable criteria but rather on the appearance of the body.  Notes in 
pathology autopsy reports contain such phrases as “marked cachexia of the extremities,” “the 
muscles appear somewhat atrophic,” “there is grossly apparent muscle wasting that is more 
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prominent in the torso and upper extremities,” “the body is that of a thin/cachectic elderly 
male,” and “the extremities are thin.”  Differences in diagnostic criteria among pathologists 
performing autopsies could result in inconsistent status designations over the course of many 
autopsies.  In the studies presented in Chapter III, we have tried to minimize this potential bias 
by including additional clinical criteria in our subgroup analysis.  While definitions of clinically-
meaningful weight loss vary and may be confounded by the rising numbers of overweight and 
obese patients, one of the hallmark features of cachexia is significant unintentional weight loss; 
thus, we included it in our modified cachexia status stratification strategy.  Other clinical notes, 
too, provided some insight into deterioration of patient function that could be linked to 
cachexia with such phrases as, “presented with weight loss, extreme weakness, fatigue, 
decreased energy, decreased oral intake” etc., “required parenteral nutrition secondary to 
malnutrition,” “complains of decreased body mass and weight,” and the somewhat 
contradictory “cachectic but comfortable-appearing,” documented in the records of RAP 
patients.  Other factors linked to end-stage disease may also contribute to inconsistencies in 
designation of cachexia status at autopsy.  In at least one RAP case cachexia status was 
determined to be negative, but this was qualified by the note that “if present, [cachexia] was 
masked by anasarca8.”  Another case notes the presence of pitting edema9 in the extremities, 
which might also conceal cachexia.   
 A new use of an old imaging technology may help to ameliorate challenges in cachexia 
status designation (Martin et al., 2013a; Tan et al., 2009).  Trunk CT scans are routinely used in 
                                                          
 
8
 Anasarca is generalized edema throughout large portions of the body due to accumulation of fluid 
subcutaneously or in connective tissue.   
9




PDAC diagnosis and repeated over time to track tumor progression, metastasis, and response to 
treatment.  These scans capture a region of the lumbar spine that can be used to compute 
lumbar skeletal muscle index.  This metric objectively quantifies muscle mass independent of 
BMI and is not complicated by factors that may confound visual cachexia diagnosis such as 
increased subcutaneous fat or generalized edema.  The majority of the patients in our RAP 
program have the necessary scans available, and we are currently working to apply this method 
to obtain an unbiased skeletal muscle index to serve as an additional criterion in the final 
designation of cachexia status.   
 The broad spectrum of tissues available from our cohort of PDAC RAP patients would 
facilitate many additional musculature-based studies.  In addition to skeletal muscle, changes to 
cardiac muscle have also been reported in models of cachexia.  Cachectic C26 colon tumor-
bearing mice had impaired cardiac function associated with structural changes in musculature 
and appearance of fibrosis (Tian et al., 2010).  A differential gene expression signature in tumor-
bearing mice compared to tumor-free controls included increased levels of the E3 ubiquitin 
ligases MuRF-1 and atrogin-1 as well as differential expression of B-type natriuretic peptide 
(BNP), c-Fos, peroxisome proliferator-activated receptor-α (PPAR- α), and carnitine 
palmitoyltransferase1-β (CPT1- β), and the re-emergence of fetal proteins MHC-β and Glucose 
transporter (GLUT)-1 (from MHC-α and GLUT-4) (Tian et al., 2011).  Murine adenocarcinoma cell 
line 16 (MAC16) tumor-bearing nude mice developed cancer cachexia and also showed 
increased MuRF-1 and MAFbx gene expression; these changes were attributed to increased 
oxidation in cardiac muscle (Hinch et al., 2013).  Another group has recently identified a 
“cachexokine cocktail” of seven tumor-secreted factors that are necessary and sufficient to alter 
cardiomyocyte metabolic pathways and cause cellular atrophy; these factors are:  bridging 
integrator 1, syntaxin 7, multiple inositol-polyphosphate phosphatase 1, glucosidase alpha acid, 
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chemokine ligand 2, adamts like 4, and ataxin-10 (Schafer et al., 2015).  Studies of cardiac 
cachexia in mouse models of PDAC or human PDAC tissue samples are lacking.  Heart apex is 
routinely harvested as part of our rapid autopsy procedures.  An examination of molecular 
changes in cardiac muscle in cachectic vs. non-cachectic patients would provide another level of 
insight into this systemic disease.  Of particular interest in PDAC samples would be studies of 
GLUT transporter dysregulation and oxidative stress.  The interplay between cardiac cachexia 
and chemotherapy-induced cardiac toxicity is poorly understood and could also be investigated.  
Similarly understudied are the effects of PDAC-associated cachexia on smooth muscle.  Many 
patients succumb to respiratory failure in end stage PDAC; little is known about effects of 
cachexia on diaphragm.  Studies of alterations in vasculature- and gastrointestinal tract-
associated smooth muscle could also be carried out in our sample set.   
The nature of systemic inflammation in PDAC-associated cachexia could also be 
interrogated with these samples.  One of the most important aspects of our RAP program is that 
it is ongoing; new patients are continuously enrolled, and studies that require fresh tissue 
samples can be designed along with use of clinical samples taken throughout disease 
progression.  A set of interesting questions would be how serum inflammatory cytokine profiles 
change as cachexia develops, how chemotherapy cycles affect these systemic markers, and how 
the composition of intratumoral infiltrating immune cell populations responds to or drives these 
changes.  Fresh tumor harvest could facilitate expansion of specific inflammatory cell 
subpopulations and tumor cells for more detailed study of paracrine signaling and supportive vs. 
anti-tumor properties of immune cells in the PDAC tumor microenvironment.  Similarly, 
relationships between glucose toxicity and perineural invasion or chemotherapy-induced 
peripheral neuropathy could be investigated in these well-annotated samples. 
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Outlook for the Future 
Advances in surgical, radiation, and chemotherapeutic treatment regimens for 
pancreatic cancer have not greatly impacted overall survival rates for patients afflicted with this 
devastating disease.  Early spread of tumor cells to lymph nodes, into nerves, and to distant sites 
often precludes curative resection, facilitates cancer chemoresistance and immune evasion, and 
decreases overall survival.  The lymphatic and nervous systems represent two of the major 
understudied players in the tumor microenvironment and in the process of tumor metastasis. 
The intrinsic functional and structural characteristics of the lymphatic system suggest roles in 
immune regulation, cell trafficking, and interactions with other tissue networks and cell types, 
while the nearly 100% incidence of PDAC perineural invasion, mutual tumor-nerve tropism and 
paracrine secretions, and debilitating pain highlight the importance of nerves in the tumor 
microenvironment. Distortion of the physiological processes of lymphangiogenesis and 
neurogenesis in the tumor microenvironment and consequent effects on the biology of 
lymphatics, nerves, and tumor cells are complex and complicate targeting strategies.  Clinical 
efforts to detect and use lymph node status or presence of PNI to inform treatment decisions, 
guide pancreatectomy, and stratify patients into prognostic cohorts have improved but remain 
inconsistent across groups and are not yet standardized or broadly applied.  Identification, 
refinement, and directed studies of lymphatic- and nerve-specific metrics have highlighted the 
importance of these criteria as additional prognostic factors in this disease.  Development of 
pre-clinical models of tumor-associated neurolymphatic remodeling, PNI, and lymph node 
metastasis and new lymphatic-directed clinical therapeutics represent two significant areas of 
current research.  Live imaging studies in genetically engineered models that recapitulate both 
molecular and behavioral signatures of specific cancer types will improve our understanding of 
the earliest events in tumor-associated neurolymphatic remodeling, tumor-lymphatic/-nerve 
219 
 
interactions, and lymph node and perineural invasion.  Translation of these and other preclinical 
findings to clinically-relevant diagnostic criteria or therapeutic interventions remains an 
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Appendix A:  Skeletal Muscle Total RNA Extraction Protocol 
DAY 1: 
Homogenization 
1. Spray with RNaseZap, rinse, and wipe dry work surface, pipettor, spatulas, tweezers and 
gloves.  Get liquid nitrogen, dry ice, and wet ice.  May also need mortar and pestle to 
break up tissue pieces. 
2. Place spatulas, tweezers, and polycons containing tissue on dry ice. 
3. Work in fume hood with double gloves and lab coat.  Lay down paper towels to work 
over. 
4. Add 3 mL TRIzol to one 15 mL conical per sample. 
5. Clean VirTishear homogenizer with 1 N NaOH and rinse with several L of purified water.   
6. Use tweezers to place piece of tissue in conical.   
7. Homogenize tissue using VirTishear homogenizer until in suspension.  Three to four 
cycles at speed 5 for about 10 - 15 seconds each works well.   
8. Add another 7 mL TRIzol to each sample. 
9. Vortex vigorously; incubate 5 minutes at room temperature. 
10. Add 0.2 mL chloroform per 1 mL of TRIzol (2 mL) and shake vigorously by hand for 30 
seconds.  Incubate 5 minutes at room temperature. 






1. Remove the top aqueous phase and transfer to a new tube without disturbing the 
interphase or lower organic phase.  Organic phase can be stored overnight at 4°C. 
2. Add 0.5 mL isopropanol per 1 mL TRIzol (5 mL) and incubate overnight at -20°C. 
DAY 2: 
3. Centrifuge 45 minutes at 3200 rpm at 4°C; decant supernatant. 
4. Wash in 1 mL 75% EtOH per 1 mL TRIzol (10 mL).  Vortex and centrifuge 45 minutes at 
3200 rpm at 4°C; decant supernatant. 
5. Resuspend pellet in small volume (<500 μL) 75% EtOH.  Transfer to microfuge tube.  
Rinse conical with 500 μL 75% EtOH and add to microfuge tube.  Mix well.  RNA can be 
stored in 75% EtOH at -20°C if necessary. 
6. Centrifuge 5 minutes at 16,100 rcf at 4°C.  Remove supernatant.  Repeat. 
7. Allow pellet to air dry in hood for 10 minutes. 
8. Resuspend pellet in 50 μL RNase-free water. 
9. Analyze RNA concentration and quality by NanoDrop spectroscopy and 
BioAnalyzer/Fragment Analyzer RNA Integrity Number/RNA Quality Number. 
10. Store RNA at -80°C. 
 
